data_1jjz_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1jjz _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.26 -39.84 1.68 Allowed Glycine 0 CA--C 1.529 0.942 0 O-C-N 124.544 1.152 . . . . 0.0 111.021 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -61.95 113.49 8.64 Favored Pre-proline 0 C--N 1.325 -0.457 0 O-C-N 124.437 0.728 . . . . 0.0 109.271 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.42 ' CA ' HG22 ' A' ' 35' ' ' THR . 18.5 Cg_endo -75.08 64.97 6.15 Favored 'Trans proline' 0 C--N 1.36 1.165 0 O-C-N 124.479 1.778 . . . . 0.0 110.983 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -138.85 21.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.435 1.085 . . . . 0.0 109.335 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 26.7 t -57.96 -41.96 83.98 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.475 1.109 . . . . 0.0 108.283 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.65 -7.68 68.27 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.434 ' CG ' HG21 ' A' ' 24' ' ' THR . 15.4 mm-40 -124.03 155.89 37.48 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.466 0.745 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.415 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -105.52 176.63 5.1 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.566 1.166 . . . . 0.0 110.459 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.2 p -154.46 68.76 0.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.52 1.138 . . . . 0.0 108.329 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.538 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -74.78 -21.32 16.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.533 1.145 . . . . 0.0 109.338 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.95 -6.31 40.12 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.552 1.158 . . . . 0.0 111.035 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.82 21.46 28.41 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 2.5 m -131.7 79.4 1.87 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.538 0.787 . . . . 0.0 110.428 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.5 p -45.16 -30.94 1.27 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.54 1.15 . . . . 0.0 108.36 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 59.86 16.01 5.34 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.477 1.111 . . . . 0.0 109.312 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.493 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -111.3 150.3 41.84 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.498 1.124 . . . . 0.0 110.393 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.493 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.09 141.54 26.51 Favored 'Trans proline' 0 C--N 1.359 1.103 0 O-C-N 124.52 1.8 . . . . 0.0 111.009 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.84 50.1 5.08 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.506 1.129 . . . . 0.0 110.95 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.406 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -107.13 175.52 5.47 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.484 ' O ' ' CG2' ' A' ' 28' ' ' THR . 1.1 m -141.33 72.15 1.38 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.457 1.098 . . . . 0.0 110.357 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.7 t -38.81 114.56 0.4 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.521 1.138 . . . . 0.0 108.305 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 15.9 t -120.89 -12.09 8.85 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.552 1.158 . . . . 0.0 110.009 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.629 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.46 137.26 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.52 1.138 . . . . 0.0 108.007 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.629 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -74.97 -19.72 17.25 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.058 -2.476 . . . . 0.0 110.99 -0.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.1 t -113.84 150.27 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.263 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -77.62 166.59 22.83 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.482 1.113 . . . . 0.0 108.366 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 28' ' ' THR . 3.0 p -133.36 174.58 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.51 1.131 . . . . 0.0 110.375 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 . . . . . 0 C--N 1.324 -0.524 0 O-C-N 124.527 1.142 . . . . 0.0 110.36 179.932 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.23 -48.62 0.7 Allowed Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.532 1.145 . . . . 0.0 111.009 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -61.5 111.73 4.83 Favored Pre-proline 0 C--N 1.324 -0.525 0 O-C-N 124.585 0.815 . . . . 0.0 109.311 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -75.05 69.39 5.6 Favored 'Trans proline' 0 C--N 1.361 1.186 0 O-C-N 124.43 1.753 . . . . 0.0 110.967 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.57 21.79 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 O-C-N 124.483 1.114 . . . . 0.0 109.299 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 5.3 t -60.76 -46.08 91.82 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.535 1.147 . . . . 0.0 108.346 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.21 -5.63 65.67 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.452 1.095 . . . . 0.0 110.944 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -123.35 146.15 48.17 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.49 0.759 . . . . 0.0 110.354 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.44 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.81 175.47 5.95 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.409 1.068 . . . . 0.0 110.41 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.56 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.2 p -153.93 65.9 0.72 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 108.27 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.535 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -71.86 -22.39 21.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 O-C-N 124.388 1.055 . . . . 0.0 109.327 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.08 -7.19 50.53 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.491 1.119 . . . . 0.0 110.994 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.97 21.34 23.51 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 22.9 m -138.39 93.71 2.77 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.447 0.733 . . . . 0.0 110.387 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 7.4 p -47.33 -37.6 11.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.384 1.053 . . . . 0.0 108.283 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.494 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER 82.43 -1.05 1.38 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.56 1.162 . . . . 0.0 109.311 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.9 t -127.83 144.53 51.64 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.492 1.12 . . . . 0.0 110.436 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -75.05 179.42 6.12 Favored 'Trans proline' 0 C--N 1.359 1.116 0 O-C-N 124.505 1.792 . . . . 0.0 110.969 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 40.84 32.15 0.5 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.511 1.132 . . . . 0.0 111.019 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.43 166.47 11.85 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 35' ' ' THR . 17.3 m -136.64 74.43 1.49 Allowed 'General case' 0 C--N 1.324 -0.516 0 O-C-N 124.574 1.171 . . . . 0.0 110.385 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.427 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.8 t -39.93 109.78 0.12 Allowed 'General case' 0 C--N 1.326 -0.444 0 O-C-N 124.463 1.102 . . . . 0.0 108.322 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.1 OUTLIER -118.1 -11.27 10.19 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.495 1.122 . . . . 0.0 109.996 179.979 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.614 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.73 137.62 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.546 1.154 . . . . 0.0 108.028 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.614 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.99 -20.09 16.87 Favored 'Cis proline' 0 C--N 1.359 1.114 0 C-N-CA 121.026 -2.489 . . . . 0.0 111.001 0.016 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -114.56 148.76 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.492 1.12 . . . . 0.0 109.411 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 21.1 p -74.77 160.18 31.05 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.46 ' O ' ' N ' ' A' ' 28' ' ' THR . 23.3 p -127.35 -177.86 4.23 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.52 1.138 . . . . 0.0 110.383 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 . . . . . 0 C--N 1.324 -0.506 0 O-C-N 124.533 1.146 . . . . 0.0 110.322 179.963 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.1 p-10 . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.48 -51.12 0.63 Allowed Glycine 0 CA--C 1.53 0.978 0 O-C-N 124.484 1.115 . . . . 0.0 111.047 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.8 mt -56.22 114.73 8.17 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.46 0.741 . . . . 0.0 109.297 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 70.86 5.16 Favored 'Trans proline' 0 C--N 1.361 1.191 0 O-C-N 124.446 1.761 . . . . 0.0 111.002 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.1 m -142.24 22.82 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.494 1.121 . . . . 0.0 109.302 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.6 t -55.94 -43.96 77.93 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.559 1.162 . . . . 0.0 108.239 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.19 -6.13 61.51 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.505 1.128 . . . . 0.0 110.971 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -125.57 175.15 7.75 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.512 0.772 . . . . 0.0 110.363 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.419 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.4 OUTLIER -122.52 176.08 6.11 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 124.493 1.121 . . . . 0.0 110.432 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.605 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 27.3 p -153.36 66.7 0.77 Allowed 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.454 1.096 . . . . 0.0 108.312 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.536 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -73.8 -22.82 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.49 1.119 . . . . 0.0 109.362 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.06 -10.97 44.22 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.466 1.104 . . . . 0.0 111.021 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 103.65 16.17 20.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.475 ' CG2' ' O ' ' A' ' 21' ' ' THR . 14.5 t -132.84 100.31 4.87 Favored 'General case' 0 C--N 1.326 -0.443 0 O-C-N 124.529 0.782 . . . . 0.0 110.424 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 25.8 p -59.02 -39.45 81.95 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.519 1.137 . . . . 0.0 108.301 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 69.3 10.09 7.62 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.529 1.143 . . . . 0.0 109.31 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.499 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.6 OUTLIER -107.87 150.14 39.93 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 124.502 1.126 . . . . 0.0 110.338 -179.936 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.08 141.75 26.78 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.498 1.788 . . . . 0.0 111.003 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 43.45 49.39 6.96 Favored Glycine 0 CA--C 1.531 1.04 0 O-C-N 124.5 1.125 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.2 OUTLIER -107.28 178.42 4.55 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.468 ' N ' ' O ' ' A' ' 35' ' ' THR . 1.2 m -145.01 72.22 1.32 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.498 1.124 . . . . 0.0 110.471 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.45 ' C ' ' O ' ' A' ' 28' ' ' THR . 37.2 t -38.26 113.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.525 1.141 . . . . 0.0 108.368 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 45.5 t -120.93 -12.64 8.75 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.513 1.133 . . . . 0.0 109.963 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.634 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.37 136.22 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.47 0 O-C-N 124.489 1.118 . . . . 0.0 108.003 -179.946 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -74.96 -22.0 14.51 Favored 'Cis proline' 0 C--N 1.361 1.188 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -0.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.9 t -109.32 148.79 12.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.558 1.161 . . . . 0.0 109.297 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.4 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.1 p -81.14 162.65 23.57 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.503 1.127 . . . . 0.0 108.291 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.468 ' O ' ' N ' ' A' ' 28' ' ' THR . 40.8 p -121.2 -171.98 2.31 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.484 1.115 . . . . 0.0 110.403 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 76.0 mtp180 . . . . . 0 C--N 1.325 -0.492 0 O-C-N 124.559 1.162 . . . . 0.0 110.281 -179.994 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 36' ' ' ARG . 20.6 p30 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.49 -57.32 0.66 Allowed Glycine 0 CA--C 1.53 0.988 0 O-C-N 124.49 1.119 . . . . 0.0 110.987 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 mt -52.54 109.41 1.42 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.486 0.756 . . . . 0.0 109.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 69.18 5.66 Favored 'Trans proline' 0 C--N 1.361 1.19 0 O-C-N 124.409 1.742 . . . . 0.0 110.972 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -138.5 19.98 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.297 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.408 ' SG ' ' CB ' ' A' ' 24' ' ' THR . 3.3 t -52.88 -43.53 66.2 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.527 1.142 . . . . 0.0 108.321 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.65 -3.99 63.48 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.471 1.107 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.498 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.43 173.46 9.8 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.49 0.759 . . . . 0.0 110.358 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.466 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.8 OUTLIER -120.73 178.81 4.55 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.509 1.131 . . . . 0.0 110.43 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.612 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 31.7 p -155.54 62.86 0.61 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.524 1.14 . . . . 0.0 108.328 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.535 ' HA ' ' CE2' ' A' ' 31' ' ' TRP . 3.3 t -70.34 -21.0 23.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.509 1.131 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.07 -4.15 33.57 Favored Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.535 1.147 . . . . 0.0 110.994 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.57 22.16 29.68 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 22' ' ' CYS . 49.9 m -126.69 80.5 1.94 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.482 0.754 . . . . 0.0 110.473 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 21' ' ' THR . 41.1 t -41.56 -49.16 4.07 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.424 1.077 . . . . 0.0 108.327 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.5 t30 71.27 10.0 6.65 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.471 1.107 . . . . 0.0 109.327 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.487 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -113.0 148.54 39.62 Favored Pre-proline 0 C--N 1.324 -0.502 0 O-C-N 124.439 1.087 . . . . 0.0 110.436 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.487 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 142.84 28.41 Favored 'Trans proline' 0 C--N 1.36 1.158 0 O-C-N 124.464 1.771 . . . . 0.0 111.054 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.02 49.06 7.9 Favored Glycine 0 CA--C 1.53 0.996 0 O-C-N 124.473 1.108 . . . . 0.0 110.987 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.469 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -108.92 178.11 4.57 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.477 ' O ' ' C ' ' A' ' 29' ' ' CYS . 1.2 m -145.77 73.33 1.34 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.518 1.136 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.477 ' C ' ' O ' ' A' ' 28' ' ' THR . 40.0 t -36.68 112.37 0.18 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.47 1.106 . . . . 0.0 108.258 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 16.5 t -119.97 -13.99 8.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.425 1.078 . . . . 0.0 110.001 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.631 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.59 136.72 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.523 0 O-C-N 124.564 1.165 . . . . 0.0 108.013 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.631 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -74.98 -20.99 15.88 Favored 'Cis proline' 0 C--N 1.36 1.172 0 C-N-CA 120.986 -2.506 . . . . 0.0 111.005 -0.042 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.4 t -112.62 146.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.458 1.099 . . . . 0.0 109.3 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 1.8 p -78.36 161.46 27.17 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 124.544 1.153 . . . . 0.0 108.249 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.441 ' O ' ' N ' ' A' ' 28' ' ' THR . 22.1 p -126.07 -175.99 3.52 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.526 1.141 . . . . 0.0 110.391 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.404 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.463 1.102 . . . . 0.0 110.299 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 140.7 -49.24 0.79 Allowed Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.545 1.153 . . . . 0.0 110.976 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 mt -54.79 114.15 6.47 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.568 0.805 . . . . 0.0 109.26 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -75.01 71.46 5.01 Favored 'Trans proline' 0 C--N 1.36 1.16 0 O-C-N 124.522 1.801 . . . . 0.0 111.003 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 m -142.39 23.52 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 O-C-N 124.595 1.185 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 11.8 t -64.02 -45.68 87.83 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.499 1.125 . . . . 0.0 108.32 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.33 -6.43 71.68 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 124.575 1.172 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.407 ' O ' ' SG ' ' A' ' 34' ' ' CYS . 3.4 mm-40 -121.76 144.76 48.61 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.416 0.715 . . . . 0.0 110.258 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.477 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -95.82 174.72 6.82 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.487 1.117 . . . . 0.0 110.398 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.506 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.1 p -154.28 66.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.455 1.097 . . . . 0.0 108.342 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.526 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -71.69 -22.54 21.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.585 1.178 . . . . 0.0 109.377 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.38 -7.56 45.69 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.465 1.103 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.8 20.66 23.49 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 111.016 -0.833 . . . . 0.0 111.016 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 98.4 m -136.11 94.11 3.0 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 0.773 . . . . 0.0 110.394 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 4.7 m -46.59 -38.2 9.19 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.583 1.177 . . . . 0.0 108.303 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.0 t-20 84.33 -0.93 0.97 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.506 1.129 . . . . 0.0 109.213 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -128.03 144.95 53.42 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.457 1.098 . . . . 0.0 110.378 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.92 166.05 30.07 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.418 1.747 . . . . 0.0 111.006 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 50.61 47.48 45.36 Favored Glycine 0 CA--C 1.531 1.064 0 O-C-N 124.483 1.115 . . . . 0.0 111.003 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.448 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -128.14 174.96 8.8 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 -179.995 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.449 ' O ' ' C ' ' A' ' 29' ' ' CYS . 1.3 m -145.4 82.01 1.64 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.471 1.107 . . . . 0.0 110.409 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.449 ' C ' ' O ' ' A' ' 28' ' ' THR . 34.0 t -38.29 114.43 0.36 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.52 1.138 . . . . 0.0 108.273 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.3 t -119.73 -19.79 7.89 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 109.978 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.642 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.22 135.97 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.531 0 O-C-N 124.546 1.154 . . . . 0.0 108.033 -179.922 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.642 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -75.0 -17.52 19.9 Favored 'Cis proline' 0 C--N 1.36 1.175 0 C-N-CA 121.035 -2.486 . . . . 0.0 110.963 0.052 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.05 148.97 16.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.547 1.155 . . . . 0.0 109.287 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.456 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 16.3 p -78.24 163.96 25.32 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.512 1.133 . . . . 0.0 108.233 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 28' ' ' THR . 44.4 p -131.17 -177.62 4.47 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.473 1.108 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 . . . . . 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.297 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.04 -36.07 2.2 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.533 1.146 . . . . 0.0 111.034 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -74.34 116.88 57.21 Favored Pre-proline 0 C--N 1.324 -0.513 0 O-C-N 124.555 0.797 . . . . 0.0 109.208 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HA ' ' CG2' ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.02 68.37 5.79 Favored 'Trans proline' 0 C--N 1.361 1.217 0 O-C-N 124.506 1.793 . . . . 0.0 111.036 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.89 16.33 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 O-C-N 124.496 1.122 . . . . 0.0 109.269 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 9.6 t -64.31 -47.65 78.63 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.434 1.084 . . . . 0.0 108.248 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.22 3.36 75.84 Favored Glycine 0 CA--C 1.529 0.935 0 O-C-N 124.58 1.175 . . . . 0.0 111.041 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.0 mm-40 -121.98 145.92 47.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.438 0.728 . . . . 0.0 110.315 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.434 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -105.75 162.77 13.24 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.509 1.131 . . . . 0.0 110.458 179.957 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' N ' ' A' ' 22' ' ' CYS . 1.2 p -135.42 53.25 1.98 Allowed 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.481 1.113 . . . . 0.0 108.325 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.51 HG11 ' CZ2' ' A' ' 31' ' ' TRP . 2.2 t -67.05 -20.85 27.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.509 1.13 . . . . 0.0 109.316 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.54 -3.16 59.83 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.464 1.102 . . . . 0.0 110.978 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.48 24.21 19.24 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.1 t -158.58 115.76 2.83 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.556 0.797 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.497 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 6.4 p -55.51 -36.1 66.33 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.496 1.122 . . . . 0.0 108.278 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.497 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.2 t30 82.53 -0.93 1.35 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 109.337 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.2 t -127.32 144.75 51.85 Favored Pre-proline 0 C--N 1.326 -0.446 0 O-C-N 124.461 1.101 . . . . 0.0 110.438 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.04 177.81 8.1 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.454 1.765 . . . . 0.0 110.986 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.83 35.89 0.7 Allowed Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.543 1.152 . . . . 0.0 111.022 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -119.44 158.19 26.72 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.494 ' O ' ' CG2' ' A' ' 28' ' ' THR . 1.1 m -125.48 71.02 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.538 1.148 . . . . 0.0 110.384 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.438 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 12.5 t -41.11 114.29 0.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.547 1.154 . . . . 0.0 108.318 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 85.4 p -125.4 -7.56 6.96 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.517 1.135 . . . . 0.0 109.985 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.631 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 61.87 138.69 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.518 0 O-C-N 124.497 1.123 . . . . 0.0 107.97 179.963 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.631 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -75.0 -20.67 16.26 Favored 'Cis proline' 0 C--N 1.36 1.165 0 C-N-CA 120.976 -2.51 . . . . 0.0 110.974 -0.007 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t -118.46 144.43 26.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.451 1.094 . . . . 0.0 109.313 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.438 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 25.4 p -71.29 164.65 25.3 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.556 1.16 . . . . 0.0 108.244 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.476 ' CG2' ' HA ' ' A' ' 11' ' ' PRO . 15.2 p -131.19 177.01 7.79 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.524 1.14 . . . . 0.0 110.396 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.513 1.133 . . . . 0.0 110.305 179.96 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 36' ' ' ARG . 24.6 t30 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.43 25.85 5.88 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.569 1.168 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.9 mt -127.12 121.34 22.72 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.46 0.741 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 60.93 5.57 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.537 1.809 . . . . 0.0 111.015 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -143.79 20.77 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.53 1.144 . . . . 0.0 109.288 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.2 t -51.31 -46.01 62.42 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.467 1.105 . . . . 0.0 108.284 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.92 -3.75 45.26 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.422 1.076 . . . . 0.0 111.037 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -130.8 171.29 13.3 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.543 0.79 . . . . 0.0 110.242 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.06 175.39 6.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.431 1.082 . . . . 0.0 110.425 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.606 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.5 p -153.13 68.91 0.82 Allowed 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.531 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.4 -23.36 16.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.516 1.135 . . . . 0.0 109.287 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.59 -12.63 50.26 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 111.022 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.23 15.13 16.68 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 t -138.02 113.16 9.25 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.453 0.737 . . . . 0.0 110.397 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 2.1 p -59.86 -35.34 74.59 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.516 1.135 . . . . 0.0 108.313 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.459 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.3 t30 79.26 -0.98 2.28 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.495 1.122 . . . . 0.0 109.272 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -124.46 145.48 49.16 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.535 1.147 . . . . 0.0 110.465 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.3 Cg_endo -75.02 176.93 9.27 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.561 1.821 . . . . 0.0 111.007 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.82 43.99 0.89 Allowed Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.441 1.088 . . . . 0.0 110.999 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -122.77 173.5 7.71 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 35' ' ' THR . 1.2 m -142.59 73.34 1.4 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.54 1.15 . . . . 0.0 110.447 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.428 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 30.5 t -41.4 117.0 0.83 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.512 1.133 . . . . 0.0 108.346 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 31' ' ' TRP . 92.2 p -124.94 -10.79 7.17 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.481 1.113 . . . . 0.0 109.99 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.653 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.16 135.61 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.46 0 O-C-N 124.505 1.128 . . . . 0.0 107.997 -179.983 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.653 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.1 Cg_endo -74.99 -23.73 12.26 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.987 -2.505 . . . . 0.0 110.952 -0.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.1 t -110.7 147.71 14.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.462 1.101 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.428 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 7.3 p -77.39 167.33 21.85 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.523 1.139 . . . . 0.0 108.297 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 28' ' ' THR . 1.4 p -124.96 172.56 9.3 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.549 1.156 . . . . 0.0 110.425 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 8' ' ' ASN . 6.6 ptm180 . . . . . 0 C--N 1.324 -0.518 0 O-C-N 124.513 1.133 . . . . 0.0 110.345 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.456 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -143.55 -89.66 0.11 Allowed Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.512 1.133 . . . . 0.0 111.002 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.48 161.74 28.5 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.517 0.775 . . . . 0.0 109.29 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 70.69 5.27 Favored 'Trans proline' 0 C--N 1.36 1.159 0 O-C-N 124.456 1.766 . . . . 0.0 110.988 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.24 20.92 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.296 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.522 ' SG ' ' CG2' ' A' ' 24' ' ' THR . 8.9 t -51.93 -40.54 60.96 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.446 1.091 . . . . 0.0 108.289 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.61 -4.65 69.45 Favored Glycine 0 CA--C 1.53 0.987 0 O-C-N 124.518 1.136 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.5 OUTLIER -125.27 173.74 8.6 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.502 0.766 . . . . 0.0 110.343 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.38 176.13 5.81 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.393 1.058 . . . . 0.0 110.382 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.598 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 10.7 p -155.93 71.57 0.74 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.609 1.193 . . . . 0.0 108.319 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.54 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.37 -24.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.537 1.148 . . . . 0.0 109.334 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -92.31 -11.58 59.57 Favored Glycine 0 CA--C 1.529 0.952 0 O-C-N 124.44 1.087 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.58 19.99 20.97 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.0 t -149.83 104.53 3.32 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.485 0.756 . . . . 0.0 110.385 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 1.9 p -55.65 147.05 19.21 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.547 1.154 . . . . 0.0 108.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -81.22 -0.7 41.76 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.507 1.13 . . . . 0.0 109.292 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.522 ' CG2' ' SG ' ' A' ' 13' ' ' CYS . 15.2 t -126.36 144.02 47.94 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.561 1.163 . . . . 0.0 110.385 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.01 -178.05 3.9 Favored 'Trans proline' 0 C--N 1.361 1.192 0 O-C-N 124.422 1.749 . . . . 0.0 110.984 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 48.27 1.7 Allowed Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.521 1.138 . . . . 0.0 111.037 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -123.75 168.37 12.79 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.483 ' O ' ' CG2' ' A' ' 28' ' ' THR . 1.1 m -127.27 71.95 1.35 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.496 1.123 . . . . 0.0 110.406 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.436 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.0 t -39.59 118.94 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.495 1.122 . . . . 0.0 108.33 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.3 OUTLIER -121.66 -14.89 8.08 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.505 1.128 . . . . 0.0 110.018 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.661 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.32 135.27 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.661 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.08 -21.83 14.82 Favored 'Cis proline' 0 C--N 1.36 1.132 0 C-N-CA 120.961 -2.516 . . . . 0.0 110.971 0.014 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.2 t -106.35 149.44 9.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.485 1.116 . . . . 0.0 109.277 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 8.0 p -84.26 171.04 13.1 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.527 1.142 . . . . 0.0 108.309 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.404 ' O ' ' N ' ' A' ' 28' ' ' THR . 22.3 p -133.33 -173.76 3.31 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.53 1.144 . . . . 0.0 110.372 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.456 ' C ' ' N ' ' A' ' 9' ' ' GLY . 2.0 ttp180 . . . . . 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.16 . . . . 0.0 110.292 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.443 ' CA ' ' HB ' ' A' ' 35' ' ' THR . . . 149.36 -52.34 0.53 Allowed Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.479 1.112 . . . . 0.0 110.963 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.33 111.64 2.71 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.533 0.784 . . . . 0.0 109.32 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -74.97 66.5 6.0 Favored 'Trans proline' 0 C--N 1.361 1.189 0 O-C-N 124.401 1.738 . . . . 0.0 110.955 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.81 20.73 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.448 1.092 . . . . 0.0 109.223 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.404 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -65.39 -47.95 74.57 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.471 1.107 . . . . 0.0 108.329 -179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.24 -5.1 78.03 Favored Glycine 0 CA--C 1.531 1.066 0 O-C-N 124.468 1.105 . . . . 0.0 111.013 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.404 ' OE2' ' O ' ' A' ' 13' ' ' CYS . 20.1 mp0 -117.89 141.69 48.15 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.497 0.763 . . . . 0.0 110.271 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.34 173.36 7.02 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.476 1.11 . . . . 0.0 110.395 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.563 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.0 p -152.28 71.63 0.96 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.594 1.184 . . . . 0.0 108.314 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.529 HG11 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.2 -22.84 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.516 1.135 . . . . 0.0 109.26 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.62 -10.35 55.58 Favored Glycine 0 CA--C 1.529 0.924 0 O-C-N 124.476 1.11 . . . . 0.0 110.995 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.13 20.05 21.91 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.516 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.6 t -143.82 93.09 2.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.507 0.769 . . . . 0.0 110.428 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.466 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 9.4 p -45.91 -31.37 2.13 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.336 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 1.5 t-20 79.57 -1.2 2.18 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.402 1.064 . . . . 0.0 109.354 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.441 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 5.8 t -118.66 147.72 42.73 Favored Pre-proline 0 C--N 1.325 -0.487 0 O-C-N 124.509 1.131 . . . . 0.0 110.475 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.3 Cg_endo -74.94 172.64 15.95 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.459 1.768 . . . . 0.0 110.961 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 45.17 1.36 Allowed Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.532 1.145 . . . . 0.0 110.997 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.447 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -118.78 161.26 20.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.467 ' O ' ' C ' ' A' ' 29' ' ' CYS . 1.5 m -130.61 70.98 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.412 1.07 . . . . 0.0 110.427 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.467 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -37.51 112.53 0.21 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.56 1.163 . . . . 0.0 108.327 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.0 p -117.16 -15.67 10.46 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.504 1.127 . . . . 0.0 109.999 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.627 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.58 136.71 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.627 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.05 -19.01 18.11 Favored 'Cis proline' 0 C--N 1.361 1.193 0 C-N-CA 120.96 -2.517 . . . . 0.0 110.947 0.049 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -112.17 149.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.405 1.066 . . . . 0.0 109.335 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.447 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -67.3 171.68 5.62 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.571 1.17 . . . . 0.0 108.305 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.443 ' HB ' ' CA ' ' A' ' 9' ' ' GLY . 34.2 p -136.55 161.73 35.06 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.5 1.125 . . . . 0.0 110.395 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.464 1.102 . . . . 0.0 110.318 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.453 -0.324 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.61 -44.24 1.24 Allowed Glycine 0 CA--C 1.531 1.043 0 O-C-N 124.499 1.124 . . . . 0.0 110.982 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.36 114.6 9.71 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.515 0.773 . . . . 0.0 109.308 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.07 67.44 5.99 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.52 1.8 . . . . 0.0 110.981 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 m -140.0 21.59 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.533 1.146 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.5 t -57.29 -43.83 83.51 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 124.504 1.128 . . . . 0.0 108.299 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.28 -5.24 71.13 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.525 1.141 . . . . 0.0 110.958 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.4 ' O ' ' SG ' ' A' ' 34' ' ' CYS . 6.7 mm-40 -124.43 143.36 50.67 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.449 0.735 . . . . 0.0 110.289 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.27 174.13 7.04 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.396 1.06 . . . . 0.0 110.416 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.583 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.9 p -152.5 74.8 1.09 Allowed 'General case' 0 C--N 1.326 -0.432 0 O-C-N 124.48 1.113 . . . . 0.0 108.273 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.482 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.0 t -81.81 -20.52 10.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.511 1.132 . . . . 0.0 109.364 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.17 -8.57 44.15 Favored Glycine 0 CA--C 1.53 1.005 0 O-C-N 124.541 1.15 . . . . 0.0 110.994 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.24 21.89 23.78 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.511 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.7 t -133.15 94.0 3.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.534 0.785 . . . . 0.0 110.414 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 2.8 t -41.7 -43.75 2.95 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.552 1.157 . . . . 0.0 108.344 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.1 t-20 83.27 -1.8 1.19 Allowed 'General case' 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 109.339 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -136.73 144.64 47.73 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.53 1.144 . . . . 0.0 110.406 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 177.6 8.38 Favored 'Trans proline' 0 C--N 1.361 1.209 0 O-C-N 124.527 1.804 . . . . 0.0 111.014 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.86 43.79 5.41 Favored Glycine 0 CA--C 1.529 0.944 0 O-C-N 124.565 1.166 . . . . 0.0 111.006 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -127.85 177.13 7.05 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.997 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.484 ' CG2' ' O ' ' A' ' 28' ' ' THR . 1.1 m -148.23 72.99 1.23 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.475 1.109 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.1 t -38.86 114.85 0.42 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 108.272 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.9 t -121.74 -11.82 8.55 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.509 1.131 . . . . 0.0 109.966 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.653 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.65 135.94 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.982 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.653 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -75.06 -22.6 13.77 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.948 -2.522 . . . . 0.0 111.033 -0.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.31 148.81 13.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.459 1.1 . . . . 0.0 109.29 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 15.6 p -79.23 163.96 24.55 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.593 1.183 . . . . 0.0 108.311 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 73.3 p -123.99 -176.88 3.6 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.542 1.152 . . . . 0.0 110.5 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.6 ttp85 . . . . . 0 C--N 1.324 -0.526 0 O-C-N 124.475 1.109 . . . . 0.0 110.333 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.25 -39.35 2.09 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.46 1.1 . . . . 0.0 110.942 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.9 mt -67.02 123.06 85.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.471 0.747 . . . . 0.0 109.29 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.01 71.85 4.86 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.509 1.794 . . . . 0.0 111.035 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.1 22.42 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.514 1.134 . . . . 0.0 109.314 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.3 t -57.08 -45.06 83.63 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.464 1.103 . . . . 0.0 108.302 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.31 -5.12 58.81 Favored Glycine 0 CA--C 1.531 1.074 0 O-C-N 124.498 1.124 . . . . 0.0 110.995 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.1 OUTLIER -126.09 175.01 8.05 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.572 0.807 . . . . 0.0 110.284 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.47 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.66 175.75 5.86 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 124.558 1.161 . . . . 0.0 110.419 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 28.3 p -154.59 68.75 0.73 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.526 HG11 ' CZ2' ' A' ' 31' ' ' TRP . 3.5 t -73.4 -23.29 19.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.548 1.155 . . . . 0.0 109.368 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.06 -8.37 53.9 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.51 1.131 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.92 23.75 26.96 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 m -146.92 97.69 2.93 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.55 0.794 . . . . 0.0 110.399 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.499 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 3.3 m -57.2 140.29 50.09 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.445 1.091 . . . . 0.0 108.312 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -78.75 -0.25 29.55 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.506 1.129 . . . . 0.0 109.253 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.1 t -124.62 144.99 47.95 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.455 1.097 . . . . 0.0 110.423 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.99 179.8 5.73 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.508 1.794 . . . . 0.0 110.983 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.07 52.42 2.68 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.458 1.099 . . . . 0.0 110.997 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -124.03 176.41 6.37 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 29' ' ' CYS . 3.1 m -137.8 75.92 1.55 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.494 1.122 . . . . 0.0 110.391 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.435 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.9 t -39.05 113.98 0.36 Allowed 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.544 1.153 . . . . 0.0 108.237 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 1.4 p -120.27 -20.02 7.46 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.483 1.114 . . . . 0.0 109.959 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.667 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.42 134.26 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.667 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.01 -19.65 17.37 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 121.011 -2.496 . . . . 0.0 110.946 0.069 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.6 t -110.76 149.01 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.492 1.12 . . . . 0.0 109.289 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.499 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 2.7 p -83.44 169.43 15.55 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 124.521 1.138 . . . . 0.0 108.27 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.414 ' O ' ' N ' ' A' ' 28' ' ' THR . 25.3 p -129.06 -177.99 4.45 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.477 1.111 . . . . 0.0 110.376 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.326 -0.441 0 O-C-N 124.43 1.081 . . . . 0.0 110.257 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.9 p-10 . . . . . 0 N--CA 1.453 -0.299 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.429 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -135.9 -72.47 0.07 OUTLIER Glycine 0 CA--C 1.53 1.018 0 O-C-N 124.488 1.117 . . . . 0.0 110.935 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -137.09 162.97 52.53 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.454 0.738 . . . . 0.0 109.336 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HA ' ' CG2' ' A' ' 35' ' ' THR . 18.0 Cg_endo -75.01 57.04 4.44 Favored 'Trans proline' 0 C--N 1.359 1.122 0 O-C-N 124.472 1.775 . . . . 0.0 110.943 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.78 12.59 4.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 O-C-N 124.451 1.095 . . . . 0.0 109.302 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.4 ' SG ' HG22 ' A' ' 24' ' ' THR . 1.4 t -44.41 -39.35 4.63 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.487 1.117 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.53 -1.66 62.17 Favored Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.444 1.09 . . . . 0.0 110.986 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -128.4 173.47 10.17 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.489 0.758 . . . . 0.0 110.331 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.04 175.04 8.01 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.488 1.118 . . . . 0.0 110.447 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.587 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 4.6 p -155.18 72.58 0.83 Allowed 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.478 1.111 . . . . 0.0 108.281 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.52 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.8 t -78.73 -24.33 13.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 O-C-N 124.544 1.152 . . . . 0.0 109.321 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.69 -9.49 64.36 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.459 1.099 . . . . 0.0 110.951 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.7 24.85 24.59 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.447 ' O ' ' CG2' ' A' ' 21' ' ' THR . 15.1 t -146.87 103.45 3.63 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.489 0.758 . . . . 0.0 110.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.9 OUTLIER -52.41 130.24 30.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.442 1.089 . . . . 0.0 108.299 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -77.79 -0.84 28.65 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.474 1.109 . . . . 0.0 109.325 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.4 HG22 ' SG ' ' A' ' 13' ' ' CYS . 14.1 t -130.31 143.82 50.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.591 1.182 . . . . 0.0 110.385 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.98 -178.56 4.25 Favored 'Trans proline' 0 C--N 1.36 1.148 0 O-C-N 124.535 1.808 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.54 39.95 0.62 Allowed Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.486 1.116 . . . . 0.0 111.031 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.05 176.45 5.09 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.456 ' N ' ' O ' ' A' ' 35' ' ' THR . 2.9 m -135.9 70.72 1.42 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.401 1.063 . . . . 0.0 110.417 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.467 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 31.9 t -42.59 116.4 0.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.566 1.166 . . . . 0.0 108.25 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 18.0 m -123.12 -11.36 8.04 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.444 1.09 . . . . 0.0 110.017 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.642 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.33 135.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.979 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.642 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.96 -23.72 12.26 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 121.064 -2.473 . . . . 0.0 110.984 -0.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.41 ' HA ' HG21 ' A' ' 16' ' ' THR . 0.1 OUTLIER -110.37 146.47 15.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.53 1.144 . . . . 0.0 109.278 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 10.6 p -77.54 173.68 11.73 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.455 1.097 . . . . 0.0 108.344 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 63.4 p -136.74 -177.3 4.68 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.489 1.118 . . . . 0.0 110.398 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.429 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.528 0 O-C-N 124.578 1.174 . . . . 0.0 110.319 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' A' ' 36' ' ' ARG . 20.1 p30 . . . . . 0 N--CA 1.454 -0.275 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.14 -63.63 0.32 Allowed Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.549 1.156 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -53.62 110.89 2.29 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.512 0.772 . . . . 0.0 109.316 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 77.7 3.06 Favored 'Trans proline' 0 C--N 1.361 1.201 0 O-C-N 124.436 1.756 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -140.77 24.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.525 1.14 . . . . 0.0 109.297 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 56.2 m -69.7 -45.5 68.12 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.508 1.13 . . . . 0.0 108.282 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.8 -10.39 72.39 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.522 1.139 . . . . 0.0 110.966 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 1.1 tp10 -112.68 175.46 5.43 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.482 0.754 . . . . 0.0 110.309 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -125.92 177.26 6.42 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.483 1.114 . . . . 0.0 110.414 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.9 p -154.58 71.86 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 O-C-N 124.456 1.097 . . . . 0.0 108.236 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.528 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -76.95 -23.09 14.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.533 1.145 . . . . 0.0 109.31 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.99 -8.74 56.67 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.548 1.155 . . . . 0.0 111.019 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.74 23.0 26.93 Favored Glycine 0 CA--C 1.531 1.065 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 m -149.18 91.43 1.84 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.56 0.8 . . . . 0.0 110.358 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.4 p -50.02 153.7 1.3 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.541 1.151 . . . . 0.0 108.353 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.18 -0.73 57.68 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.478 1.111 . . . . 0.0 109.355 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 7.8 t -117.64 146.17 38.07 Favored Pre-proline 0 C--N 1.326 -0.435 0 O-C-N 124.481 1.113 . . . . 0.0 110.389 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.2 Cg_endo -74.99 177.95 7.9 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.549 1.815 . . . . 0.0 110.995 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 34.71 51.7 0.79 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.567 1.167 . . . . 0.0 111.047 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.472 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -121.92 159.06 27.66 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.5 ' CG2' ' O ' ' A' ' 28' ' ' THR . 1.0 OUTLIER -120.32 72.83 0.96 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.447 1.092 . . . . 0.0 110.402 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.451 ' C ' ' O ' ' A' ' 28' ' ' THR . 41.8 t -38.55 118.88 0.78 Allowed 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.536 1.147 . . . . 0.0 108.285 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 31' ' ' TRP . 46.3 t -120.63 -16.36 8.28 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.474 1.109 . . . . 0.0 110.002 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.655 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 134.99 0.04 OUTLIER Pre-proline 0 C--N 1.326 -0.43 0 O-C-N 124.493 1.12 . . . . 0.0 108.006 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.655 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.96 -21.17 15.64 Favored 'Cis proline' 0 C--N 1.36 1.145 0 C-N-CA 121.027 -2.489 . . . . 0.0 110.98 0.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -110.97 148.33 14.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.489 1.118 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.488 ' SG ' ' N ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -67.05 177.98 1.56 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.531 1.144 . . . . 0.0 108.305 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.488 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 8.4 p -146.24 161.53 40.07 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.543 1.152 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.442 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 2.8 ttp85 . . . . . 0 C--N 1.325 -0.471 0 O-C-N 124.47 1.106 . . . . 0.0 110.346 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.05 -55.13 0.36 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.464 1.103 . . . . 0.0 111.046 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.458 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 3.8 mt -62.9 114.97 14.05 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.476 0.751 . . . . 0.0 109.372 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 81.26 2.25 Favored 'Trans proline' 0 C--N 1.36 1.137 0 O-C-N 124.503 1.791 . . . . 0.0 110.937 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m -147.84 23.64 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.531 1.144 . . . . 0.0 109.276 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.412 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -66.51 -53.95 29.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.485 1.115 . . . . 0.0 108.3 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.531 1.041 0 O-C-N 124.458 1.099 . . . . 0.0 111.019 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.423 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 9.1 mp0 -124.96 141.99 51.77 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.605 0.826 . . . . 0.0 110.245 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.429 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.02 173.67 7.31 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.495 1.122 . . . . 0.0 110.425 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.569 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 20.6 p -151.81 73.46 1.06 Allowed 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.523 1.139 . . . . 0.0 108.243 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.522 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -79.62 -24.62 12.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 124.561 1.163 . . . . 0.0 109.348 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.73 -13.29 55.49 Favored Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.515 1.134 . . . . 0.0 111.004 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.1 17.78 19.36 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 m -143.23 94.98 2.69 Favored 'General case' 0 C--N 1.326 -0.438 0 O-C-N 124.478 0.752 . . . . 0.0 110.375 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 12.7 p -45.99 -31.09 2.06 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.523 1.139 . . . . 0.0 108.316 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.482 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 21.4 t30 80.72 -1.36 1.86 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.429 1.081 . . . . 0.0 109.285 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.445 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.0 t -119.72 147.81 44.75 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.47 1.106 . . . . 0.0 110.342 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.445 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.02 173.16 15.0 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.485 1.782 . . . . 0.0 110.994 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.91 44.91 1.52 Allowed Glycine 0 CA--C 1.529 0.963 0 O-C-N 124.487 1.117 . . . . 0.0 110.977 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.48 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -118.48 160.77 21.14 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 29' ' ' CYS . 2.0 m -129.57 70.31 1.42 Allowed 'General case' 0 C--N 1.324 -0.515 0 O-C-N 124.496 1.122 . . . . 0.0 110.388 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.447 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -38.55 113.35 0.29 Allowed 'General case' 0 C--N 1.323 -0.553 0 O-C-N 124.572 1.17 . . . . 0.0 108.23 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -118.93 -14.72 9.4 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.528 1.143 . . . . 0.0 110.056 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.63 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.49 136.38 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 107.935 179.92 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.63 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -75.01 -19.86 17.15 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 121.057 -2.476 . . . . 0.0 110.977 0.056 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.89 149.2 14.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.542 1.151 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.48 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -68.46 171.27 7.63 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.484 1.115 . . . . 0.0 108.333 179.919 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.402 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 33.6 p -135.21 166.58 22.76 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.137 . . . . 0.0 110.435 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.458 ' CG ' ' HB2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.473 0 O-C-N 124.507 1.129 . . . . 0.0 110.309 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.93 45.16 4.91 Favored Glycine 0 CA--C 1.53 1.007 0 O-C-N 124.47 1.106 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 mt -128.58 125.62 23.18 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.543 0.79 . . . . 0.0 109.289 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -75.04 55.47 3.98 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.528 1.804 . . . . 0.0 110.977 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 m -144.25 17.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.597 1.186 . . . . 0.0 109.256 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 51.1 t -48.94 -26.58 2.57 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.52 1.138 . . . . 0.0 108.304 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.99 -11.54 56.94 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.436 1.085 . . . . 0.0 111.017 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.41 ' HB2' ' OG1' ' A' ' 24' ' ' THR . 4.4 mm-40 -124.58 145.51 49.56 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.502 0.766 . . . . 0.0 110.276 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.401 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -95.84 179.69 5.01 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.551 1.157 . . . . 0.0 110.399 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.604 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 32.0 p -156.69 69.16 0.6 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.506 1.129 . . . . 0.0 108.262 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.93 -22.0 15.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.598 1.186 . . . . 0.0 109.327 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.85 -8.28 34.69 Favored Glycine 0 CA--C 1.531 1.032 0 O-C-N 124.49 1.119 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.74 19.8 28.36 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.0 m -124.53 72.37 1.2 Allowed 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.499 0.764 . . . . 0.0 110.401 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.7 p -41.42 -36.07 0.79 Allowed 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.529 1.143 . . . . 0.0 108.357 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.5 t30 60.91 21.9 12.09 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 124.565 1.165 . . . . 0.0 109.297 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.479 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -116.76 151.0 46.73 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.363 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.479 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.3 Cg_endo -75.0 139.65 24.51 Favored 'Trans proline' 0 C--N 1.36 1.17 0 O-C-N 124.448 1.762 . . . . 0.0 111.002 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.6 50.45 8.33 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.464 1.103 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -109.75 169.6 8.61 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.623 ' O ' ' C ' ' A' ' 29' ' ' CYS . 13.4 t -139.68 63.62 1.48 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.427 1.079 . . . . 0.0 110.461 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.623 ' C ' ' O ' ' A' ' 28' ' ' THR . 39.2 t -24.05 116.55 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.604 1.19 . . . . 0.0 108.34 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 40.5 t -119.51 -13.8 9.18 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.571 1.169 . . . . 0.0 109.989 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.637 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.54 137.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.478 0 O-C-N 124.58 1.175 . . . . 0.0 107.986 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.637 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -74.98 -19.27 17.75 Favored 'Cis proline' 0 C--N 1.36 1.183 0 C-N-CA 120.975 -2.51 . . . . 0.0 110.933 0.017 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.8 t -110.7 152.4 12.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.556 1.16 . . . . 0.0 109.21 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.2 158.0 22.5 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.532 1.145 . . . . 0.0 108.275 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 28' ' ' THR . 0.9 OUTLIER -126.37 152.83 45.76 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.501 1.126 . . . . 0.0 110.401 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 8.9 mtp180 . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.482 1.114 . . . . 0.0 110.339 179.932 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.85 -53.61 0.57 Allowed Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.557 1.161 . . . . 0.0 110.938 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -57.45 109.54 1.83 Allowed Pre-proline 0 C--N 1.325 -0.468 0 O-C-N 124.444 0.732 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.97 69.29 5.57 Favored 'Trans proline' 0 C--N 1.36 1.171 0 O-C-N 124.486 1.782 . . . . 0.0 111.03 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 m -135.32 20.77 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.469 1.106 . . . . 0.0 109.288 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 17.6 m -63.35 -43.39 97.84 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.474 1.109 . . . . 0.0 108.3 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.87 -6.44 82.85 Favored Glycine 0 CA--C 1.529 0.923 0 O-C-N 124.474 1.109 . . . . 0.0 110.993 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -120.3 141.53 49.93 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.456 0.739 . . . . 0.0 110.268 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.413 ' O ' ' HA ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER -96.28 176.56 6.02 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.454 1.096 . . . . 0.0 110.383 -179.965 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.61 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.4 p -152.2 74.15 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.447 1.092 . . . . 0.0 108.316 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.521 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -80.37 -21.91 11.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.443 1.089 . . . . 0.0 109.286 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.67 -10.56 43.39 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.448 1.092 . . . . 0.0 111.035 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.8 18.36 25.42 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.599 0.823 . . . . 0.0 111.047 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.417 ' C ' ' N ' ' A' ' 23' ' ' ASN . 57.2 m -137.31 86.26 2.18 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.526 0.78 . . . . 0.0 110.391 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.462 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 0.8 OUTLIER -41.79 -31.89 0.35 Allowed 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.462 1.101 . . . . 0.0 108.263 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.462 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 5.8 t-20 79.61 -1.7 2.15 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 109.261 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.434 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 5.0 t -119.57 147.89 44.66 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.533 1.146 . . . . 0.0 110.414 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 174.05 13.44 Favored 'Trans proline' 0 C--N 1.36 1.146 0 O-C-N 124.421 1.748 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.69 47.19 1.2 Allowed Glycine 0 CA--C 1.53 0.98 0 O-C-N 124.422 1.076 . . . . 0.0 111.049 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.481 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -127.26 148.88 50.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.974 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.551 ' CG2' ' O ' ' A' ' 28' ' ' THR . 9.5 t -119.74 70.47 0.86 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.499 1.125 . . . . 0.0 110.414 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.491 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.6 t -34.5 117.2 0.35 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.459 1.099 . . . . 0.0 108.305 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 22.5 p -119.6 -12.43 9.29 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.459 1.099 . . . . 0.0 110.034 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.643 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.73 137.02 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.462 0 O-C-N 124.511 1.132 . . . . 0.0 107.988 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.643 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.04 -20.89 16.05 Favored 'Cis proline' 0 C--N 1.361 1.223 0 C-N-CA 120.969 -2.513 . . . . 0.0 111.01 0.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.81 148.99 17.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 O-C-N 124.468 1.105 . . . . 0.0 109.289 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.481 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -67.09 177.31 1.8 Allowed 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.579 1.174 . . . . 0.0 108.349 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.471 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 1.0 OUTLIER -147.29 151.71 37.07 Favored 'General case' 0 C--N 1.323 -0.546 0 O-C-N 124.538 1.149 . . . . 0.0 110.443 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.519 1.137 . . . . 0.0 110.246 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.47 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -150.16 -92.65 0.1 OUTLIER Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.54 1.15 . . . . 0.0 110.981 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.86 158.39 35.06 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.485 0.756 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 74.24 4.07 Favored 'Trans proline' 0 C--N 1.36 1.183 0 O-C-N 124.445 1.76 . . . . 0.0 110.981 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 m -131.46 15.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 O-C-N 124.492 1.12 . . . . 0.0 109.268 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.415 ' SG ' ' CB ' ' A' ' 24' ' ' THR . 9.7 t -51.04 -42.85 60.75 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.513 1.133 . . . . 0.0 108.342 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.75 62.74 Favored Glycine 0 CA--C 1.529 0.949 0 O-C-N 124.559 1.162 . . . . 0.0 111.033 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -130.83 173.13 11.26 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.517 0.775 . . . . 0.0 110.315 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.468 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.05 173.88 6.82 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.511 1.132 . . . . 0.0 110.402 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.593 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 23.3 p -151.78 67.43 0.88 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.501 1.125 . . . . 0.0 108.276 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.523 ' HA ' ' CE2' ' A' ' 31' ' ' TRP . 4.2 t -73.97 -20.88 17.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 O-C-N 124.474 1.109 . . . . 0.0 109.306 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.51 -10.56 28.92 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.513 1.133 . . . . 0.0 111.019 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.3 17.85 20.98 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 m -129.68 87.43 2.54 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.432 0.724 . . . . 0.0 110.418 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' THR . 26.5 p -53.45 -39.28 64.31 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 124.446 1.091 . . . . 0.0 108.343 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 69.64 8.19 6.61 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.524 1.14 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.484 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -104.27 150.46 38.42 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.539 1.149 . . . . 0.0 110.36 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.484 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.99 139.79 24.72 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.563 1.822 . . . . 0.0 110.968 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 47.25 50.42 17.08 Favored Glycine 0 CA--C 1.529 0.939 0 O-C-N 124.462 1.101 . . . . 0.0 110.988 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.75 165.6 13.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.98 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.641 ' CG2' ' O ' ' A' ' 28' ' ' THR . 2.6 t -137.24 90.82 2.56 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.538 1.149 . . . . 0.0 110.424 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.438 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.6 t -38.49 112.82 0.25 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.427 1.08 . . . . 0.0 108.268 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.7 t -116.45 -21.14 9.37 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.452 1.095 . . . . 0.0 109.982 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.664 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.35 136.28 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 108.043 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.664 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.99 -16.42 21.19 Favored 'Cis proline' 0 C--N 1.359 1.12 0 C-N-CA 121.025 -2.49 . . . . 0.0 110.983 0.064 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.05 150.72 18.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.486 1.117 . . . . 0.0 109.284 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 27' ' ' CYS . 1.4 p -82.69 162.51 21.79 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.443 1.089 . . . . 0.0 108.296 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.433 ' OG1' HG21 ' A' ' 28' ' ' THR . 16.8 p -131.97 178.21 6.95 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.527 1.142 . . . . 0.0 110.377 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.47 ' C ' ' N ' ' A' ' 9' ' ' GLY . 4.7 mtp180 . . . . . 0 C--N 1.325 -0.481 0 O-C-N 124.571 1.17 . . . . 0.0 110.341 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 . . . . . 0 N--CA 1.453 -0.321 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.481 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -149.14 -60.39 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.536 1.147 . . . . 0.0 110.994 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.408 HD21 ' CD ' ' A' ' 11' ' ' PRO . 27.1 mt -141.84 160.53 55.58 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.529 0.782 . . . . 0.0 109.326 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.408 ' CD ' HD21 ' A' ' 10' ' ' LEU . 18.3 Cg_endo -74.98 70.84 5.18 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.416 1.745 . . . . 0.0 111.023 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 m -127.71 16.61 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.476 1.11 . . . . 0.0 109.313 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -46.1 87.35 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.543 1.152 . . . . 0.0 108.381 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.73 -5.88 76.86 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -116.7 165.46 13.25 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.425 0.721 . . . . 0.0 110.327 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.424 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -118.52 174.22 6.38 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.521 1.138 . . . . 0.0 110.319 -179.912 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.532 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 8.6 p -153.89 72.33 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.5 1.125 . . . . 0.0 108.312 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.53 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -77.83 -25.06 14.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.558 1.162 . . . . 0.0 109.331 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.2 -11.71 64.38 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.525 1.14 . . . . 0.0 110.966 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.81 22.02 19.44 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.1 m -157.85 97.05 1.53 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.52 0.777 . . . . 0.0 110.445 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 24' ' ' THR . 17.4 p -47.84 165.29 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.565 1.165 . . . . 0.0 108.274 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -97.16 -0.77 46.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.437 1.086 . . . . 0.0 109.311 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.439 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.9 t -117.53 147.53 40.96 Favored Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.536 1.147 . . . . 0.0 110.383 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.439 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.97 174.57 12.55 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.538 1.809 . . . . 0.0 110.996 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.41 51.6 1.34 Allowed Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.481 1.113 . . . . 0.0 110.96 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -115.75 162.78 16.79 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 179.943 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 29' ' ' CYS . 8.3 m -120.92 68.35 0.87 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.491 1.12 . . . . 0.0 110.364 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 28' ' ' THR . 49.3 t -40.99 115.49 0.6 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.481 1.113 . . . . 0.0 108.313 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.435 ' O ' ' O ' ' A' ' 31' ' ' TRP . 23.1 t -120.32 -14.4 8.76 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.498 1.124 . . . . 0.0 110.057 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.648 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.14 135.74 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.648 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -74.95 -21.16 15.63 Favored 'Cis proline' 0 C--N 1.359 1.112 0 C-N-CA 121.029 -2.488 . . . . 0.0 111.001 -0.01 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.55 149.15 13.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.493 1.12 . . . . 0.0 109.274 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -71.24 177.46 3.85 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.52 1.138 . . . . 0.0 108.255 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.458 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 41.6 p -141.05 167.2 22.75 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.472 1.108 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.481 ' C ' ' N ' ' A' ' 9' ' ' GLY . 12.3 ttp85 . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.562 1.164 . . . . 0.0 110.21 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.38 43.49 0.29 Allowed Glycine 0 CA--C 1.529 0.936 0 O-C-N 124.487 1.117 . . . . 0.0 111.06 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' HG21 ' A' ' 35' ' ' THR . 23.3 mt -141.32 109.72 6.31 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.399 0.705 . . . . 0.0 109.309 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 56.51 4.26 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.458 1.767 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -138.38 21.37 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 124.515 1.135 . . . . 0.0 109.307 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -46.09 86.61 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.576 1.172 . . . . 0.0 108.278 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.84 -7.17 62.8 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.105 . . . . 0.0 110.935 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -124.44 147.87 48.01 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.523 0.778 . . . . 0.0 110.288 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.415 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -101.42 179.38 4.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.462 1.101 . . . . 0.0 110.374 -179.935 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.6 p -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.453 1.096 . . . . 0.0 108.319 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.543 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -79.83 -23.46 11.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.519 1.137 . . . . 0.0 109.367 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.96 -11.2 37.88 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.538 1.149 . . . . 0.0 111.002 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.46 18.93 26.84 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.428 ' O ' ' C ' ' A' ' 22' ' ' CYS . 5.4 t -123.17 76.61 1.4 Allowed 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.504 0.767 . . . . 0.0 110.38 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.601 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 41.9 t -39.99 -45.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.556 1.16 . . . . 0.0 108.312 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 68.52 8.96 7.01 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.522 1.139 . . . . 0.0 109.296 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.494 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -107.74 151.22 41.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.493 1.12 . . . . 0.0 110.42 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.494 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.01 140.76 25.8 Favored 'Trans proline' 0 C--N 1.36 1.161 0 O-C-N 124.529 1.805 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.68 50.8 5.8 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 124.527 1.142 . . . . 0.0 111.018 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.447 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -112.18 163.64 14.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.569 ' O ' ' C ' ' A' ' 29' ' ' CYS . 8.0 t -133.67 69.32 1.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.478 1.111 . . . . 0.0 110.363 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.569 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.6 t -28.56 119.5 0.12 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.478 1.111 . . . . 0.0 108.292 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 31' ' ' TRP . 53.7 p -120.54 -14.57 8.63 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.473 1.108 . . . . 0.0 109.975 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.64 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 136.67 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.64 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.5 Cg_endo -74.93 -20.87 15.96 Favored 'Cis proline' 0 C--N 1.361 1.187 0 C-N-CA 121.007 -2.497 . . . . 0.0 111.027 -0.065 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -113.34 148.46 16.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 O-C-N 124.432 1.083 . . . . 0.0 109.282 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.601 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER -65.62 177.92 1.11 Allowed 'General case' 0 C--N 1.326 -0.427 0 O-C-N 124.45 1.094 . . . . 0.0 108.274 -179.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.468 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -151.67 158.21 43.13 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.514 1.134 . . . . 0.0 110.36 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 . . . . . 0 C--N 1.326 -0.444 0 O-C-N 124.459 1.1 . . . . 0.0 110.343 -179.944 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.468 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -131.27 -71.78 0.1 Allowed Glycine 0 CA--C 1.53 0.989 0 O-C-N 124.477 1.11 . . . . 0.0 110.978 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.25 159.74 65.0 Favored Pre-proline 0 C--N 1.325 -0.473 0 O-C-N 124.457 0.74 . . . . 0.0 109.341 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 67.18 5.98 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.511 1.796 . . . . 0.0 111.033 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.0 m -137.83 26.68 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.549 1.155 . . . . 0.0 109.258 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.449 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.5 OUTLIER -58.72 -36.42 74.27 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.506 1.129 . . . . 0.0 108.29 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.48 -11.24 64.23 Favored Glycine 0 CA--C 1.529 0.913 0 O-C-N 124.532 1.145 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.495 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -116.55 169.54 9.26 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.433 0.725 . . . . 0.0 110.334 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.422 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.61 173.47 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.419 1.074 . . . . 0.0 110.348 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.567 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 7.0 p -150.13 60.53 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.471 1.107 . . . . 0.0 108.228 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.543 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.6 t -70.45 -23.7 24.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 O-C-N 124.476 1.11 . . . . 0.0 109.324 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.77 -7.46 55.47 Favored Glycine 0 CA--C 1.531 1.059 0 O-C-N 124.467 1.104 . . . . 0.0 110.984 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.88 19.8 23.29 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.487 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.8 t -137.8 94.67 2.93 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.551 0.795 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 25.9 p -54.87 -32.88 61.28 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.517 1.136 . . . . 0.0 108.251 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 63.41 13.14 6.87 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.472 1.107 . . . . 0.0 109.292 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.496 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -108.49 151.53 41.64 Favored Pre-proline 0 C--N 1.325 -0.486 0 O-C-N 124.466 1.104 . . . . 0.0 110.419 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.496 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.5 Cg_endo -74.9 141.42 26.93 Favored 'Trans proline' 0 C--N 1.359 1.096 0 O-C-N 124.475 1.776 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.42 50.95 4.62 Favored Glycine 0 CA--C 1.53 1.026 0 O-C-N 124.43 1.081 . . . . 0.0 111.026 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.449 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -109.28 163.62 13.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.599 ' O ' ' C ' ' A' ' 29' ' ' CYS . 13.8 t -129.75 61.24 1.57 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.533 1.145 . . . . 0.0 110.427 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.599 ' C ' ' O ' ' A' ' 28' ' ' THR . 22.6 t -26.09 117.36 0.07 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.546 1.154 . . . . 0.0 108.314 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -120.19 -14.23 8.83 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.428 1.08 . . . . 0.0 109.968 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.656 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.53 138.01 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.512 1.133 . . . . 0.0 107.983 179.965 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.656 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.03 -19.71 17.33 Favored 'Cis proline' 0 C--N 1.36 1.15 0 C-N-CA 121.054 -2.478 . . . . 0.0 110.94 0.029 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.8 t -113.67 147.93 16.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.485 1.116 . . . . 0.0 109.307 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -77.22 174.0 11.24 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.459 1.1 . . . . 0.0 108.303 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.1 p -145.01 164.64 30.54 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.539 1.149 . . . . 0.0 110.397 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.468 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.478 0 O-C-N 124.507 1.129 . . . . 0.0 110.306 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.26 -39.84 1.68 Allowed Glycine 0 CA--C 1.529 0.942 0 O-C-N 124.544 1.152 . . . . 0.0 111.021 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -61.95 113.49 8.64 Favored Pre-proline 0 C--N 1.325 -0.457 0 O-C-N 124.437 0.728 . . . . 0.0 109.271 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.42 ' CA ' HG22 ' A' ' 35' ' ' THR . 18.5 Cg_endo -75.08 64.97 6.15 Favored 'Trans proline' 0 C--N 1.36 1.165 0 O-C-N 124.479 1.778 . . . . 0.0 110.983 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -138.85 21.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.435 1.085 . . . . 0.0 109.335 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 26.7 t -57.96 -41.96 83.98 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.475 1.109 . . . . 0.0 108.283 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.65 -7.68 68.27 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.434 ' CG ' HG21 ' A' ' 24' ' ' THR . 15.4 mm-40 -124.03 155.89 37.48 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.466 0.745 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.415 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -105.52 176.63 5.1 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.566 1.166 . . . . 0.0 110.459 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.2 p -154.46 68.76 0.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.52 1.138 . . . . 0.0 108.329 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.538 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -74.78 -21.32 16.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.533 1.145 . . . . 0.0 109.338 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.95 -6.31 40.12 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.552 1.158 . . . . 0.0 111.035 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.82 21.46 28.41 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 2.5 m -131.7 79.4 1.87 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.538 0.787 . . . . 0.0 110.428 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.5 p -45.16 -30.94 1.27 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.54 1.15 . . . . 0.0 108.36 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 59.86 16.01 5.34 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.477 1.111 . . . . 0.0 109.312 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.493 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -111.3 150.3 41.84 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.498 1.124 . . . . 0.0 110.393 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.493 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.09 141.54 26.51 Favored 'Trans proline' 0 C--N 1.359 1.103 0 O-C-N 124.52 1.8 . . . . 0.0 111.009 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.84 50.1 5.08 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.506 1.129 . . . . 0.0 110.95 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.406 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -107.13 175.52 5.47 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.484 ' O ' ' CG2' ' A' ' 28' ' ' THR . 1.1 m -141.33 72.15 1.38 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.457 1.098 . . . . 0.0 110.357 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.7 t -38.81 114.56 0.4 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.521 1.138 . . . . 0.0 108.305 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 15.9 t -120.89 -12.09 8.85 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.552 1.158 . . . . 0.0 110.009 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.629 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.46 137.26 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.52 1.138 . . . . 0.0 108.007 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.629 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -74.97 -19.72 17.25 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.058 -2.476 . . . . 0.0 110.99 -0.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.1 t -113.84 150.27 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.263 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -77.62 166.59 22.83 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.482 1.113 . . . . 0.0 108.366 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 28' ' ' THR . 3.0 p -133.36 174.58 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.51 1.131 . . . . 0.0 110.375 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 . . . . . 0 C--N 1.324 -0.524 0 O-C-N 124.527 1.142 . . . . 0.0 110.36 179.932 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.23 -48.62 0.7 Allowed Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.532 1.145 . . . . 0.0 111.009 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -61.5 111.73 4.83 Favored Pre-proline 0 C--N 1.324 -0.525 0 O-C-N 124.585 0.815 . . . . 0.0 109.311 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -75.05 69.39 5.6 Favored 'Trans proline' 0 C--N 1.361 1.186 0 O-C-N 124.43 1.753 . . . . 0.0 110.967 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.57 21.79 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 O-C-N 124.483 1.114 . . . . 0.0 109.299 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 5.3 t -60.76 -46.08 91.82 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.535 1.147 . . . . 0.0 108.346 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.21 -5.63 65.67 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.452 1.095 . . . . 0.0 110.944 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -123.35 146.15 48.17 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.49 0.759 . . . . 0.0 110.354 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.44 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.81 175.47 5.95 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.409 1.068 . . . . 0.0 110.41 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.56 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.2 p -153.93 65.9 0.72 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 108.27 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.535 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -71.86 -22.39 21.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 O-C-N 124.388 1.055 . . . . 0.0 109.327 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.08 -7.19 50.53 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.491 1.119 . . . . 0.0 110.994 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.97 21.34 23.51 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 22.9 m -138.39 93.71 2.77 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.447 0.733 . . . . 0.0 110.387 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 7.4 p -47.33 -37.6 11.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.384 1.053 . . . . 0.0 108.283 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.494 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER 82.43 -1.05 1.38 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.56 1.162 . . . . 0.0 109.311 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.9 t -127.83 144.53 51.64 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.492 1.12 . . . . 0.0 110.436 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -75.05 179.42 6.12 Favored 'Trans proline' 0 C--N 1.359 1.116 0 O-C-N 124.505 1.792 . . . . 0.0 110.969 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 40.84 32.15 0.5 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.511 1.132 . . . . 0.0 111.019 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -115.43 166.47 11.85 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 35' ' ' THR . 17.3 m -136.64 74.43 1.49 Allowed 'General case' 0 C--N 1.324 -0.516 0 O-C-N 124.574 1.171 . . . . 0.0 110.385 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.427 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.8 t -39.93 109.78 0.12 Allowed 'General case' 0 C--N 1.326 -0.444 0 O-C-N 124.463 1.102 . . . . 0.0 108.322 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.1 OUTLIER -118.1 -11.27 10.19 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.495 1.122 . . . . 0.0 109.996 179.979 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.614 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.73 137.62 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.546 1.154 . . . . 0.0 108.028 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.614 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.99 -20.09 16.87 Favored 'Cis proline' 0 C--N 1.359 1.114 0 C-N-CA 121.026 -2.489 . . . . 0.0 111.001 0.016 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -114.56 148.76 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.492 1.12 . . . . 0.0 109.411 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 21.1 p -74.77 160.18 31.05 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.46 ' O ' ' N ' ' A' ' 28' ' ' THR . 23.3 p -127.35 -177.86 4.23 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.52 1.138 . . . . 0.0 110.383 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 . . . . . 0 C--N 1.324 -0.506 0 O-C-N 124.533 1.146 . . . . 0.0 110.322 179.963 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.1 p-10 . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.48 -51.12 0.63 Allowed Glycine 0 CA--C 1.53 0.978 0 O-C-N 124.484 1.115 . . . . 0.0 111.047 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.8 mt -56.22 114.73 8.17 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.46 0.741 . . . . 0.0 109.297 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 70.86 5.16 Favored 'Trans proline' 0 C--N 1.361 1.191 0 O-C-N 124.446 1.761 . . . . 0.0 111.002 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.1 m -142.24 22.82 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.494 1.121 . . . . 0.0 109.302 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.6 t -55.94 -43.96 77.93 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.559 1.162 . . . . 0.0 108.239 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.19 -6.13 61.51 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.505 1.128 . . . . 0.0 110.971 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -125.57 175.15 7.75 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.512 0.772 . . . . 0.0 110.363 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.419 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.4 OUTLIER -122.52 176.08 6.11 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 124.493 1.121 . . . . 0.0 110.432 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.605 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 27.3 p -153.36 66.7 0.77 Allowed 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.454 1.096 . . . . 0.0 108.312 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.536 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -73.8 -22.82 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.49 1.119 . . . . 0.0 109.362 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.06 -10.97 44.22 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.466 1.104 . . . . 0.0 111.021 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 103.65 16.17 20.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.475 ' CG2' ' O ' ' A' ' 21' ' ' THR . 14.5 t -132.84 100.31 4.87 Favored 'General case' 0 C--N 1.326 -0.443 0 O-C-N 124.529 0.782 . . . . 0.0 110.424 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 25.8 p -59.02 -39.45 81.95 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.519 1.137 . . . . 0.0 108.301 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 69.3 10.09 7.62 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.529 1.143 . . . . 0.0 109.31 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.499 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.6 OUTLIER -107.87 150.14 39.93 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 124.502 1.126 . . . . 0.0 110.338 -179.936 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.499 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.08 141.75 26.78 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.498 1.788 . . . . 0.0 111.003 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 43.45 49.39 6.96 Favored Glycine 0 CA--C 1.531 1.04 0 O-C-N 124.5 1.125 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.2 OUTLIER -107.28 178.42 4.55 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.468 ' N ' ' O ' ' A' ' 35' ' ' THR . 1.2 m -145.01 72.22 1.32 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.498 1.124 . . . . 0.0 110.471 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.45 ' C ' ' O ' ' A' ' 28' ' ' THR . 37.2 t -38.26 113.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.525 1.141 . . . . 0.0 108.368 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 45.5 t -120.93 -12.64 8.75 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.513 1.133 . . . . 0.0 109.963 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.634 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.37 136.22 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.47 0 O-C-N 124.489 1.118 . . . . 0.0 108.003 -179.946 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -74.96 -22.0 14.51 Favored 'Cis proline' 0 C--N 1.361 1.188 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -0.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.9 t -109.32 148.79 12.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.558 1.161 . . . . 0.0 109.297 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.4 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.1 p -81.14 162.65 23.57 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.503 1.127 . . . . 0.0 108.291 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.468 ' O ' ' N ' ' A' ' 28' ' ' THR . 40.8 p -121.2 -171.98 2.31 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.484 1.115 . . . . 0.0 110.403 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 76.0 mtp180 . . . . . 0 C--N 1.325 -0.492 0 O-C-N 124.559 1.162 . . . . 0.0 110.281 -179.994 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 36' ' ' ARG . 20.6 p30 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.49 -57.32 0.66 Allowed Glycine 0 CA--C 1.53 0.988 0 O-C-N 124.49 1.119 . . . . 0.0 110.987 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 mt -52.54 109.41 1.42 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.486 0.756 . . . . 0.0 109.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 69.18 5.66 Favored 'Trans proline' 0 C--N 1.361 1.19 0 O-C-N 124.409 1.742 . . . . 0.0 110.972 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -138.5 19.98 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.297 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.408 ' SG ' ' CB ' ' A' ' 24' ' ' THR . 3.3 t -52.88 -43.53 66.2 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.527 1.142 . . . . 0.0 108.321 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.65 -3.99 63.48 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.471 1.107 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.498 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.43 173.46 9.8 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.49 0.759 . . . . 0.0 110.358 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.466 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.8 OUTLIER -120.73 178.81 4.55 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.509 1.131 . . . . 0.0 110.43 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.612 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 31.7 p -155.54 62.86 0.61 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.524 1.14 . . . . 0.0 108.328 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.535 ' HA ' ' CE2' ' A' ' 31' ' ' TRP . 3.3 t -70.34 -21.0 23.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.509 1.131 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.07 -4.15 33.57 Favored Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.535 1.147 . . . . 0.0 110.994 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.57 22.16 29.68 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 22' ' ' CYS . 49.9 m -126.69 80.5 1.94 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.482 0.754 . . . . 0.0 110.473 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 21' ' ' THR . 41.1 t -41.56 -49.16 4.07 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.424 1.077 . . . . 0.0 108.327 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.5 t30 71.27 10.0 6.65 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.471 1.107 . . . . 0.0 109.327 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.487 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -113.0 148.54 39.62 Favored Pre-proline 0 C--N 1.324 -0.502 0 O-C-N 124.439 1.087 . . . . 0.0 110.436 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.487 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 142.84 28.41 Favored 'Trans proline' 0 C--N 1.36 1.158 0 O-C-N 124.464 1.771 . . . . 0.0 111.054 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.02 49.06 7.9 Favored Glycine 0 CA--C 1.53 0.996 0 O-C-N 124.473 1.108 . . . . 0.0 110.987 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.469 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -108.92 178.11 4.57 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.477 ' O ' ' C ' ' A' ' 29' ' ' CYS . 1.2 m -145.77 73.33 1.34 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.518 1.136 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.477 ' C ' ' O ' ' A' ' 28' ' ' THR . 40.0 t -36.68 112.37 0.18 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.47 1.106 . . . . 0.0 108.258 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 16.5 t -119.97 -13.99 8.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.425 1.078 . . . . 0.0 110.001 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.631 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.59 136.72 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.523 0 O-C-N 124.564 1.165 . . . . 0.0 108.013 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.631 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -74.98 -20.99 15.88 Favored 'Cis proline' 0 C--N 1.36 1.172 0 C-N-CA 120.986 -2.506 . . . . 0.0 111.005 -0.042 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.4 t -112.62 146.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.458 1.099 . . . . 0.0 109.3 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 1.8 p -78.36 161.46 27.17 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 124.544 1.153 . . . . 0.0 108.249 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.441 ' O ' ' N ' ' A' ' 28' ' ' THR . 22.1 p -126.07 -175.99 3.52 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.526 1.141 . . . . 0.0 110.391 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.404 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.463 1.102 . . . . 0.0 110.299 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 140.7 -49.24 0.79 Allowed Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.545 1.153 . . . . 0.0 110.976 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 mt -54.79 114.15 6.47 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.568 0.805 . . . . 0.0 109.26 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -75.01 71.46 5.01 Favored 'Trans proline' 0 C--N 1.36 1.16 0 O-C-N 124.522 1.801 . . . . 0.0 111.003 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 m -142.39 23.52 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 O-C-N 124.595 1.185 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 11.8 t -64.02 -45.68 87.83 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.499 1.125 . . . . 0.0 108.32 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.33 -6.43 71.68 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 124.575 1.172 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.407 ' O ' ' SG ' ' A' ' 34' ' ' CYS . 3.4 mm-40 -121.76 144.76 48.61 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.416 0.715 . . . . 0.0 110.258 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.477 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -95.82 174.72 6.82 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.487 1.117 . . . . 0.0 110.398 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.506 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.1 p -154.28 66.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.455 1.097 . . . . 0.0 108.342 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.526 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -71.69 -22.54 21.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.585 1.178 . . . . 0.0 109.377 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.38 -7.56 45.69 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.465 1.103 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.8 20.66 23.49 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 111.016 -0.833 . . . . 0.0 111.016 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 98.4 m -136.11 94.11 3.0 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 0.773 . . . . 0.0 110.394 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 4.7 m -46.59 -38.2 9.19 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.583 1.177 . . . . 0.0 108.303 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.0 t-20 84.33 -0.93 0.97 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.506 1.129 . . . . 0.0 109.213 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -128.03 144.95 53.42 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.457 1.098 . . . . 0.0 110.378 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.92 166.05 30.07 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.418 1.747 . . . . 0.0 111.006 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 50.61 47.48 45.36 Favored Glycine 0 CA--C 1.531 1.064 0 O-C-N 124.483 1.115 . . . . 0.0 111.003 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.448 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -128.14 174.96 8.8 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 -179.995 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.449 ' O ' ' C ' ' A' ' 29' ' ' CYS . 1.3 m -145.4 82.01 1.64 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.471 1.107 . . . . 0.0 110.409 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.449 ' C ' ' O ' ' A' ' 28' ' ' THR . 34.0 t -38.29 114.43 0.36 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.52 1.138 . . . . 0.0 108.273 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.3 t -119.73 -19.79 7.89 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 109.978 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.642 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.22 135.97 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.531 0 O-C-N 124.546 1.154 . . . . 0.0 108.033 -179.922 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.642 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -75.0 -17.52 19.9 Favored 'Cis proline' 0 C--N 1.36 1.175 0 C-N-CA 121.035 -2.486 . . . . 0.0 110.963 0.052 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.0 t -114.05 148.97 16.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.547 1.155 . . . . 0.0 109.287 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.456 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 16.3 p -78.24 163.96 25.32 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.512 1.133 . . . . 0.0 108.233 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 28' ' ' THR . 44.4 p -131.17 -177.62 4.47 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.473 1.108 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 . . . . . 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.297 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.04 -36.07 2.2 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.533 1.146 . . . . 0.0 111.034 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -74.34 116.88 57.21 Favored Pre-proline 0 C--N 1.324 -0.513 0 O-C-N 124.555 0.797 . . . . 0.0 109.208 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HA ' ' CG2' ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.02 68.37 5.79 Favored 'Trans proline' 0 C--N 1.361 1.217 0 O-C-N 124.506 1.793 . . . . 0.0 111.036 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.89 16.33 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 O-C-N 124.496 1.122 . . . . 0.0 109.269 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 9.6 t -64.31 -47.65 78.63 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.434 1.084 . . . . 0.0 108.248 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.22 3.36 75.84 Favored Glycine 0 CA--C 1.529 0.935 0 O-C-N 124.58 1.175 . . . . 0.0 111.041 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.0 mm-40 -121.98 145.92 47.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.438 0.728 . . . . 0.0 110.315 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.434 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -105.75 162.77 13.24 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.509 1.131 . . . . 0.0 110.458 179.957 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' N ' ' A' ' 22' ' ' CYS . 1.2 p -135.42 53.25 1.98 Allowed 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.481 1.113 . . . . 0.0 108.325 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.51 HG11 ' CZ2' ' A' ' 31' ' ' TRP . 2.2 t -67.05 -20.85 27.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.509 1.13 . . . . 0.0 109.316 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.54 -3.16 59.83 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.464 1.102 . . . . 0.0 110.978 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.48 24.21 19.24 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.1 t -158.58 115.76 2.83 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.556 0.797 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.497 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 6.4 p -55.51 -36.1 66.33 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.496 1.122 . . . . 0.0 108.278 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.497 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.2 t30 82.53 -0.93 1.35 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 109.337 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.2 t -127.32 144.75 51.85 Favored Pre-proline 0 C--N 1.326 -0.446 0 O-C-N 124.461 1.101 . . . . 0.0 110.438 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.04 177.81 8.1 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.454 1.765 . . . . 0.0 110.986 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.83 35.89 0.7 Allowed Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.543 1.152 . . . . 0.0 111.022 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -119.44 158.19 26.72 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.494 ' O ' ' CG2' ' A' ' 28' ' ' THR . 1.1 m -125.48 71.02 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.538 1.148 . . . . 0.0 110.384 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.438 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 12.5 t -41.11 114.29 0.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.547 1.154 . . . . 0.0 108.318 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 85.4 p -125.4 -7.56 6.96 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.517 1.135 . . . . 0.0 109.985 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.631 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 61.87 138.69 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.518 0 O-C-N 124.497 1.123 . . . . 0.0 107.97 179.963 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.631 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -75.0 -20.67 16.26 Favored 'Cis proline' 0 C--N 1.36 1.165 0 C-N-CA 120.976 -2.51 . . . . 0.0 110.974 -0.007 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t -118.46 144.43 26.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.451 1.094 . . . . 0.0 109.313 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.438 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 25.4 p -71.29 164.65 25.3 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.556 1.16 . . . . 0.0 108.244 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.476 ' CG2' ' HA ' ' A' ' 11' ' ' PRO . 15.2 p -131.19 177.01 7.79 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.524 1.14 . . . . 0.0 110.396 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.513 1.133 . . . . 0.0 110.305 179.96 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 36' ' ' ARG . 24.6 t30 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.43 25.85 5.88 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.569 1.168 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.9 mt -127.12 121.34 22.72 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.46 0.741 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 60.93 5.57 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.537 1.809 . . . . 0.0 111.015 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -143.79 20.77 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.53 1.144 . . . . 0.0 109.288 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.2 t -51.31 -46.01 62.42 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.467 1.105 . . . . 0.0 108.284 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.92 -3.75 45.26 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.422 1.076 . . . . 0.0 111.037 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -130.8 171.29 13.3 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.543 0.79 . . . . 0.0 110.242 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.06 175.39 6.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.431 1.082 . . . . 0.0 110.425 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.606 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.5 p -153.13 68.91 0.82 Allowed 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.531 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.4 -23.36 16.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.516 1.135 . . . . 0.0 109.287 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.59 -12.63 50.26 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 111.022 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.23 15.13 16.68 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 t -138.02 113.16 9.25 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.453 0.737 . . . . 0.0 110.397 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 2.1 p -59.86 -35.34 74.59 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.516 1.135 . . . . 0.0 108.313 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.459 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.3 t30 79.26 -0.98 2.28 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.495 1.122 . . . . 0.0 109.272 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -124.46 145.48 49.16 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.535 1.147 . . . . 0.0 110.465 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.3 Cg_endo -75.02 176.93 9.27 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.561 1.821 . . . . 0.0 111.007 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.82 43.99 0.89 Allowed Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.441 1.088 . . . . 0.0 110.999 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -122.77 173.5 7.71 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 35' ' ' THR . 1.2 m -142.59 73.34 1.4 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.54 1.15 . . . . 0.0 110.447 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.428 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 30.5 t -41.4 117.0 0.83 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.512 1.133 . . . . 0.0 108.346 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 31' ' ' TRP . 92.2 p -124.94 -10.79 7.17 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.481 1.113 . . . . 0.0 109.99 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.653 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.16 135.61 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.46 0 O-C-N 124.505 1.128 . . . . 0.0 107.997 -179.983 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.653 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.1 Cg_endo -74.99 -23.73 12.26 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.987 -2.505 . . . . 0.0 110.952 -0.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.1 t -110.7 147.71 14.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.462 1.101 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.428 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 7.3 p -77.39 167.33 21.85 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.523 1.139 . . . . 0.0 108.297 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 28' ' ' THR . 1.4 p -124.96 172.56 9.3 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.549 1.156 . . . . 0.0 110.425 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 8' ' ' ASN . 6.6 ptm180 . . . . . 0 C--N 1.324 -0.518 0 O-C-N 124.513 1.133 . . . . 0.0 110.345 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.456 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -143.55 -89.66 0.11 Allowed Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.512 1.133 . . . . 0.0 111.002 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.48 161.74 28.5 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.517 0.775 . . . . 0.0 109.29 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 70.69 5.27 Favored 'Trans proline' 0 C--N 1.36 1.159 0 O-C-N 124.456 1.766 . . . . 0.0 110.988 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.24 20.92 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.296 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.522 ' SG ' ' CG2' ' A' ' 24' ' ' THR . 8.9 t -51.93 -40.54 60.96 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.446 1.091 . . . . 0.0 108.289 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.61 -4.65 69.45 Favored Glycine 0 CA--C 1.53 0.987 0 O-C-N 124.518 1.136 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.5 OUTLIER -125.27 173.74 8.6 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.502 0.766 . . . . 0.0 110.343 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.38 176.13 5.81 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.393 1.058 . . . . 0.0 110.382 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.598 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 10.7 p -155.93 71.57 0.74 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.609 1.193 . . . . 0.0 108.319 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.54 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.37 -24.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.537 1.148 . . . . 0.0 109.334 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -92.31 -11.58 59.57 Favored Glycine 0 CA--C 1.529 0.952 0 O-C-N 124.44 1.087 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.58 19.99 20.97 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.0 t -149.83 104.53 3.32 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.485 0.756 . . . . 0.0 110.385 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 1.9 p -55.65 147.05 19.21 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.547 1.154 . . . . 0.0 108.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -81.22 -0.7 41.76 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.507 1.13 . . . . 0.0 109.292 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.522 ' CG2' ' SG ' ' A' ' 13' ' ' CYS . 15.2 t -126.36 144.02 47.94 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.561 1.163 . . . . 0.0 110.385 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.01 -178.05 3.9 Favored 'Trans proline' 0 C--N 1.361 1.192 0 O-C-N 124.422 1.749 . . . . 0.0 110.984 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 48.27 1.7 Allowed Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.521 1.138 . . . . 0.0 111.037 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -123.75 168.37 12.79 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.483 ' O ' ' CG2' ' A' ' 28' ' ' THR . 1.1 m -127.27 71.95 1.35 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.496 1.123 . . . . 0.0 110.406 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.436 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.0 t -39.59 118.94 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.495 1.122 . . . . 0.0 108.33 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.3 OUTLIER -121.66 -14.89 8.08 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.505 1.128 . . . . 0.0 110.018 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.661 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.32 135.27 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.661 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.08 -21.83 14.82 Favored 'Cis proline' 0 C--N 1.36 1.132 0 C-N-CA 120.961 -2.516 . . . . 0.0 110.971 0.014 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.2 t -106.35 149.44 9.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.485 1.116 . . . . 0.0 109.277 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 8.0 p -84.26 171.04 13.1 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.527 1.142 . . . . 0.0 108.309 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.404 ' O ' ' N ' ' A' ' 28' ' ' THR . 22.3 p -133.33 -173.76 3.31 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.53 1.144 . . . . 0.0 110.372 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.456 ' C ' ' N ' ' A' ' 9' ' ' GLY . 2.0 ttp180 . . . . . 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.16 . . . . 0.0 110.292 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.443 ' CA ' ' HB ' ' A' ' 35' ' ' THR . . . 149.36 -52.34 0.53 Allowed Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.479 1.112 . . . . 0.0 110.963 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.33 111.64 2.71 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.533 0.784 . . . . 0.0 109.32 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -74.97 66.5 6.0 Favored 'Trans proline' 0 C--N 1.361 1.189 0 O-C-N 124.401 1.738 . . . . 0.0 110.955 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.81 20.73 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.448 1.092 . . . . 0.0 109.223 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.404 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -65.39 -47.95 74.57 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.471 1.107 . . . . 0.0 108.329 -179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.24 -5.1 78.03 Favored Glycine 0 CA--C 1.531 1.066 0 O-C-N 124.468 1.105 . . . . 0.0 111.013 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.404 ' OE2' ' O ' ' A' ' 13' ' ' CYS . 20.1 mp0 -117.89 141.69 48.15 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.497 0.763 . . . . 0.0 110.271 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.34 173.36 7.02 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.476 1.11 . . . . 0.0 110.395 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.563 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.0 p -152.28 71.63 0.96 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.594 1.184 . . . . 0.0 108.314 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.529 HG11 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.2 -22.84 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.516 1.135 . . . . 0.0 109.26 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.62 -10.35 55.58 Favored Glycine 0 CA--C 1.529 0.924 0 O-C-N 124.476 1.11 . . . . 0.0 110.995 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.13 20.05 21.91 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.516 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.6 t -143.82 93.09 2.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.507 0.769 . . . . 0.0 110.428 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.466 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 9.4 p -45.91 -31.37 2.13 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.336 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 1.5 t-20 79.57 -1.2 2.18 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.402 1.064 . . . . 0.0 109.354 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.441 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 5.8 t -118.66 147.72 42.73 Favored Pre-proline 0 C--N 1.325 -0.487 0 O-C-N 124.509 1.131 . . . . 0.0 110.475 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.3 Cg_endo -74.94 172.64 15.95 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.459 1.768 . . . . 0.0 110.961 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 45.17 1.36 Allowed Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.532 1.145 . . . . 0.0 110.997 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.447 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -118.78 161.26 20.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.467 ' O ' ' C ' ' A' ' 29' ' ' CYS . 1.5 m -130.61 70.98 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.412 1.07 . . . . 0.0 110.427 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.467 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -37.51 112.53 0.21 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.56 1.163 . . . . 0.0 108.327 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.0 p -117.16 -15.67 10.46 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.504 1.127 . . . . 0.0 109.999 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.627 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.58 136.71 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.627 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.05 -19.01 18.11 Favored 'Cis proline' 0 C--N 1.361 1.193 0 C-N-CA 120.96 -2.517 . . . . 0.0 110.947 0.049 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -112.17 149.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.405 1.066 . . . . 0.0 109.335 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.447 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -67.3 171.68 5.62 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.571 1.17 . . . . 0.0 108.305 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.443 ' HB ' ' CA ' ' A' ' 9' ' ' GLY . 34.2 p -136.55 161.73 35.06 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.5 1.125 . . . . 0.0 110.395 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.464 1.102 . . . . 0.0 110.318 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.453 -0.324 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.61 -44.24 1.24 Allowed Glycine 0 CA--C 1.531 1.043 0 O-C-N 124.499 1.124 . . . . 0.0 110.982 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.36 114.6 9.71 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.515 0.773 . . . . 0.0 109.308 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.07 67.44 5.99 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.52 1.8 . . . . 0.0 110.981 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 m -140.0 21.59 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.533 1.146 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.5 t -57.29 -43.83 83.51 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 124.504 1.128 . . . . 0.0 108.299 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.28 -5.24 71.13 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.525 1.141 . . . . 0.0 110.958 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.4 ' O ' ' SG ' ' A' ' 34' ' ' CYS . 6.7 mm-40 -124.43 143.36 50.67 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.449 0.735 . . . . 0.0 110.289 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.27 174.13 7.04 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.396 1.06 . . . . 0.0 110.416 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.583 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.9 p -152.5 74.8 1.09 Allowed 'General case' 0 C--N 1.326 -0.432 0 O-C-N 124.48 1.113 . . . . 0.0 108.273 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.482 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.0 t -81.81 -20.52 10.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.511 1.132 . . . . 0.0 109.364 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.17 -8.57 44.15 Favored Glycine 0 CA--C 1.53 1.005 0 O-C-N 124.541 1.15 . . . . 0.0 110.994 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.24 21.89 23.78 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.511 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.7 t -133.15 94.0 3.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.534 0.785 . . . . 0.0 110.414 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 2.8 t -41.7 -43.75 2.95 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.552 1.157 . . . . 0.0 108.344 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.1 t-20 83.27 -1.8 1.19 Allowed 'General case' 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 109.339 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -136.73 144.64 47.73 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.53 1.144 . . . . 0.0 110.406 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 177.6 8.38 Favored 'Trans proline' 0 C--N 1.361 1.209 0 O-C-N 124.527 1.804 . . . . 0.0 111.014 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.86 43.79 5.41 Favored Glycine 0 CA--C 1.529 0.944 0 O-C-N 124.565 1.166 . . . . 0.0 111.006 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -127.85 177.13 7.05 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.997 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.484 ' CG2' ' O ' ' A' ' 28' ' ' THR . 1.1 m -148.23 72.99 1.23 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.475 1.109 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.1 t -38.86 114.85 0.42 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 108.272 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.9 t -121.74 -11.82 8.55 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.509 1.131 . . . . 0.0 109.966 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.653 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.65 135.94 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.982 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.653 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -75.06 -22.6 13.77 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.948 -2.522 . . . . 0.0 111.033 -0.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.31 148.81 13.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.459 1.1 . . . . 0.0 109.29 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 15.6 p -79.23 163.96 24.55 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.593 1.183 . . . . 0.0 108.311 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 73.3 p -123.99 -176.88 3.6 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.542 1.152 . . . . 0.0 110.5 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.6 ttp85 . . . . . 0 C--N 1.324 -0.526 0 O-C-N 124.475 1.109 . . . . 0.0 110.333 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.25 -39.35 2.09 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.46 1.1 . . . . 0.0 110.942 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.9 mt -67.02 123.06 85.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.471 0.747 . . . . 0.0 109.29 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.01 71.85 4.86 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.509 1.794 . . . . 0.0 111.035 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.1 22.42 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.514 1.134 . . . . 0.0 109.314 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.3 t -57.08 -45.06 83.63 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.464 1.103 . . . . 0.0 108.302 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.31 -5.12 58.81 Favored Glycine 0 CA--C 1.531 1.074 0 O-C-N 124.498 1.124 . . . . 0.0 110.995 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.1 OUTLIER -126.09 175.01 8.05 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.572 0.807 . . . . 0.0 110.284 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.47 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.66 175.75 5.86 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 124.558 1.161 . . . . 0.0 110.419 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 28.3 p -154.59 68.75 0.73 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.526 HG11 ' CZ2' ' A' ' 31' ' ' TRP . 3.5 t -73.4 -23.29 19.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.548 1.155 . . . . 0.0 109.368 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.06 -8.37 53.9 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.51 1.131 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.92 23.75 26.96 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 m -146.92 97.69 2.93 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.55 0.794 . . . . 0.0 110.399 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.499 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 3.3 m -57.2 140.29 50.09 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.445 1.091 . . . . 0.0 108.312 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -78.75 -0.25 29.55 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.506 1.129 . . . . 0.0 109.253 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.1 t -124.62 144.99 47.95 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.455 1.097 . . . . 0.0 110.423 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.99 179.8 5.73 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.508 1.794 . . . . 0.0 110.983 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.07 52.42 2.68 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.458 1.099 . . . . 0.0 110.997 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -124.03 176.41 6.37 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.435 ' O ' ' C ' ' A' ' 29' ' ' CYS . 3.1 m -137.8 75.92 1.55 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.494 1.122 . . . . 0.0 110.391 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.435 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.9 t -39.05 113.98 0.36 Allowed 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.544 1.153 . . . . 0.0 108.237 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 1.4 p -120.27 -20.02 7.46 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.483 1.114 . . . . 0.0 109.959 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.667 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.42 134.26 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.667 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.01 -19.65 17.37 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 121.011 -2.496 . . . . 0.0 110.946 0.069 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.6 t -110.76 149.01 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.492 1.12 . . . . 0.0 109.289 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.499 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 2.7 p -83.44 169.43 15.55 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 124.521 1.138 . . . . 0.0 108.27 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.414 ' O ' ' N ' ' A' ' 28' ' ' THR . 25.3 p -129.06 -177.99 4.45 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.477 1.111 . . . . 0.0 110.376 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.326 -0.441 0 O-C-N 124.43 1.081 . . . . 0.0 110.257 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.9 p-10 . . . . . 0 N--CA 1.453 -0.299 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.429 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -135.9 -72.47 0.07 OUTLIER Glycine 0 CA--C 1.53 1.018 0 O-C-N 124.488 1.117 . . . . 0.0 110.935 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -137.09 162.97 52.53 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.454 0.738 . . . . 0.0 109.336 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HA ' ' CG2' ' A' ' 35' ' ' THR . 18.0 Cg_endo -75.01 57.04 4.44 Favored 'Trans proline' 0 C--N 1.359 1.122 0 O-C-N 124.472 1.775 . . . . 0.0 110.943 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.78 12.59 4.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 O-C-N 124.451 1.095 . . . . 0.0 109.302 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.4 ' SG ' HG22 ' A' ' 24' ' ' THR . 1.4 t -44.41 -39.35 4.63 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.487 1.117 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.53 -1.66 62.17 Favored Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.444 1.09 . . . . 0.0 110.986 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -128.4 173.47 10.17 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.489 0.758 . . . . 0.0 110.331 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.04 175.04 8.01 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.488 1.118 . . . . 0.0 110.447 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.587 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 4.6 p -155.18 72.58 0.83 Allowed 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.478 1.111 . . . . 0.0 108.281 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.52 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.8 t -78.73 -24.33 13.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 O-C-N 124.544 1.152 . . . . 0.0 109.321 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.69 -9.49 64.36 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.459 1.099 . . . . 0.0 110.951 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.7 24.85 24.59 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.447 ' O ' ' CG2' ' A' ' 21' ' ' THR . 15.1 t -146.87 103.45 3.63 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.489 0.758 . . . . 0.0 110.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.9 OUTLIER -52.41 130.24 30.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.442 1.089 . . . . 0.0 108.299 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -77.79 -0.84 28.65 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.474 1.109 . . . . 0.0 109.325 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.4 HG22 ' SG ' ' A' ' 13' ' ' CYS . 14.1 t -130.31 143.82 50.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.591 1.182 . . . . 0.0 110.385 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.98 -178.56 4.25 Favored 'Trans proline' 0 C--N 1.36 1.148 0 O-C-N 124.535 1.808 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.54 39.95 0.62 Allowed Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.486 1.116 . . . . 0.0 111.031 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.05 176.45 5.09 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.456 ' N ' ' O ' ' A' ' 35' ' ' THR . 2.9 m -135.9 70.72 1.42 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.401 1.063 . . . . 0.0 110.417 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.467 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 31.9 t -42.59 116.4 0.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.566 1.166 . . . . 0.0 108.25 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 18.0 m -123.12 -11.36 8.04 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.444 1.09 . . . . 0.0 110.017 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.642 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.33 135.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.979 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.642 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.96 -23.72 12.26 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 121.064 -2.473 . . . . 0.0 110.984 -0.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.41 ' HA ' HG21 ' A' ' 16' ' ' THR . 0.1 OUTLIER -110.37 146.47 15.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.53 1.144 . . . . 0.0 109.278 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 10.6 p -77.54 173.68 11.73 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.455 1.097 . . . . 0.0 108.344 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 63.4 p -136.74 -177.3 4.68 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.489 1.118 . . . . 0.0 110.398 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.429 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.528 0 O-C-N 124.578 1.174 . . . . 0.0 110.319 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' A' ' 36' ' ' ARG . 20.1 p30 . . . . . 0 N--CA 1.454 -0.275 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.14 -63.63 0.32 Allowed Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.549 1.156 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -53.62 110.89 2.29 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.512 0.772 . . . . 0.0 109.316 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 77.7 3.06 Favored 'Trans proline' 0 C--N 1.361 1.201 0 O-C-N 124.436 1.756 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -140.77 24.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.525 1.14 . . . . 0.0 109.297 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 56.2 m -69.7 -45.5 68.12 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.508 1.13 . . . . 0.0 108.282 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.8 -10.39 72.39 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.522 1.139 . . . . 0.0 110.966 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 1.1 tp10 -112.68 175.46 5.43 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.482 0.754 . . . . 0.0 110.309 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -125.92 177.26 6.42 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.483 1.114 . . . . 0.0 110.414 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.9 p -154.58 71.86 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 O-C-N 124.456 1.097 . . . . 0.0 108.236 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.528 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -76.95 -23.09 14.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.533 1.145 . . . . 0.0 109.31 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.99 -8.74 56.67 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.548 1.155 . . . . 0.0 111.019 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.74 23.0 26.93 Favored Glycine 0 CA--C 1.531 1.065 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 m -149.18 91.43 1.84 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.56 0.8 . . . . 0.0 110.358 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.4 p -50.02 153.7 1.3 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.541 1.151 . . . . 0.0 108.353 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.18 -0.73 57.68 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.478 1.111 . . . . 0.0 109.355 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 7.8 t -117.64 146.17 38.07 Favored Pre-proline 0 C--N 1.326 -0.435 0 O-C-N 124.481 1.113 . . . . 0.0 110.389 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.2 Cg_endo -74.99 177.95 7.9 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.549 1.815 . . . . 0.0 110.995 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 34.71 51.7 0.79 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.567 1.167 . . . . 0.0 111.047 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.472 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -121.92 159.06 27.66 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.5 ' CG2' ' O ' ' A' ' 28' ' ' THR . 1.0 OUTLIER -120.32 72.83 0.96 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.447 1.092 . . . . 0.0 110.402 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.451 ' C ' ' O ' ' A' ' 28' ' ' THR . 41.8 t -38.55 118.88 0.78 Allowed 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.536 1.147 . . . . 0.0 108.285 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 31' ' ' TRP . 46.3 t -120.63 -16.36 8.28 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.474 1.109 . . . . 0.0 110.002 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.655 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 134.99 0.04 OUTLIER Pre-proline 0 C--N 1.326 -0.43 0 O-C-N 124.493 1.12 . . . . 0.0 108.006 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.655 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.96 -21.17 15.64 Favored 'Cis proline' 0 C--N 1.36 1.145 0 C-N-CA 121.027 -2.489 . . . . 0.0 110.98 0.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -110.97 148.33 14.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.489 1.118 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.488 ' SG ' ' N ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -67.05 177.98 1.56 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.531 1.144 . . . . 0.0 108.305 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.488 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 8.4 p -146.24 161.53 40.07 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.543 1.152 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.442 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 2.8 ttp85 . . . . . 0 C--N 1.325 -0.471 0 O-C-N 124.47 1.106 . . . . 0.0 110.346 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.05 -55.13 0.36 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.464 1.103 . . . . 0.0 111.046 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.458 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 3.8 mt -62.9 114.97 14.05 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.476 0.751 . . . . 0.0 109.372 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 81.26 2.25 Favored 'Trans proline' 0 C--N 1.36 1.137 0 O-C-N 124.503 1.791 . . . . 0.0 110.937 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m -147.84 23.64 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.531 1.144 . . . . 0.0 109.276 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.412 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -66.51 -53.95 29.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.485 1.115 . . . . 0.0 108.3 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.531 1.041 0 O-C-N 124.458 1.099 . . . . 0.0 111.019 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.423 ' N ' ' CD ' ' A' ' 15' ' ' GLU . 9.1 mp0 -124.96 141.99 51.77 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.605 0.826 . . . . 0.0 110.245 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.429 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.02 173.67 7.31 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.495 1.122 . . . . 0.0 110.425 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.569 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 20.6 p -151.81 73.46 1.06 Allowed 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.523 1.139 . . . . 0.0 108.243 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.522 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -79.62 -24.62 12.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 124.561 1.163 . . . . 0.0 109.348 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.73 -13.29 55.49 Favored Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.515 1.134 . . . . 0.0 111.004 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.1 17.78 19.36 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 m -143.23 94.98 2.69 Favored 'General case' 0 C--N 1.326 -0.438 0 O-C-N 124.478 0.752 . . . . 0.0 110.375 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 12.7 p -45.99 -31.09 2.06 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.523 1.139 . . . . 0.0 108.316 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.482 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 21.4 t30 80.72 -1.36 1.86 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.429 1.081 . . . . 0.0 109.285 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.445 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.0 t -119.72 147.81 44.75 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.47 1.106 . . . . 0.0 110.342 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.445 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.02 173.16 15.0 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.485 1.782 . . . . 0.0 110.994 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.91 44.91 1.52 Allowed Glycine 0 CA--C 1.529 0.963 0 O-C-N 124.487 1.117 . . . . 0.0 110.977 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.48 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -118.48 160.77 21.14 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 29' ' ' CYS . 2.0 m -129.57 70.31 1.42 Allowed 'General case' 0 C--N 1.324 -0.515 0 O-C-N 124.496 1.122 . . . . 0.0 110.388 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.447 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -38.55 113.35 0.29 Allowed 'General case' 0 C--N 1.323 -0.553 0 O-C-N 124.572 1.17 . . . . 0.0 108.23 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -118.93 -14.72 9.4 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.528 1.143 . . . . 0.0 110.056 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.63 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.49 136.38 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 107.935 179.92 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.63 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.4 Cg_endo -75.01 -19.86 17.15 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 121.057 -2.476 . . . . 0.0 110.977 0.056 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.89 149.2 14.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.542 1.151 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.48 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -68.46 171.27 7.63 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.484 1.115 . . . . 0.0 108.333 179.919 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.402 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 33.6 p -135.21 166.58 22.76 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.137 . . . . 0.0 110.435 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.458 ' CG ' ' HB2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.473 0 O-C-N 124.507 1.129 . . . . 0.0 110.309 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.93 45.16 4.91 Favored Glycine 0 CA--C 1.53 1.007 0 O-C-N 124.47 1.106 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 mt -128.58 125.62 23.18 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.543 0.79 . . . . 0.0 109.289 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -75.04 55.47 3.98 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.528 1.804 . . . . 0.0 110.977 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 m -144.25 17.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.597 1.186 . . . . 0.0 109.256 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 51.1 t -48.94 -26.58 2.57 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.52 1.138 . . . . 0.0 108.304 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.99 -11.54 56.94 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.436 1.085 . . . . 0.0 111.017 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.41 ' HB2' ' OG1' ' A' ' 24' ' ' THR . 4.4 mm-40 -124.58 145.51 49.56 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.502 0.766 . . . . 0.0 110.276 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.401 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -95.84 179.69 5.01 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.551 1.157 . . . . 0.0 110.399 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.604 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 32.0 p -156.69 69.16 0.6 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.506 1.129 . . . . 0.0 108.262 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.93 -22.0 15.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.598 1.186 . . . . 0.0 109.327 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.85 -8.28 34.69 Favored Glycine 0 CA--C 1.531 1.032 0 O-C-N 124.49 1.119 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.74 19.8 28.36 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.0 m -124.53 72.37 1.2 Allowed 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.499 0.764 . . . . 0.0 110.401 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.7 p -41.42 -36.07 0.79 Allowed 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.529 1.143 . . . . 0.0 108.357 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.5 t30 60.91 21.9 12.09 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 124.565 1.165 . . . . 0.0 109.297 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.479 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -116.76 151.0 46.73 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.363 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.479 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.3 Cg_endo -75.0 139.65 24.51 Favored 'Trans proline' 0 C--N 1.36 1.17 0 O-C-N 124.448 1.762 . . . . 0.0 111.002 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.6 50.45 8.33 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.464 1.103 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -109.75 169.6 8.61 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.623 ' O ' ' C ' ' A' ' 29' ' ' CYS . 13.4 t -139.68 63.62 1.48 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.427 1.079 . . . . 0.0 110.461 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.623 ' C ' ' O ' ' A' ' 28' ' ' THR . 39.2 t -24.05 116.55 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.604 1.19 . . . . 0.0 108.34 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 40.5 t -119.51 -13.8 9.18 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.571 1.169 . . . . 0.0 109.989 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.637 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.54 137.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.478 0 O-C-N 124.58 1.175 . . . . 0.0 107.986 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.637 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -74.98 -19.27 17.75 Favored 'Cis proline' 0 C--N 1.36 1.183 0 C-N-CA 120.975 -2.51 . . . . 0.0 110.933 0.017 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.8 t -110.7 152.4 12.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.556 1.16 . . . . 0.0 109.21 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.2 158.0 22.5 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.532 1.145 . . . . 0.0 108.275 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 28' ' ' THR . 0.9 OUTLIER -126.37 152.83 45.76 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.501 1.126 . . . . 0.0 110.401 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 8.9 mtp180 . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.482 1.114 . . . . 0.0 110.339 179.932 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.85 -53.61 0.57 Allowed Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.557 1.161 . . . . 0.0 110.938 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -57.45 109.54 1.83 Allowed Pre-proline 0 C--N 1.325 -0.468 0 O-C-N 124.444 0.732 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.97 69.29 5.57 Favored 'Trans proline' 0 C--N 1.36 1.171 0 O-C-N 124.486 1.782 . . . . 0.0 111.03 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 m -135.32 20.77 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.469 1.106 . . . . 0.0 109.288 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 17.6 m -63.35 -43.39 97.84 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.474 1.109 . . . . 0.0 108.3 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.87 -6.44 82.85 Favored Glycine 0 CA--C 1.529 0.923 0 O-C-N 124.474 1.109 . . . . 0.0 110.993 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -120.3 141.53 49.93 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.456 0.739 . . . . 0.0 110.268 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.413 ' O ' ' HA ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER -96.28 176.56 6.02 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.454 1.096 . . . . 0.0 110.383 -179.965 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.61 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.4 p -152.2 74.15 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.447 1.092 . . . . 0.0 108.316 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.521 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -80.37 -21.91 11.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.443 1.089 . . . . 0.0 109.286 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.67 -10.56 43.39 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.448 1.092 . . . . 0.0 111.035 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.8 18.36 25.42 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.599 0.823 . . . . 0.0 111.047 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.417 ' C ' ' N ' ' A' ' 23' ' ' ASN . 57.2 m -137.31 86.26 2.18 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.526 0.78 . . . . 0.0 110.391 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.462 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 0.8 OUTLIER -41.79 -31.89 0.35 Allowed 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.462 1.101 . . . . 0.0 108.263 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.462 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 5.8 t-20 79.61 -1.7 2.15 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 109.261 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.434 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 5.0 t -119.57 147.89 44.66 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.533 1.146 . . . . 0.0 110.414 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 174.05 13.44 Favored 'Trans proline' 0 C--N 1.36 1.146 0 O-C-N 124.421 1.748 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.69 47.19 1.2 Allowed Glycine 0 CA--C 1.53 0.98 0 O-C-N 124.422 1.076 . . . . 0.0 111.049 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.481 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -127.26 148.88 50.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.974 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.551 ' CG2' ' O ' ' A' ' 28' ' ' THR . 9.5 t -119.74 70.47 0.86 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.499 1.125 . . . . 0.0 110.414 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.491 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.6 t -34.5 117.2 0.35 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.459 1.099 . . . . 0.0 108.305 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 22.5 p -119.6 -12.43 9.29 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.459 1.099 . . . . 0.0 110.034 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.643 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.73 137.02 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.462 0 O-C-N 124.511 1.132 . . . . 0.0 107.988 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.643 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.04 -20.89 16.05 Favored 'Cis proline' 0 C--N 1.361 1.223 0 C-N-CA 120.969 -2.513 . . . . 0.0 111.01 0.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.81 148.99 17.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 O-C-N 124.468 1.105 . . . . 0.0 109.289 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.481 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -67.09 177.31 1.8 Allowed 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.579 1.174 . . . . 0.0 108.349 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.471 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 1.0 OUTLIER -147.29 151.71 37.07 Favored 'General case' 0 C--N 1.323 -0.546 0 O-C-N 124.538 1.149 . . . . 0.0 110.443 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.519 1.137 . . . . 0.0 110.246 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.47 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -150.16 -92.65 0.1 OUTLIER Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.54 1.15 . . . . 0.0 110.981 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.86 158.39 35.06 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.485 0.756 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 74.24 4.07 Favored 'Trans proline' 0 C--N 1.36 1.183 0 O-C-N 124.445 1.76 . . . . 0.0 110.981 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 m -131.46 15.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 O-C-N 124.492 1.12 . . . . 0.0 109.268 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.415 ' SG ' ' CB ' ' A' ' 24' ' ' THR . 9.7 t -51.04 -42.85 60.75 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.513 1.133 . . . . 0.0 108.342 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.75 62.74 Favored Glycine 0 CA--C 1.529 0.949 0 O-C-N 124.559 1.162 . . . . 0.0 111.033 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -130.83 173.13 11.26 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.517 0.775 . . . . 0.0 110.315 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.468 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.05 173.88 6.82 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.511 1.132 . . . . 0.0 110.402 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.593 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 23.3 p -151.78 67.43 0.88 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.501 1.125 . . . . 0.0 108.276 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.523 ' HA ' ' CE2' ' A' ' 31' ' ' TRP . 4.2 t -73.97 -20.88 17.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 O-C-N 124.474 1.109 . . . . 0.0 109.306 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.51 -10.56 28.92 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.513 1.133 . . . . 0.0 111.019 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.3 17.85 20.98 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 m -129.68 87.43 2.54 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.432 0.724 . . . . 0.0 110.418 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' THR . 26.5 p -53.45 -39.28 64.31 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 124.446 1.091 . . . . 0.0 108.343 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 69.64 8.19 6.61 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.524 1.14 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.484 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -104.27 150.46 38.42 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.539 1.149 . . . . 0.0 110.36 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.484 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.99 139.79 24.72 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.563 1.822 . . . . 0.0 110.968 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 47.25 50.42 17.08 Favored Glycine 0 CA--C 1.529 0.939 0 O-C-N 124.462 1.101 . . . . 0.0 110.988 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.75 165.6 13.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.98 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.641 ' CG2' ' O ' ' A' ' 28' ' ' THR . 2.6 t -137.24 90.82 2.56 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.538 1.149 . . . . 0.0 110.424 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.438 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.6 t -38.49 112.82 0.25 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.427 1.08 . . . . 0.0 108.268 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.7 t -116.45 -21.14 9.37 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.452 1.095 . . . . 0.0 109.982 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.664 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.35 136.28 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 108.043 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.664 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.3 Cg_endo -74.99 -16.42 21.19 Favored 'Cis proline' 0 C--N 1.359 1.12 0 C-N-CA 121.025 -2.49 . . . . 0.0 110.983 0.064 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.05 150.72 18.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.486 1.117 . . . . 0.0 109.284 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 27' ' ' CYS . 1.4 p -82.69 162.51 21.79 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.443 1.089 . . . . 0.0 108.296 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.433 ' OG1' HG21 ' A' ' 28' ' ' THR . 16.8 p -131.97 178.21 6.95 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.527 1.142 . . . . 0.0 110.377 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.47 ' C ' ' N ' ' A' ' 9' ' ' GLY . 4.7 mtp180 . . . . . 0 C--N 1.325 -0.481 0 O-C-N 124.571 1.17 . . . . 0.0 110.341 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 . . . . . 0 N--CA 1.453 -0.321 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.481 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -149.14 -60.39 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.536 1.147 . . . . 0.0 110.994 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.408 HD21 ' CD ' ' A' ' 11' ' ' PRO . 27.1 mt -141.84 160.53 55.58 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.529 0.782 . . . . 0.0 109.326 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.408 ' CD ' HD21 ' A' ' 10' ' ' LEU . 18.3 Cg_endo -74.98 70.84 5.18 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.416 1.745 . . . . 0.0 111.023 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 m -127.71 16.61 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.476 1.11 . . . . 0.0 109.313 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -46.1 87.35 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.543 1.152 . . . . 0.0 108.381 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.73 -5.88 76.86 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -116.7 165.46 13.25 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.425 0.721 . . . . 0.0 110.327 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.424 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -118.52 174.22 6.38 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.521 1.138 . . . . 0.0 110.319 -179.912 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.532 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 8.6 p -153.89 72.33 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.5 1.125 . . . . 0.0 108.312 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.53 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -77.83 -25.06 14.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.558 1.162 . . . . 0.0 109.331 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.2 -11.71 64.38 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.525 1.14 . . . . 0.0 110.966 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.81 22.02 19.44 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.1 m -157.85 97.05 1.53 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.52 0.777 . . . . 0.0 110.445 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 24' ' ' THR . 17.4 p -47.84 165.29 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.565 1.165 . . . . 0.0 108.274 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -97.16 -0.77 46.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.437 1.086 . . . . 0.0 109.311 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.439 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.9 t -117.53 147.53 40.96 Favored Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.536 1.147 . . . . 0.0 110.383 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.439 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.97 174.57 12.55 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.538 1.809 . . . . 0.0 110.996 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.41 51.6 1.34 Allowed Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.481 1.113 . . . . 0.0 110.96 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -115.75 162.78 16.79 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 179.943 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 29' ' ' CYS . 8.3 m -120.92 68.35 0.87 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.491 1.12 . . . . 0.0 110.364 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 28' ' ' THR . 49.3 t -40.99 115.49 0.6 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.481 1.113 . . . . 0.0 108.313 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.435 ' O ' ' O ' ' A' ' 31' ' ' TRP . 23.1 t -120.32 -14.4 8.76 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.498 1.124 . . . . 0.0 110.057 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.648 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.14 135.74 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.648 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -74.95 -21.16 15.63 Favored 'Cis proline' 0 C--N 1.359 1.112 0 C-N-CA 121.029 -2.488 . . . . 0.0 111.001 -0.01 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.55 149.15 13.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.493 1.12 . . . . 0.0 109.274 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -71.24 177.46 3.85 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.52 1.138 . . . . 0.0 108.255 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.458 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 41.6 p -141.05 167.2 22.75 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.472 1.108 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.481 ' C ' ' N ' ' A' ' 9' ' ' GLY . 12.3 ttp85 . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.562 1.164 . . . . 0.0 110.21 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.38 43.49 0.29 Allowed Glycine 0 CA--C 1.529 0.936 0 O-C-N 124.487 1.117 . . . . 0.0 111.06 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' HG21 ' A' ' 35' ' ' THR . 23.3 mt -141.32 109.72 6.31 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.399 0.705 . . . . 0.0 109.309 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 56.51 4.26 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.458 1.767 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -138.38 21.37 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 124.515 1.135 . . . . 0.0 109.307 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -46.09 86.61 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.576 1.172 . . . . 0.0 108.278 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.84 -7.17 62.8 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.105 . . . . 0.0 110.935 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -124.44 147.87 48.01 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.523 0.778 . . . . 0.0 110.288 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.415 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -101.42 179.38 4.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.462 1.101 . . . . 0.0 110.374 -179.935 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.6 p -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.453 1.096 . . . . 0.0 108.319 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.543 HG12 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -79.83 -23.46 11.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.519 1.137 . . . . 0.0 109.367 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.96 -11.2 37.88 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.538 1.149 . . . . 0.0 111.002 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.46 18.93 26.84 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.428 ' O ' ' C ' ' A' ' 22' ' ' CYS . 5.4 t -123.17 76.61 1.4 Allowed 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.504 0.767 . . . . 0.0 110.38 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.601 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 41.9 t -39.99 -45.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.556 1.16 . . . . 0.0 108.312 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 68.52 8.96 7.01 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.522 1.139 . . . . 0.0 109.296 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.494 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -107.74 151.22 41.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.493 1.12 . . . . 0.0 110.42 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.494 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.01 140.76 25.8 Favored 'Trans proline' 0 C--N 1.36 1.161 0 O-C-N 124.529 1.805 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.68 50.8 5.8 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 124.527 1.142 . . . . 0.0 111.018 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.447 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -112.18 163.64 14.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.569 ' O ' ' C ' ' A' ' 29' ' ' CYS . 8.0 t -133.67 69.32 1.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.478 1.111 . . . . 0.0 110.363 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.569 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.6 t -28.56 119.5 0.12 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.478 1.111 . . . . 0.0 108.292 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 31' ' ' TRP . 53.7 p -120.54 -14.57 8.63 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.473 1.108 . . . . 0.0 109.975 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.64 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 136.67 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.64 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.5 Cg_endo -74.93 -20.87 15.96 Favored 'Cis proline' 0 C--N 1.361 1.187 0 C-N-CA 121.007 -2.497 . . . . 0.0 111.027 -0.065 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -113.34 148.46 16.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 O-C-N 124.432 1.083 . . . . 0.0 109.282 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.601 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER -65.62 177.92 1.11 Allowed 'General case' 0 C--N 1.326 -0.427 0 O-C-N 124.45 1.094 . . . . 0.0 108.274 -179.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.468 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -151.67 158.21 43.13 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.514 1.134 . . . . 0.0 110.36 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 . . . . . 0 C--N 1.326 -0.444 0 O-C-N 124.459 1.1 . . . . 0.0 110.343 -179.944 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.468 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -131.27 -71.78 0.1 Allowed Glycine 0 CA--C 1.53 0.989 0 O-C-N 124.477 1.11 . . . . 0.0 110.978 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.25 159.74 65.0 Favored Pre-proline 0 C--N 1.325 -0.473 0 O-C-N 124.457 0.74 . . . . 0.0 109.341 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 67.18 5.98 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.511 1.796 . . . . 0.0 111.033 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.0 m -137.83 26.68 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.549 1.155 . . . . 0.0 109.258 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.449 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.5 OUTLIER -58.72 -36.42 74.27 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.506 1.129 . . . . 0.0 108.29 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.48 -11.24 64.23 Favored Glycine 0 CA--C 1.529 0.913 0 O-C-N 124.532 1.145 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.495 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -116.55 169.54 9.26 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.433 0.725 . . . . 0.0 110.334 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.422 ' CG2' ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.61 173.47 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.419 1.074 . . . . 0.0 110.348 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.567 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 7.0 p -150.13 60.53 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.471 1.107 . . . . 0.0 108.228 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.543 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.6 t -70.45 -23.7 24.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 O-C-N 124.476 1.11 . . . . 0.0 109.324 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.77 -7.46 55.47 Favored Glycine 0 CA--C 1.531 1.059 0 O-C-N 124.467 1.104 . . . . 0.0 110.984 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.88 19.8 23.29 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.487 ' O ' ' CG2' ' A' ' 21' ' ' THR . 14.8 t -137.8 94.67 2.93 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.551 0.795 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 25.9 p -54.87 -32.88 61.28 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.517 1.136 . . . . 0.0 108.251 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 63.41 13.14 6.87 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.472 1.107 . . . . 0.0 109.292 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.496 ' CG2' ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -108.49 151.53 41.64 Favored Pre-proline 0 C--N 1.325 -0.486 0 O-C-N 124.466 1.104 . . . . 0.0 110.419 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.496 ' HD2' ' CG2' ' A' ' 24' ' ' THR . 18.5 Cg_endo -74.9 141.42 26.93 Favored 'Trans proline' 0 C--N 1.359 1.096 0 O-C-N 124.475 1.776 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.42 50.95 4.62 Favored Glycine 0 CA--C 1.53 1.026 0 O-C-N 124.43 1.081 . . . . 0.0 111.026 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.449 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -109.28 163.62 13.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.599 ' O ' ' C ' ' A' ' 29' ' ' CYS . 13.8 t -129.75 61.24 1.57 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.533 1.145 . . . . 0.0 110.427 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.599 ' C ' ' O ' ' A' ' 28' ' ' THR . 22.6 t -26.09 117.36 0.07 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.546 1.154 . . . . 0.0 108.314 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -120.19 -14.23 8.83 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.428 1.08 . . . . 0.0 109.968 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.656 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.53 138.01 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.512 1.133 . . . . 0.0 107.983 179.965 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.656 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 18.2 Cg_endo -75.03 -19.71 17.33 Favored 'Cis proline' 0 C--N 1.36 1.15 0 C-N-CA 121.054 -2.478 . . . . 0.0 110.94 0.029 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.8 t -113.67 147.93 16.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.485 1.116 . . . . 0.0 109.307 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -77.22 174.0 11.24 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.459 1.1 . . . . 0.0 108.303 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.1 p -145.01 164.64 30.54 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.539 1.149 . . . . 0.0 110.397 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.468 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.478 0 O-C-N 124.507 1.129 . . . . 0.0 110.306 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.26 -39.84 1.68 Allowed Glycine 0 CA--C 1.529 0.942 0 O-C-N 124.544 1.152 . . . . 0.0 111.021 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -61.95 113.49 8.64 Favored Pre-proline 0 C--N 1.325 -0.457 0 O-C-N 124.437 0.728 . . . . 0.0 109.271 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.881 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.5 Cg_endo -75.08 64.97 6.15 Favored 'Trans proline' 0 C--N 1.36 1.165 0 O-C-N 124.479 1.778 . . . . 0.0 110.983 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -138.85 21.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.435 1.085 . . . . 0.0 109.335 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.428 ' SG ' HG21 ' A' ' 24' ' ' THR . 26.7 t -57.96 -41.96 83.98 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.475 1.109 . . . . 0.0 108.283 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.65 -7.68 68.27 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.416 ' O ' HG12 ' A' ' 33' ' ' VAL . 15.4 mm-40 -124.03 155.89 37.48 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.466 0.745 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -105.52 176.63 5.1 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.566 1.166 . . . . 0.0 110.459 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.2 p -154.46 68.76 0.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.52 1.138 . . . . 0.0 108.329 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.672 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -74.78 -21.32 16.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.533 1.145 . . . . 0.0 109.338 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.95 -6.31 40.12 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.552 1.158 . . . . 0.0 111.035 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.82 21.46 28.41 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 21' ' ' THR . 2.5 m -131.7 79.4 1.87 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.538 0.787 . . . . 0.0 110.428 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.5 p -45.16 -30.94 1.27 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.54 1.15 . . . . 0.0 108.36 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 59.86 16.01 5.34 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.477 1.111 . . . . 0.0 109.312 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.851 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -111.3 150.3 41.84 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.498 1.124 . . . . 0.0 110.393 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.851 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.09 141.54 26.51 Favored 'Trans proline' 0 C--N 1.359 1.103 0 O-C-N 124.52 1.8 . . . . 0.0 111.009 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.84 50.1 5.08 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.506 1.129 . . . . 0.0 110.95 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.406 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -107.13 175.52 5.47 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -141.33 72.15 1.38 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.457 1.098 . . . . 0.0 110.357 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.7 t -38.81 114.56 0.4 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.521 1.138 . . . . 0.0 108.305 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 15.9 t -120.89 -12.09 8.85 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.552 1.158 . . . . 0.0 110.009 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.672 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.46 137.26 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.52 1.138 . . . . 0.0 108.007 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.97 -19.72 17.25 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.058 -2.476 . . . . 0.0 110.99 -0.022 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -113.84 150.27 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.263 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -77.62 166.59 22.83 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.482 1.113 . . . . 0.0 108.366 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.881 HG22 ' HA ' ' A' ' 11' ' ' PRO . 3.0 p -133.36 174.58 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.51 1.131 . . . . 0.0 110.375 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 . . . . . 0 C--N 1.324 -0.524 0 O-C-N 124.527 1.142 . . . . 0.0 110.36 179.932 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.23 -48.62 0.7 Allowed Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.532 1.145 . . . . 0.0 111.009 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -61.5 111.73 4.83 Favored Pre-proline 0 C--N 1.324 -0.525 0 O-C-N 124.585 0.815 . . . . 0.0 109.311 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.7 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.05 69.39 5.6 Favored 'Trans proline' 0 C--N 1.361 1.186 0 O-C-N 124.43 1.753 . . . . 0.0 110.967 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.57 21.79 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 O-C-N 124.483 1.114 . . . . 0.0 109.299 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.593 ' SG ' HG21 ' A' ' 24' ' ' THR . 5.3 t -60.76 -46.08 91.82 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.535 1.147 . . . . 0.0 108.346 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.21 -5.63 65.67 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.452 1.095 . . . . 0.0 110.944 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -123.35 146.15 48.17 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.49 0.759 . . . . 0.0 110.354 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.782 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.81 175.47 5.95 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.409 1.068 . . . . 0.0 110.41 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.56 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.2 p -153.93 65.9 0.72 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 108.27 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.682 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -71.86 -22.39 21.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 O-C-N 124.388 1.055 . . . . 0.0 109.327 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.08 -7.19 50.53 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.491 1.119 . . . . 0.0 110.994 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.97 21.34 23.51 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 22.9 m -138.39 93.71 2.77 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.447 0.733 . . . . 0.0 110.387 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 7.4 p -47.33 -37.6 11.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.384 1.053 . . . . 0.0 108.283 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.494 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER 82.43 -1.05 1.38 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.56 1.162 . . . . 0.0 109.311 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.652 HG23 ' HB3' ' A' ' 27' ' ' CYS . 14.9 t -127.83 144.53 51.64 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.492 1.12 . . . . 0.0 110.436 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.05 179.42 6.12 Favored 'Trans proline' 0 C--N 1.359 1.116 0 O-C-N 124.505 1.792 . . . . 0.0 110.969 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 40.84 32.15 0.5 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.511 1.132 . . . . 0.0 111.019 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.652 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -115.43 166.47 11.85 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 35' ' ' THR . 17.3 m -136.64 74.43 1.49 Allowed 'General case' 0 C--N 1.324 -0.516 0 O-C-N 124.574 1.171 . . . . 0.0 110.385 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.427 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.8 t -39.93 109.78 0.12 Allowed 'General case' 0 C--N 1.326 -0.444 0 O-C-N 124.463 1.102 . . . . 0.0 108.322 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.1 OUTLIER -118.1 -11.27 10.19 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.495 1.122 . . . . 0.0 109.996 179.979 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.682 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.62 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.546 1.154 . . . . 0.0 108.028 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.782 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -20.09 16.87 Favored 'Cis proline' 0 C--N 1.359 1.114 0 C-N-CA 121.026 -2.489 . . . . 0.0 111.001 0.016 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -114.56 148.76 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.492 1.12 . . . . 0.0 109.411 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 21.1 p -74.77 160.18 31.05 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.7 HG22 ' HA ' ' A' ' 11' ' ' PRO . 23.3 p -127.35 -177.86 4.23 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.52 1.138 . . . . 0.0 110.383 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 . . . . . 0 C--N 1.324 -0.506 0 O-C-N 124.533 1.146 . . . . 0.0 110.322 179.963 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.1 p-10 . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.48 -51.12 0.63 Allowed Glycine 0 CA--C 1.53 0.978 0 O-C-N 124.484 1.115 . . . . 0.0 111.047 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.8 mt -56.22 114.73 8.17 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.46 0.741 . . . . 0.0 109.297 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.415 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -74.97 70.86 5.16 Favored 'Trans proline' 0 C--N 1.361 1.191 0 O-C-N 124.446 1.761 . . . . 0.0 111.002 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.1 m -142.24 22.82 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.494 1.121 . . . . 0.0 109.302 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.482 ' SG ' HG21 ' A' ' 24' ' ' THR . 4.6 t -55.94 -43.96 77.93 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.559 1.162 . . . . 0.0 108.239 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.19 -6.13 61.51 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.505 1.128 . . . . 0.0 110.971 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -125.57 175.15 7.75 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.512 0.772 . . . . 0.0 110.363 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.708 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.4 OUTLIER -122.52 176.08 6.11 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 124.493 1.121 . . . . 0.0 110.432 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.605 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 27.3 p -153.36 66.7 0.77 Allowed 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.454 1.096 . . . . 0.0 108.312 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.668 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -73.8 -22.82 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.49 1.119 . . . . 0.0 109.362 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.06 -10.97 44.22 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.466 1.104 . . . . 0.0 111.021 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 103.65 16.17 20.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 21' ' ' THR . 14.5 t -132.84 100.31 4.87 Favored 'General case' 0 C--N 1.326 -0.443 0 O-C-N 124.529 0.782 . . . . 0.0 110.424 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.8 p -59.02 -39.45 81.95 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.519 1.137 . . . . 0.0 108.301 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 69.3 10.09 7.62 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.529 1.143 . . . . 0.0 109.31 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.856 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.6 OUTLIER -107.87 150.14 39.93 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 124.502 1.126 . . . . 0.0 110.338 -179.936 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.856 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.08 141.75 26.78 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.498 1.788 . . . . 0.0 111.003 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 43.45 49.39 6.96 Favored Glycine 0 CA--C 1.531 1.04 0 O-C-N 124.5 1.125 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.28 178.42 4.55 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 28' ' ' THR . 1.2 m -145.01 72.22 1.32 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.498 1.124 . . . . 0.0 110.471 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.45 ' C ' ' O ' ' A' ' 28' ' ' THR . 37.2 t -38.26 113.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.525 1.141 . . . . 0.0 108.368 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 45.5 t -120.93 -12.64 8.75 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.513 1.133 . . . . 0.0 109.963 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.668 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.37 136.22 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.47 0 O-C-N 124.489 1.118 . . . . 0.0 108.003 -179.946 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.708 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.96 -22.0 14.51 Favored 'Cis proline' 0 C--N 1.361 1.188 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -0.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.9 t -109.32 148.79 12.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.558 1.161 . . . . 0.0 109.297 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.4 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.1 p -81.14 162.65 23.57 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.503 1.127 . . . . 0.0 108.291 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.468 ' O ' ' N ' ' A' ' 28' ' ' THR . 40.8 p -121.2 -171.98 2.31 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.484 1.115 . . . . 0.0 110.403 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 76.0 mtp180 . . . . . 0 C--N 1.325 -0.492 0 O-C-N 124.559 1.162 . . . . 0.0 110.281 -179.994 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 36' ' ' ARG . 20.6 p30 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.49 -57.32 0.66 Allowed Glycine 0 CA--C 1.53 0.988 0 O-C-N 124.49 1.119 . . . . 0.0 110.987 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 mt -52.54 109.41 1.42 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.486 0.756 . . . . 0.0 109.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.741 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.06 69.18 5.66 Favored 'Trans proline' 0 C--N 1.361 1.19 0 O-C-N 124.409 1.742 . . . . 0.0 110.972 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -138.5 19.98 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.297 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.545 ' SG ' HG21 ' A' ' 24' ' ' THR . 3.3 t -52.88 -43.53 66.2 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.527 1.142 . . . . 0.0 108.321 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.65 -3.99 63.48 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.471 1.107 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.43 173.46 9.8 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.49 0.759 . . . . 0.0 110.358 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.72 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.8 OUTLIER -120.73 178.81 4.55 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.509 1.131 . . . . 0.0 110.43 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.612 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 31.7 p -155.54 62.86 0.61 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.524 1.14 . . . . 0.0 108.328 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.654 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -70.34 -21.0 23.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.509 1.131 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.07 -4.15 33.57 Favored Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.535 1.147 . . . . 0.0 110.994 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.57 22.16 29.68 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 22' ' ' CYS . 49.9 m -126.69 80.5 1.94 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.482 0.754 . . . . 0.0 110.473 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 21' ' ' THR . 41.1 t -41.56 -49.16 4.07 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.424 1.077 . . . . 0.0 108.327 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.5 t30 71.27 10.0 6.65 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.471 1.107 . . . . 0.0 109.327 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.841 HG22 ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -113.0 148.54 39.62 Favored Pre-proline 0 C--N 1.324 -0.502 0 O-C-N 124.439 1.087 . . . . 0.0 110.436 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.841 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 142.84 28.41 Favored 'Trans proline' 0 C--N 1.36 1.158 0 O-C-N 124.464 1.771 . . . . 0.0 111.054 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.02 49.06 7.9 Favored Glycine 0 CA--C 1.53 0.996 0 O-C-N 124.473 1.108 . . . . 0.0 110.987 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.469 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -108.92 178.11 4.57 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.649 HG22 ' O ' ' A' ' 28' ' ' THR . 1.2 m -145.77 73.33 1.34 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.518 1.136 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.477 ' C ' ' O ' ' A' ' 28' ' ' THR . 40.0 t -36.68 112.37 0.18 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.47 1.106 . . . . 0.0 108.258 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 16.5 t -119.97 -13.99 8.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.425 1.078 . . . . 0.0 110.001 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.67 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.59 136.72 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.523 0 O-C-N 124.564 1.165 . . . . 0.0 108.013 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.98 -20.99 15.88 Favored 'Cis proline' 0 C--N 1.36 1.172 0 C-N-CA 120.986 -2.506 . . . . 0.0 111.005 -0.042 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 15' ' ' GLU . 1.4 t -112.62 146.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.458 1.099 . . . . 0.0 109.3 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 1.8 p -78.36 161.46 27.17 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 124.544 1.153 . . . . 0.0 108.249 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.741 HG22 ' HA ' ' A' ' 11' ' ' PRO . 22.1 p -126.07 -175.99 3.52 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.526 1.141 . . . . 0.0 110.391 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.404 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.463 1.102 . . . . 0.0 110.299 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 140.7 -49.24 0.79 Allowed Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.545 1.153 . . . . 0.0 110.976 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 mt -54.79 114.15 6.47 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.568 0.805 . . . . 0.0 109.26 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -75.01 71.46 5.01 Favored 'Trans proline' 0 C--N 1.36 1.16 0 O-C-N 124.522 1.801 . . . . 0.0 111.003 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 m -142.39 23.52 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 O-C-N 124.595 1.185 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.443 ' SG ' HG21 ' A' ' 24' ' ' THR . 11.8 t -64.02 -45.68 87.83 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.499 1.125 . . . . 0.0 108.32 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.33 -6.43 71.68 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 124.575 1.172 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.407 ' HG3' HG21 ' A' ' 24' ' ' THR . 3.4 mm-40 -121.76 144.76 48.61 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.416 0.715 . . . . 0.0 110.258 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.808 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -95.82 174.72 6.82 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.487 1.117 . . . . 0.0 110.398 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.506 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.1 p -154.28 66.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.455 1.097 . . . . 0.0 108.342 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.693 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -71.69 -22.54 21.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.585 1.178 . . . . 0.0 109.377 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.38 -7.56 45.69 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.465 1.103 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.8 20.66 23.49 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 111.016 -0.833 . . . . 0.0 111.016 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 98.4 m -136.11 94.11 3.0 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 0.773 . . . . 0.0 110.394 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 4.7 m -46.59 -38.2 9.19 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.583 1.177 . . . . 0.0 108.303 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER 84.33 -0.93 0.97 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.506 1.129 . . . . 0.0 109.213 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.443 HG21 ' SG ' ' A' ' 13' ' ' CYS . 13.7 t -128.03 144.95 53.42 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.457 1.098 . . . . 0.0 110.378 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.92 166.05 30.07 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.418 1.747 . . . . 0.0 111.006 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 50.61 47.48 45.36 Favored Glycine 0 CA--C 1.531 1.064 0 O-C-N 124.483 1.115 . . . . 0.0 111.003 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.448 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -128.14 174.96 8.8 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 -179.995 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.523 HG22 ' O ' ' A' ' 28' ' ' THR . 1.3 m -145.4 82.01 1.64 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.471 1.107 . . . . 0.0 110.409 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.449 ' C ' ' O ' ' A' ' 28' ' ' THR . 34.0 t -38.29 114.43 0.36 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.52 1.138 . . . . 0.0 108.273 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.3 t -119.73 -19.79 7.89 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 109.978 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.22 135.97 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.531 0 O-C-N 124.546 1.154 . . . . 0.0 108.033 -179.922 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.808 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -17.52 19.9 Favored 'Cis proline' 0 C--N 1.36 1.175 0 C-N-CA 121.035 -2.486 . . . . 0.0 110.963 0.052 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -114.05 148.97 16.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.547 1.155 . . . . 0.0 109.287 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.456 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 16.3 p -78.24 163.96 25.32 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.512 1.133 . . . . 0.0 108.233 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 28' ' ' THR . 44.4 p -131.17 -177.62 4.47 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.473 1.108 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 . . . . . 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.297 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.04 -36.07 2.2 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.533 1.146 . . . . 0.0 111.034 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.446 HD23 ' HA ' ' A' ' 10' ' ' LEU . 12.5 mt -74.34 116.88 57.21 Favored Pre-proline 0 C--N 1.324 -0.513 0 O-C-N 124.555 0.797 . . . . 0.0 109.208 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 1.006 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.02 68.37 5.79 Favored 'Trans proline' 0 C--N 1.361 1.217 0 O-C-N 124.506 1.793 . . . . 0.0 111.036 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.89 16.33 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 O-C-N 124.496 1.122 . . . . 0.0 109.269 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.557 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.6 t -64.31 -47.65 78.63 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.434 1.084 . . . . 0.0 108.248 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.22 3.36 75.84 Favored Glycine 0 CA--C 1.529 0.935 0 O-C-N 124.58 1.175 . . . . 0.0 111.041 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.0 mm-40 -121.98 145.92 47.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.438 0.728 . . . . 0.0 110.315 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.96 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -105.75 162.77 13.24 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.509 1.131 . . . . 0.0 110.458 179.957 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' N ' ' A' ' 22' ' ' CYS . 1.2 p -135.42 53.25 1.98 Allowed 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.481 1.113 . . . . 0.0 108.325 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.747 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.2 t -67.05 -20.85 27.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.509 1.13 . . . . 0.0 109.316 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.54 -3.16 59.83 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.464 1.102 . . . . 0.0 110.978 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.48 24.21 19.24 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 21' ' ' THR . 10.1 t -158.58 115.76 2.83 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.556 0.797 . . . . 0.0 110.397 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.497 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 6.4 p -55.51 -36.1 66.33 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.496 1.122 . . . . 0.0 108.278 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.497 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.2 t30 82.53 -0.93 1.35 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 109.337 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.707 HG23 ' HB3' ' A' ' 27' ' ' CYS . 15.2 t -127.32 144.75 51.85 Favored Pre-proline 0 C--N 1.326 -0.446 0 O-C-N 124.461 1.101 . . . . 0.0 110.438 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.04 177.81 8.1 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.454 1.765 . . . . 0.0 110.986 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.83 35.89 0.7 Allowed Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.543 1.152 . . . . 0.0 111.022 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.707 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -119.44 158.19 26.72 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.733 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -125.48 71.02 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.538 1.148 . . . . 0.0 110.384 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.405 ' C ' ' O ' ' A' ' 28' ' ' THR . 12.5 t -41.11 114.29 0.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.547 1.154 . . . . 0.0 108.318 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 85.4 p -125.4 -7.56 6.96 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.517 1.135 . . . . 0.0 109.985 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.747 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 61.87 138.69 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.518 0 O-C-N 124.497 1.123 . . . . 0.0 107.97 179.963 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.96 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -20.67 16.26 Favored 'Cis proline' 0 C--N 1.36 1.165 0 C-N-CA 120.976 -2.51 . . . . 0.0 110.974 -0.007 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.458 HG22 HG23 ' A' ' 16' ' ' THR . 1.6 t -118.46 144.43 26.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.451 1.094 . . . . 0.0 109.313 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.403 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 25.4 p -71.29 164.65 25.3 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.556 1.16 . . . . 0.0 108.244 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' THR . . . . . 1.006 HG22 ' HA ' ' A' ' 11' ' ' PRO . 15.2 p -131.19 177.01 7.79 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.524 1.14 . . . . 0.0 110.396 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.513 1.133 . . . . 0.0 110.305 179.96 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 36' ' ' ARG . 24.6 t30 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.43 25.85 5.88 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.569 1.168 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.462 ' HB3' HG22 ' A' ' 12' ' ' VAL . 20.9 mt -127.12 121.34 22.72 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.46 0.741 . . . . 0.0 109.284 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.2 Cg_endo -75.0 60.93 5.57 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.537 1.809 . . . . 0.0 111.015 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.462 HG22 ' HB3' ' A' ' 10' ' ' LEU . 27.4 m -143.79 20.77 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.53 1.144 . . . . 0.0 109.288 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.655 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.2 t -51.31 -46.01 62.42 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.467 1.105 . . . . 0.0 108.284 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.92 -3.75 45.26 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.422 1.076 . . . . 0.0 111.037 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -130.8 171.29 13.3 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.543 0.79 . . . . 0.0 110.242 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.714 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -122.06 175.39 6.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.431 1.082 . . . . 0.0 110.425 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.606 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.5 p -153.13 68.91 0.82 Allowed 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.662 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.4 -23.36 16.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.516 1.135 . . . . 0.0 109.287 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.59 -12.63 50.26 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 111.022 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.23 15.13 16.68 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -138.02 113.16 9.25 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.453 0.737 . . . . 0.0 110.397 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.58 ' HB2' HG22 ' A' ' 24' ' ' THR . 2.1 p -59.86 -35.34 74.59 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.516 1.135 . . . . 0.0 108.313 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.459 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.3 t30 79.26 -0.98 2.28 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.495 1.122 . . . . 0.0 109.272 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.655 HG21 ' SG ' ' A' ' 13' ' ' CYS . 9.0 t -124.46 145.48 49.16 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.535 1.147 . . . . 0.0 110.465 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.3 Cg_endo -75.02 176.93 9.27 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.561 1.821 . . . . 0.0 111.007 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.82 43.99 0.89 Allowed Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.441 1.088 . . . . 0.0 110.999 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.635 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.3 OUTLIER -122.77 173.5 7.71 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.654 HG22 ' O ' ' A' ' 28' ' ' THR . 1.2 m -142.59 73.34 1.4 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.54 1.15 . . . . 0.0 110.447 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.5 t -41.4 117.0 0.83 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.512 1.133 . . . . 0.0 108.346 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 31' ' ' TRP . 92.2 p -124.94 -10.79 7.17 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.481 1.113 . . . . 0.0 109.99 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.68 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.16 135.61 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.46 0 O-C-N 124.505 1.128 . . . . 0.0 107.997 -179.983 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 16' ' ' THR . 18.1 Cg_endo -74.99 -23.73 12.26 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.987 -2.505 . . . . 0.0 110.952 -0.04 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.1 t -110.7 147.71 14.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.462 1.101 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 7.3 p -77.39 167.33 21.85 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.523 1.139 . . . . 0.0 108.297 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 28' ' ' THR . 1.4 p -124.96 172.56 9.3 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.549 1.156 . . . . 0.0 110.425 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 8' ' ' ASN . 6.6 ptm180 . . . . . 0 C--N 1.324 -0.518 0 O-C-N 124.513 1.133 . . . . 0.0 110.345 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.456 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -143.55 -89.66 0.11 Allowed Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.512 1.133 . . . . 0.0 111.002 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.48 161.74 28.5 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.517 0.775 . . . . 0.0 109.29 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 70.69 5.27 Favored 'Trans proline' 0 C--N 1.36 1.159 0 O-C-N 124.456 1.766 . . . . 0.0 110.988 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.24 20.92 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.296 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.522 ' SG ' ' CG2' ' A' ' 24' ' ' THR . 8.9 t -51.93 -40.54 60.96 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.446 1.091 . . . . 0.0 108.289 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.61 -4.65 69.45 Favored Glycine 0 CA--C 1.53 0.987 0 O-C-N 124.518 1.136 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.5 OUTLIER -125.27 173.74 8.6 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.502 0.766 . . . . 0.0 110.343 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -121.38 176.13 5.81 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.393 1.058 . . . . 0.0 110.382 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.598 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 10.7 p -155.93 71.57 0.74 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.609 1.193 . . . . 0.0 108.319 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.685 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.37 -24.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.537 1.148 . . . . 0.0 109.334 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -92.31 -11.58 59.57 Favored Glycine 0 CA--C 1.529 0.952 0 O-C-N 124.44 1.087 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.58 19.99 20.97 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 21' ' ' THR . 14.0 t -149.83 104.53 3.32 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.485 0.756 . . . . 0.0 110.385 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 1.9 p -55.65 147.05 19.21 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.547 1.154 . . . . 0.0 108.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -81.22 -0.7 41.76 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.507 1.13 . . . . 0.0 109.292 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.522 ' CG2' ' SG ' ' A' ' 13' ' ' CYS . 15.2 t -126.36 144.02 47.94 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.561 1.163 . . . . 0.0 110.385 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.01 -178.05 3.9 Favored 'Trans proline' 0 C--N 1.361 1.192 0 O-C-N 124.422 1.749 . . . . 0.0 110.984 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 48.27 1.7 Allowed Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.521 1.138 . . . . 0.0 111.037 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -123.75 168.37 12.79 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.707 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -127.27 71.95 1.35 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.496 1.123 . . . . 0.0 110.406 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.436 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.0 t -39.59 118.94 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.495 1.122 . . . . 0.0 108.33 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.3 OUTLIER -121.66 -14.89 8.08 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.505 1.128 . . . . 0.0 110.018 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.32 135.27 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.703 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.08 -21.83 14.82 Favored 'Cis proline' 0 C--N 1.36 1.132 0 C-N-CA 120.961 -2.516 . . . . 0.0 110.971 0.014 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.2 t -106.35 149.44 9.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.485 1.116 . . . . 0.0 109.277 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 8.0 p -84.26 171.04 13.1 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.527 1.142 . . . . 0.0 108.309 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.409 ' OG1' ' HB ' ' A' ' 28' ' ' THR . 22.3 p -133.33 -173.76 3.31 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.53 1.144 . . . . 0.0 110.372 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.456 ' C ' ' N ' ' A' ' 9' ' ' GLY . 2.0 ttp180 . . . . . 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.16 . . . . 0.0 110.292 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.412 ' CA ' ' HB ' ' A' ' 35' ' ' THR . . . 149.36 -52.34 0.53 Allowed Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.479 1.112 . . . . 0.0 110.963 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.33 111.64 2.71 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.533 0.784 . . . . 0.0 109.32 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -74.97 66.5 6.0 Favored 'Trans proline' 0 C--N 1.361 1.189 0 O-C-N 124.401 1.738 . . . . 0.0 110.955 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.81 20.73 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.448 1.092 . . . . 0.0 109.223 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.404 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -65.39 -47.95 74.57 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.471 1.107 . . . . 0.0 108.329 -179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.24 -5.1 78.03 Favored Glycine 0 CA--C 1.531 1.066 0 O-C-N 124.468 1.105 . . . . 0.0 111.013 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.404 ' OE2' ' O ' ' A' ' 13' ' ' CYS . 20.1 mp0 -117.89 141.69 48.15 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.497 0.763 . . . . 0.0 110.271 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.793 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.34 173.36 7.02 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.476 1.11 . . . . 0.0 110.395 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.563 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.0 p -152.28 71.63 0.96 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.594 1.184 . . . . 0.0 108.314 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.691 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.2 -22.84 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.516 1.135 . . . . 0.0 109.26 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.62 -10.35 55.58 Favored Glycine 0 CA--C 1.529 0.924 0 O-C-N 124.476 1.11 . . . . 0.0 110.995 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.13 20.05 21.91 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.7 HG23 ' O ' ' A' ' 21' ' ' THR . 14.6 t -143.82 93.09 2.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.507 0.769 . . . . 0.0 110.428 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.581 ' HB2' HG22 ' A' ' 24' ' ' THR . 9.4 p -45.91 -31.37 2.13 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.336 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 1.5 t-20 79.57 -1.2 2.18 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.402 1.064 . . . . 0.0 109.354 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.581 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.8 t -118.66 147.72 42.73 Favored Pre-proline 0 C--N 1.325 -0.487 0 O-C-N 124.509 1.131 . . . . 0.0 110.475 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.3 Cg_endo -74.94 172.64 15.95 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.459 1.768 . . . . 0.0 110.961 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 45.17 1.36 Allowed Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.532 1.145 . . . . 0.0 110.997 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.78 161.26 20.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.626 HG22 ' O ' ' A' ' 28' ' ' THR . 1.5 m -130.61 70.98 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.412 1.07 . . . . 0.0 110.427 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.467 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -37.51 112.53 0.21 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.56 1.163 . . . . 0.0 108.327 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.0 p -117.16 -15.67 10.46 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.504 1.127 . . . . 0.0 109.999 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.58 136.71 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.793 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.05 -19.01 18.11 Favored 'Cis proline' 0 C--N 1.361 1.193 0 C-N-CA 120.96 -2.517 . . . . 0.0 110.947 0.049 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.7 t -112.17 149.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.405 1.066 . . . . 0.0 109.335 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -67.3 171.68 5.62 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.571 1.17 . . . . 0.0 108.305 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.412 ' HB ' ' CA ' ' A' ' 9' ' ' GLY . 34.2 p -136.55 161.73 35.06 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.5 1.125 . . . . 0.0 110.395 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.464 1.102 . . . . 0.0 110.318 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.453 -0.324 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.61 -44.24 1.24 Allowed Glycine 0 CA--C 1.531 1.043 0 O-C-N 124.499 1.124 . . . . 0.0 110.982 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.438 ' HB3' HG22 ' A' ' 12' ' ' VAL . 0.4 OUTLIER -59.36 114.6 9.71 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.515 0.773 . . . . 0.0 109.308 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.421 ' HD2' HD23 ' A' ' 10' ' ' LEU . 18.2 Cg_endo -75.07 67.44 5.99 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.52 1.8 . . . . 0.0 110.981 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 10' ' ' LEU . 19.2 m -140.0 21.59 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.533 1.146 . . . . 0.0 109.346 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.5 t -57.29 -43.83 83.51 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 124.504 1.128 . . . . 0.0 108.299 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.28 -5.24 71.13 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.525 1.141 . . . . 0.0 110.958 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.445 ' HG3' HG21 ' A' ' 24' ' ' THR . 6.7 mm-40 -124.43 143.36 50.67 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.449 0.735 . . . . 0.0 110.289 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.751 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.27 174.13 7.04 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.396 1.06 . . . . 0.0 110.416 179.983 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.583 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.9 p -152.5 74.8 1.09 Allowed 'General case' 0 C--N 1.326 -0.432 0 O-C-N 124.48 1.113 . . . . 0.0 108.273 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.714 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.0 t -81.81 -20.52 10.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.511 1.132 . . . . 0.0 109.364 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.17 -8.57 44.15 Favored Glycine 0 CA--C 1.53 1.005 0 O-C-N 124.541 1.15 . . . . 0.0 110.994 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.24 21.89 23.78 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 21' ' ' THR . 14.7 t -133.15 94.0 3.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.534 0.785 . . . . 0.0 110.414 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 2.8 t -41.7 -43.75 2.95 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.552 1.157 . . . . 0.0 108.344 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.1 t-20 83.27 -1.8 1.19 Allowed 'General case' 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 109.339 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.445 HG21 ' HG3' ' A' ' 15' ' ' GLU . 14.8 t -136.73 144.64 47.73 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.53 1.144 . . . . 0.0 110.406 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.0 177.6 8.38 Favored 'Trans proline' 0 C--N 1.361 1.209 0 O-C-N 124.527 1.804 . . . . 0.0 111.014 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.86 43.79 5.41 Favored Glycine 0 CA--C 1.529 0.944 0 O-C-N 124.565 1.166 . . . . 0.0 111.006 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -127.85 177.13 7.05 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.997 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.721 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -148.23 72.99 1.23 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.475 1.109 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.1 t -38.86 114.85 0.42 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 108.272 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.9 t -121.74 -11.82 8.55 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.509 1.131 . . . . 0.0 109.966 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.714 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.65 135.94 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.982 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.751 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.06 -22.6 13.77 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.948 -2.522 . . . . 0.0 111.033 -0.003 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.31 148.81 13.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.459 1.1 . . . . 0.0 109.29 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 15.6 p -79.23 163.96 24.55 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.593 1.183 . . . . 0.0 108.311 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 73.3 p -123.99 -176.88 3.6 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.542 1.152 . . . . 0.0 110.5 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.6 ttp85 . . . . . 0 C--N 1.324 -0.526 0 O-C-N 124.475 1.109 . . . . 0.0 110.333 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.25 -39.35 2.09 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.46 1.1 . . . . 0.0 110.942 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.418 ' O ' ' HB ' ' A' ' 35' ' ' THR . 5.9 mt -67.02 123.06 85.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.471 0.747 . . . . 0.0 109.29 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.876 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.01 71.85 4.86 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.509 1.794 . . . . 0.0 111.035 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.1 22.42 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.514 1.134 . . . . 0.0 109.314 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.3 t -57.08 -45.06 83.63 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.464 1.103 . . . . 0.0 108.302 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.31 -5.12 58.81 Favored Glycine 0 CA--C 1.531 1.074 0 O-C-N 124.498 1.124 . . . . 0.0 110.995 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.1 OUTLIER -126.09 175.01 8.05 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.572 0.807 . . . . 0.0 110.284 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.776 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.66 175.75 5.86 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 124.558 1.161 . . . . 0.0 110.419 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 28.3 p -154.59 68.75 0.73 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.674 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.5 t -73.4 -23.29 19.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.548 1.155 . . . . 0.0 109.368 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.06 -8.37 53.9 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.51 1.131 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.92 23.75 26.96 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 m -146.92 97.69 2.93 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.55 0.794 . . . . 0.0 110.399 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.499 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 3.3 m -57.2 140.29 50.09 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.445 1.091 . . . . 0.0 108.312 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -78.75 -0.25 29.55 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.506 1.129 . . . . 0.0 109.253 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 14.1 t -124.62 144.99 47.95 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.455 1.097 . . . . 0.0 110.423 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.99 179.8 5.73 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.508 1.794 . . . . 0.0 110.983 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.07 52.42 2.68 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.458 1.099 . . . . 0.0 110.997 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -124.03 176.41 6.37 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 28' ' ' THR . 3.1 m -137.8 75.92 1.55 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.494 1.122 . . . . 0.0 110.391 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.435 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.9 t -39.05 113.98 0.36 Allowed 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.544 1.153 . . . . 0.0 108.237 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 1.4 p -120.27 -20.02 7.46 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.483 1.114 . . . . 0.0 109.959 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.42 134.26 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.776 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.01 -19.65 17.37 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 121.011 -2.496 . . . . 0.0 110.946 0.069 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.6 t -110.76 149.01 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.492 1.12 . . . . 0.0 109.289 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.499 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 2.7 p -83.44 169.43 15.55 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 124.521 1.138 . . . . 0.0 108.27 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.876 HG22 ' HA ' ' A' ' 11' ' ' PRO . 25.3 p -129.06 -177.99 4.45 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.477 1.111 . . . . 0.0 110.376 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.326 -0.441 0 O-C-N 124.43 1.081 . . . . 0.0 110.257 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.9 p-10 . . . . . 0 N--CA 1.453 -0.299 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.429 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -135.9 -72.47 0.07 OUTLIER Glycine 0 CA--C 1.53 1.018 0 O-C-N 124.488 1.117 . . . . 0.0 110.935 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -137.09 162.97 52.53 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.454 0.738 . . . . 0.0 109.336 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.989 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.0 Cg_endo -75.01 57.04 4.44 Favored 'Trans proline' 0 C--N 1.359 1.122 0 O-C-N 124.472 1.775 . . . . 0.0 110.943 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.78 12.59 4.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 O-C-N 124.451 1.095 . . . . 0.0 109.302 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.461 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.4 t -44.41 -39.35 4.63 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.487 1.117 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.53 -1.66 62.17 Favored Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.444 1.09 . . . . 0.0 110.986 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.774 ' O ' HG12 ' A' ' 33' ' ' VAL . 2.4 tp10 -128.4 173.47 10.17 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.489 0.758 . . . . 0.0 110.331 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -126.04 175.04 8.01 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.488 1.118 . . . . 0.0 110.447 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.587 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 4.6 p -155.18 72.58 0.83 Allowed 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.478 1.111 . . . . 0.0 108.281 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.8 t -78.73 -24.33 13.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 O-C-N 124.544 1.152 . . . . 0.0 109.321 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.69 -9.49 64.36 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.459 1.099 . . . . 0.0 110.951 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.7 24.85 24.59 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 21' ' ' THR . 15.1 t -146.87 103.45 3.63 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.489 0.758 . . . . 0.0 110.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.9 OUTLIER -52.41 130.24 30.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.442 1.089 . . . . 0.0 108.299 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -77.79 -0.84 28.65 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.474 1.109 . . . . 0.0 109.325 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.461 HG21 ' SG ' ' A' ' 13' ' ' CYS . 14.1 t -130.31 143.82 50.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.591 1.182 . . . . 0.0 110.385 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.98 -178.56 4.25 Favored 'Trans proline' 0 C--N 1.36 1.148 0 O-C-N 124.535 1.808 . . . . 0.0 111.018 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.54 39.95 0.62 Allowed Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.486 1.116 . . . . 0.0 111.031 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.1 OUTLIER -116.05 176.45 5.09 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.976 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.533 HG22 ' O ' ' A' ' 28' ' ' THR . 2.9 m -135.9 70.72 1.42 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.401 1.063 . . . . 0.0 110.417 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.435 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 31.9 t -42.59 116.4 0.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.566 1.166 . . . . 0.0 108.25 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 18.0 m -123.12 -11.36 8.04 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.444 1.09 . . . . 0.0 110.017 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.33 135.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.979 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.737 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -23.72 12.26 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 121.064 -2.473 . . . . 0.0 110.984 -0.103 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -110.37 146.47 15.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.53 1.144 . . . . 0.0 109.278 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 10.6 p -77.54 173.68 11.73 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.455 1.097 . . . . 0.0 108.344 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.989 HG22 ' HA ' ' A' ' 11' ' ' PRO . 63.4 p -136.74 -177.3 4.68 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.489 1.118 . . . . 0.0 110.398 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.429 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.528 0 O-C-N 124.578 1.174 . . . . 0.0 110.319 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.418 ' HA ' HG21 ' A' ' 28' ' ' THR . 0.7 OUTLIER . . . . . 0 N--CA 1.454 -0.275 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.14 -63.63 0.32 Allowed Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.549 1.156 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -53.62 110.89 2.29 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.512 0.772 . . . . 0.0 109.316 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 77.7 3.06 Favored 'Trans proline' 0 C--N 1.361 1.201 0 O-C-N 124.436 1.756 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -140.77 24.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.525 1.14 . . . . 0.0 109.297 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 56.2 m -69.7 -45.5 68.12 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.508 1.13 . . . . 0.0 108.282 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.8 -10.39 72.39 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.522 1.139 . . . . 0.0 110.966 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.607 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -112.68 175.46 5.43 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.482 0.754 . . . . 0.0 110.309 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.746 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -125.92 177.26 6.42 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.483 1.114 . . . . 0.0 110.414 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.9 p -154.58 71.86 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 O-C-N 124.456 1.097 . . . . 0.0 108.236 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.663 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -76.95 -23.09 14.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.533 1.145 . . . . 0.0 109.31 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.99 -8.74 56.67 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.548 1.155 . . . . 0.0 111.019 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.74 23.0 26.93 Favored Glycine 0 CA--C 1.531 1.065 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 m -149.18 91.43 1.84 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.56 0.8 . . . . 0.0 110.358 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.4 p -50.02 153.7 1.3 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.541 1.151 . . . . 0.0 108.353 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.18 -0.73 57.68 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.478 1.111 . . . . 0.0 109.355 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 7.8 t -117.64 146.17 38.07 Favored Pre-proline 0 C--N 1.326 -0.435 0 O-C-N 124.481 1.113 . . . . 0.0 110.389 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.2 Cg_endo -74.99 177.95 7.9 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.549 1.815 . . . . 0.0 110.995 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 34.71 51.7 0.79 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.567 1.167 . . . . 0.0 111.047 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -121.92 159.06 27.66 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.736 HG22 ' O ' ' A' ' 28' ' ' THR . 1.0 OUTLIER -120.32 72.83 0.96 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.447 1.092 . . . . 0.0 110.402 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.451 ' C ' ' O ' ' A' ' 28' ' ' THR . 41.8 t -38.55 118.88 0.78 Allowed 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.536 1.147 . . . . 0.0 108.285 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 31' ' ' TRP . 46.3 t -120.63 -16.36 8.28 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.474 1.109 . . . . 0.0 110.002 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 134.99 0.04 OUTLIER Pre-proline 0 C--N 1.326 -0.43 0 O-C-N 124.493 1.12 . . . . 0.0 108.006 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.746 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -21.17 15.64 Favored 'Cis proline' 0 C--N 1.36 1.145 0 C-N-CA 121.027 -2.489 . . . . 0.0 110.98 0.018 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -110.97 148.33 14.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.489 1.118 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.488 ' SG ' ' N ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -67.05 177.98 1.56 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.531 1.144 . . . . 0.0 108.305 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.488 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 8.4 p -146.24 161.53 40.07 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.543 1.152 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 ttp85 . . . . . 0 C--N 1.325 -0.471 0 O-C-N 124.47 1.106 . . . . 0.0 110.346 -180.0 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.05 -55.13 0.36 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.464 1.103 . . . . 0.0 111.046 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.458 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 3.8 mt -62.9 114.97 14.05 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.476 0.751 . . . . 0.0 109.372 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 81.26 2.25 Favored 'Trans proline' 0 C--N 1.36 1.137 0 O-C-N 124.503 1.791 . . . . 0.0 110.937 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m -147.84 23.64 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.531 1.144 . . . . 0.0 109.276 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.412 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -66.51 -53.95 29.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.485 1.115 . . . . 0.0 108.3 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.531 1.041 0 O-C-N 124.458 1.099 . . . . 0.0 111.019 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.604 ' OE2' HG21 ' A' ' 24' ' ' THR . 9.1 mp0 -124.96 141.99 51.77 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.605 0.826 . . . . 0.0 110.245 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.797 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.02 173.67 7.31 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.495 1.122 . . . . 0.0 110.425 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.569 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 20.6 p -151.81 73.46 1.06 Allowed 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.523 1.139 . . . . 0.0 108.243 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -79.62 -24.62 12.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 124.561 1.163 . . . . 0.0 109.348 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.73 -13.29 55.49 Favored Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.515 1.134 . . . . 0.0 111.004 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.1 17.78 19.36 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 m -143.23 94.98 2.69 Favored 'General case' 0 C--N 1.326 -0.438 0 O-C-N 124.478 0.752 . . . . 0.0 110.375 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.52 ' HB2' HG22 ' A' ' 24' ' ' THR . 12.7 p -45.99 -31.09 2.06 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.523 1.139 . . . . 0.0 108.316 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.482 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 21.4 t30 80.72 -1.36 1.86 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.429 1.081 . . . . 0.0 109.285 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.604 HG21 ' OE2' ' A' ' 15' ' ' GLU . 6.0 t -119.72 147.81 44.75 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.47 1.106 . . . . 0.0 110.342 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.445 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.02 173.16 15.0 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.485 1.782 . . . . 0.0 110.994 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.91 44.91 1.52 Allowed Glycine 0 CA--C 1.529 0.963 0 O-C-N 124.487 1.117 . . . . 0.0 110.977 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.488 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.48 160.77 21.14 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.587 HG22 ' O ' ' A' ' 28' ' ' THR . 2.0 m -129.57 70.31 1.42 Allowed 'General case' 0 C--N 1.324 -0.515 0 O-C-N 124.496 1.122 . . . . 0.0 110.388 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.447 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -38.55 113.35 0.29 Allowed 'General case' 0 C--N 1.323 -0.553 0 O-C-N 124.572 1.17 . . . . 0.0 108.23 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -118.93 -14.72 9.4 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.528 1.143 . . . . 0.0 110.056 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.49 136.38 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 107.935 179.92 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.797 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -75.01 -19.86 17.15 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 121.057 -2.476 . . . . 0.0 110.977 0.056 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.89 149.2 14.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.542 1.151 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -68.46 171.27 7.63 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.484 1.115 . . . . 0.0 108.333 179.919 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.402 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 33.6 p -135.21 166.58 22.76 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.137 . . . . 0.0 110.435 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.458 ' CG ' ' HB2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.473 0 O-C-N 124.507 1.129 . . . . 0.0 110.309 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.93 45.16 4.91 Favored Glycine 0 CA--C 1.53 1.007 0 O-C-N 124.47 1.106 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.681 ' C ' HG22 ' A' ' 35' ' ' THR . 20.1 mt -128.58 125.62 23.18 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.543 0.79 . . . . 0.0 109.289 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.428 ' N ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.04 55.47 3.98 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.528 1.804 . . . . 0.0 110.977 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.587 HG22 ' HB3' ' A' ' 10' ' ' LEU . 14.7 m -144.25 17.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.597 1.186 . . . . 0.0 109.256 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' HG21 ' A' ' 24' ' ' THR . 51.1 t -48.94 -26.58 2.57 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.52 1.138 . . . . 0.0 108.304 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.99 -11.54 56.94 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.436 1.085 . . . . 0.0 111.017 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.521 ' HG3' HG23 ' A' ' 24' ' ' THR . 4.4 mm-40 -124.58 145.51 49.56 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.502 0.766 . . . . 0.0 110.276 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.747 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -95.84 179.69 5.01 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.551 1.157 . . . . 0.0 110.399 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.604 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 32.0 p -156.69 69.16 0.6 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.506 1.129 . . . . 0.0 108.262 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.658 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.93 -22.0 15.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.598 1.186 . . . . 0.0 109.327 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.85 -8.28 34.69 Favored Glycine 0 CA--C 1.531 1.032 0 O-C-N 124.49 1.119 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.74 19.8 28.36 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' HG22 ' A' ' 21' ' ' THR . 11.0 m -124.53 72.37 1.2 Allowed 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.499 0.764 . . . . 0.0 110.401 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.7 p -41.42 -36.07 0.79 Allowed 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.529 1.143 . . . . 0.0 108.357 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.5 t30 60.91 21.9 12.09 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 124.565 1.165 . . . . 0.0 109.297 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.906 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -116.76 151.0 46.73 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.363 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.906 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.3 Cg_endo -75.0 139.65 24.51 Favored 'Trans proline' 0 C--N 1.36 1.17 0 O-C-N 124.448 1.762 . . . . 0.0 111.002 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.6 50.45 8.33 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.464 1.103 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -109.75 169.6 8.61 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.736 ' O ' HG23 ' A' ' 28' ' ' THR . 13.4 t -139.68 63.62 1.48 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.427 1.079 . . . . 0.0 110.461 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.623 ' C ' ' O ' ' A' ' 28' ' ' THR . 39.2 t -24.05 116.55 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.604 1.19 . . . . 0.0 108.34 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 40.5 t -119.51 -13.8 9.18 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.571 1.169 . . . . 0.0 109.989 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.666 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.54 137.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.478 0 O-C-N 124.58 1.175 . . . . 0.0 107.986 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.747 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.98 -19.27 17.75 Favored 'Cis proline' 0 C--N 1.36 1.183 0 C-N-CA 120.975 -2.51 . . . . 0.0 110.933 0.017 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 16' ' ' THR . 2.8 t -110.7 152.4 12.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.556 1.16 . . . . 0.0 109.21 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.2 158.0 22.5 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.532 1.145 . . . . 0.0 108.275 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.681 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -126.37 152.83 45.76 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.501 1.126 . . . . 0.0 110.401 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 8.9 mtp180 . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.482 1.114 . . . . 0.0 110.339 179.932 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.85 -53.61 0.57 Allowed Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.557 1.161 . . . . 0.0 110.938 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -57.45 109.54 1.83 Allowed Pre-proline 0 C--N 1.325 -0.468 0 O-C-N 124.444 0.732 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.97 69.29 5.57 Favored 'Trans proline' 0 C--N 1.36 1.171 0 O-C-N 124.486 1.782 . . . . 0.0 111.03 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 m -135.32 20.77 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.469 1.106 . . . . 0.0 109.288 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 17.6 m -63.35 -43.39 97.84 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.474 1.109 . . . . 0.0 108.3 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.87 -6.44 82.85 Favored Glycine 0 CA--C 1.529 0.923 0 O-C-N 124.474 1.109 . . . . 0.0 110.993 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -120.3 141.53 49.93 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.456 0.739 . . . . 0.0 110.268 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.777 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -96.28 176.56 6.02 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.454 1.096 . . . . 0.0 110.383 -179.965 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.61 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.4 p -152.2 74.15 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.447 1.092 . . . . 0.0 108.316 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -80.37 -21.91 11.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.443 1.089 . . . . 0.0 109.286 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.67 -10.56 43.39 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.448 1.092 . . . . 0.0 111.035 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.8 18.36 25.42 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.599 0.823 . . . . 0.0 111.047 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.417 ' C ' ' N ' ' A' ' 23' ' ' ASN . 57.2 m -137.31 86.26 2.18 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.526 0.78 . . . . 0.0 110.391 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.777 ' HB2' HG22 ' A' ' 24' ' ' THR . 0.8 OUTLIER -41.79 -31.89 0.35 Allowed 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.462 1.101 . . . . 0.0 108.263 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.462 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 5.8 t-20 79.61 -1.7 2.15 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 109.261 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.777 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.0 t -119.57 147.89 44.66 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.533 1.146 . . . . 0.0 110.414 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 174.05 13.44 Favored 'Trans proline' 0 C--N 1.36 1.146 0 O-C-N 124.421 1.748 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.69 47.19 1.2 Allowed Glycine 0 CA--C 1.53 0.98 0 O-C-N 124.422 1.076 . . . . 0.0 111.049 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.509 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -127.26 148.88 50.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.974 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.84 HG22 ' O ' ' A' ' 35' ' ' THR . 9.5 t -119.74 70.47 0.86 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.499 1.125 . . . . 0.0 110.414 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.491 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.6 t -34.5 117.2 0.35 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.459 1.099 . . . . 0.0 108.305 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 22.5 p -119.6 -12.43 9.29 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.459 1.099 . . . . 0.0 110.034 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.679 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.02 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.462 0 O-C-N 124.511 1.132 . . . . 0.0 107.988 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.777 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.04 -20.89 16.05 Favored 'Cis proline' 0 C--N 1.361 1.223 0 C-N-CA 120.969 -2.513 . . . . 0.0 111.01 0.006 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.401 HG22 HG23 ' A' ' 16' ' ' THR . 0.9 OUTLIER -114.81 148.99 17.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 O-C-N 124.468 1.105 . . . . 0.0 109.289 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.481 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -67.09 177.31 1.8 Allowed 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.579 1.174 . . . . 0.0 108.349 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.84 ' O ' HG22 ' A' ' 28' ' ' THR . 1.0 OUTLIER -147.29 151.71 37.07 Favored 'General case' 0 C--N 1.323 -0.546 0 O-C-N 124.538 1.149 . . . . 0.0 110.443 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.519 1.137 . . . . 0.0 110.246 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.47 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -150.16 -92.65 0.1 OUTLIER Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.54 1.15 . . . . 0.0 110.981 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.413 ' O ' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -109.86 158.39 35.06 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.485 0.756 . . . . 0.0 109.34 179.958 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 74.24 4.07 Favored 'Trans proline' 0 C--N 1.36 1.183 0 O-C-N 124.445 1.76 . . . . 0.0 110.981 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 m -131.46 15.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 O-C-N 124.492 1.12 . . . . 0.0 109.268 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.512 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.7 t -51.04 -42.85 60.75 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.513 1.133 . . . . 0.0 108.342 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.75 62.74 Favored Glycine 0 CA--C 1.529 0.949 0 O-C-N 124.559 1.162 . . . . 0.0 111.033 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.732 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -130.83 173.13 11.26 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.517 0.775 . . . . 0.0 110.315 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.932 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -120.05 173.88 6.82 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.511 1.132 . . . . 0.0 110.402 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.593 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 23.3 p -151.78 67.43 0.88 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.501 1.125 . . . . 0.0 108.276 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.2 t -73.97 -20.88 17.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 O-C-N 124.474 1.109 . . . . 0.0 109.306 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.51 -10.56 28.92 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.513 1.133 . . . . 0.0 111.019 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.3 17.85 20.98 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 m -129.68 87.43 2.54 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.432 0.724 . . . . 0.0 110.418 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 16' ' ' THR . 26.5 p -53.45 -39.28 64.31 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 124.446 1.091 . . . . 0.0 108.343 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 69.64 8.19 6.61 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.524 1.14 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.884 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -104.27 150.46 38.42 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.539 1.149 . . . . 0.0 110.36 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.884 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.99 139.79 24.72 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.563 1.822 . . . . 0.0 110.968 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 47.25 50.42 17.08 Favored Glycine 0 CA--C 1.529 0.939 0 O-C-N 124.462 1.101 . . . . 0.0 110.988 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.75 165.6 13.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.98 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.72 ' O ' HG23 ' A' ' 28' ' ' THR . 2.6 t -137.24 90.82 2.56 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.538 1.149 . . . . 0.0 110.424 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.438 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.6 t -38.49 112.82 0.25 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.427 1.08 . . . . 0.0 108.268 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.7 t -116.45 -21.14 9.37 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.452 1.095 . . . . 0.0 109.982 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.35 136.28 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 108.043 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.813 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -16.42 21.19 Favored 'Cis proline' 0 C--N 1.359 1.12 0 C-N-CA 121.025 -2.49 . . . . 0.0 110.983 0.064 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.932 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -117.05 150.72 18.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.486 1.117 . . . . 0.0 109.284 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 27' ' ' CYS . 1.4 p -82.69 162.51 21.79 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.443 1.089 . . . . 0.0 108.296 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.518 ' OG1' HG22 ' A' ' 28' ' ' THR . 16.8 p -131.97 178.21 6.95 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.527 1.142 . . . . 0.0 110.377 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.47 ' C ' ' N ' ' A' ' 9' ' ' GLY . 4.7 mtp180 . . . . . 0 C--N 1.325 -0.481 0 O-C-N 124.571 1.17 . . . . 0.0 110.341 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HA ' HG21 ' A' ' 28' ' ' THR . 2.3 t-20 . . . . . 0 N--CA 1.453 -0.321 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.481 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -149.14 -60.39 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.536 1.147 . . . . 0.0 110.994 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 27.1 mt -141.84 160.53 55.58 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.529 0.782 . . . . 0.0 109.326 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 70.84 5.18 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.416 1.745 . . . . 0.0 111.023 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 m -127.71 16.61 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.476 1.11 . . . . 0.0 109.313 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -46.1 87.35 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.543 1.152 . . . . 0.0 108.381 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.73 -5.88 76.86 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.769 ' O ' HG12 ' A' ' 33' ' ' VAL . 8.9 tp10 -116.7 165.46 13.25 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.425 0.721 . . . . 0.0 110.327 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -118.52 174.22 6.38 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.521 1.138 . . . . 0.0 110.319 -179.912 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.532 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 8.6 p -153.89 72.33 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.5 1.125 . . . . 0.0 108.312 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -77.83 -25.06 14.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.558 1.162 . . . . 0.0 109.331 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.2 -11.71 64.38 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.525 1.14 . . . . 0.0 110.966 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.81 22.02 19.44 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.1 m -157.85 97.05 1.53 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.52 0.777 . . . . 0.0 110.445 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 24' ' ' THR . 17.4 p -47.84 165.29 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.565 1.165 . . . . 0.0 108.274 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -97.16 -0.77 46.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.437 1.086 . . . . 0.0 109.311 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.438 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.9 t -117.53 147.53 40.96 Favored Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.536 1.147 . . . . 0.0 110.383 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.438 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.97 174.57 12.55 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.538 1.809 . . . . 0.0 110.996 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.41 51.6 1.34 Allowed Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.481 1.113 . . . . 0.0 110.96 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -115.75 162.78 16.79 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 179.943 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.474 HG22 ' O ' ' A' ' 28' ' ' THR . 8.3 m -120.92 68.35 0.87 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.491 1.12 . . . . 0.0 110.364 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 28' ' ' THR . 49.3 t -40.99 115.49 0.6 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.481 1.113 . . . . 0.0 108.313 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.435 ' O ' ' O ' ' A' ' 31' ' ' TRP . 23.1 t -120.32 -14.4 8.76 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.498 1.124 . . . . 0.0 110.057 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.694 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.14 135.74 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.95 -21.16 15.63 Favored 'Cis proline' 0 C--N 1.359 1.112 0 C-N-CA 121.029 -2.488 . . . . 0.0 111.001 -0.01 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.769 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -110.55 149.15 13.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.493 1.12 . . . . 0.0 109.274 -179.964 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -71.24 177.46 3.85 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.52 1.138 . . . . 0.0 108.255 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.458 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 41.6 p -141.05 167.2 22.75 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.472 1.108 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.481 ' C ' ' N ' ' A' ' 9' ' ' GLY . 12.3 ttp85 . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.562 1.164 . . . . 0.0 110.21 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.38 43.49 0.29 Allowed Glycine 0 CA--C 1.529 0.936 0 O-C-N 124.487 1.117 . . . . 0.0 111.06 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.717 ' C ' HG22 ' A' ' 35' ' ' THR . 23.3 mt -141.32 109.72 6.31 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.399 0.705 . . . . 0.0 109.309 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 56.51 4.26 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.458 1.767 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 10' ' ' LEU . 21.9 m -138.38 21.37 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 124.515 1.135 . . . . 0.0 109.307 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -46.09 86.61 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.576 1.172 . . . . 0.0 108.278 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.84 -7.17 62.8 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.105 . . . . 0.0 110.935 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.468 ' HG3' HG23 ' A' ' 24' ' ' THR . 7.4 mm-40 -124.44 147.87 48.01 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.523 0.778 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -101.42 179.38 4.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.462 1.101 . . . . 0.0 110.374 -179.935 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.6 p -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.453 1.096 . . . . 0.0 108.319 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -79.83 -23.46 11.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.519 1.137 . . . . 0.0 109.367 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.96 -11.2 37.88 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.538 1.149 . . . . 0.0 111.002 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.46 18.93 26.84 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -123.17 76.61 1.4 Allowed 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.504 0.767 . . . . 0.0 110.38 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.601 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 41.9 t -39.99 -45.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.556 1.16 . . . . 0.0 108.312 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 68.52 8.96 7.01 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.522 1.139 . . . . 0.0 109.296 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.897 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -107.74 151.22 41.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.493 1.12 . . . . 0.0 110.42 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.897 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.01 140.76 25.8 Favored 'Trans proline' 0 C--N 1.36 1.161 0 O-C-N 124.529 1.805 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.68 50.8 5.8 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 124.527 1.142 . . . . 0.0 111.018 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.446 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -112.18 163.64 14.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.795 ' O ' HG23 ' A' ' 28' ' ' THR . 8.0 t -133.67 69.32 1.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.478 1.111 . . . . 0.0 110.363 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.569 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.6 t -28.56 119.5 0.12 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.478 1.111 . . . . 0.0 108.292 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 31' ' ' TRP . 53.7 p -120.54 -14.57 8.63 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.473 1.108 . . . . 0.0 109.975 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.681 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 136.67 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.755 ' O ' HG22 ' A' ' 16' ' ' THR . 18.5 Cg_endo -74.93 -20.87 15.96 Favored 'Cis proline' 0 C--N 1.361 1.187 0 C-N-CA 121.007 -2.497 . . . . 0.0 111.027 -0.065 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -113.34 148.46 16.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 O-C-N 124.432 1.083 . . . . 0.0 109.282 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.601 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER -65.62 177.92 1.11 Allowed 'General case' 0 C--N 1.326 -0.427 0 O-C-N 124.45 1.094 . . . . 0.0 108.274 -179.962 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.717 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -151.67 158.21 43.13 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.514 1.134 . . . . 0.0 110.36 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 . . . . . 0 C--N 1.326 -0.444 0 O-C-N 124.459 1.1 . . . . 0.0 110.343 -179.944 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.468 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -131.27 -71.78 0.1 Allowed Glycine 0 CA--C 1.53 0.989 0 O-C-N 124.477 1.11 . . . . 0.0 110.978 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.25 159.74 65.0 Favored Pre-proline 0 C--N 1.325 -0.473 0 O-C-N 124.457 0.74 . . . . 0.0 109.341 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.777 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.3 Cg_endo -75.01 67.18 5.98 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.511 1.796 . . . . 0.0 111.033 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.0 m -137.83 26.68 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.549 1.155 . . . . 0.0 109.258 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.45 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.5 OUTLIER -58.72 -36.42 74.27 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.506 1.129 . . . . 0.0 108.29 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.48 -11.24 64.23 Favored Glycine 0 CA--C 1.529 0.913 0 O-C-N 124.532 1.145 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.559 ' OE1' HG23 ' A' ' 24' ' ' THR . 0.6 OUTLIER -116.55 169.54 9.26 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.433 0.725 . . . . 0.0 110.334 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.709 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.61 173.47 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.419 1.074 . . . . 0.0 110.348 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.567 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 7.0 p -150.13 60.53 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.471 1.107 . . . . 0.0 108.228 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.6 t -70.45 -23.7 24.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 O-C-N 124.476 1.11 . . . . 0.0 109.324 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.77 -7.46 55.47 Favored Glycine 0 CA--C 1.531 1.059 0 O-C-N 124.467 1.104 . . . . 0.0 110.984 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.88 19.8 23.29 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 21' ' ' THR . 14.8 t -137.8 94.67 2.93 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.551 0.795 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.9 p -54.87 -32.88 61.28 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.517 1.136 . . . . 0.0 108.251 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 63.41 13.14 6.87 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.472 1.107 . . . . 0.0 109.292 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.918 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -108.49 151.53 41.64 Favored Pre-proline 0 C--N 1.325 -0.486 0 O-C-N 124.466 1.104 . . . . 0.0 110.419 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.918 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.5 Cg_endo -74.9 141.42 26.93 Favored 'Trans proline' 0 C--N 1.359 1.096 0 O-C-N 124.475 1.776 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.42 50.95 4.62 Favored Glycine 0 CA--C 1.53 1.026 0 O-C-N 124.43 1.081 . . . . 0.0 111.026 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.45 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -109.28 163.62 13.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.726 ' O ' HG23 ' A' ' 28' ' ' THR . 13.8 t -129.75 61.24 1.57 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.533 1.145 . . . . 0.0 110.427 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.599 ' C ' ' O ' ' A' ' 28' ' ' THR . 22.6 t -26.09 117.36 0.07 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.546 1.154 . . . . 0.0 108.314 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -120.19 -14.23 8.83 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.428 1.08 . . . . 0.0 109.968 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.53 138.01 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.512 1.133 . . . . 0.0 107.983 179.965 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.709 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.03 -19.71 17.33 Favored 'Cis proline' 0 C--N 1.36 1.15 0 C-N-CA 121.054 -2.478 . . . . 0.0 110.94 0.029 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.8 t -113.67 147.93 16.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.485 1.116 . . . . 0.0 109.307 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -77.22 174.0 11.24 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.459 1.1 . . . . 0.0 108.303 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' HA ' ' A' ' 11' ' ' PRO . 1.1 p -145.01 164.64 30.54 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.539 1.149 . . . . 0.0 110.397 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.468 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.478 0 O-C-N 124.507 1.129 . . . . 0.0 110.306 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.26 -39.84 1.68 Allowed Glycine 0 CA--C 1.529 0.942 0 O-C-N 124.544 1.152 . . . . 0.0 111.021 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -61.95 113.49 8.64 Favored Pre-proline 0 C--N 1.325 -0.457 0 O-C-N 124.437 0.728 . . . . 0.0 109.271 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.881 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.5 Cg_endo -75.08 64.97 6.15 Favored 'Trans proline' 0 C--N 1.36 1.165 0 O-C-N 124.479 1.778 . . . . 0.0 110.983 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -138.85 21.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.435 1.085 . . . . 0.0 109.335 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.428 ' SG ' HG21 ' A' ' 24' ' ' THR . 26.7 t -57.96 -41.96 83.98 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.475 1.109 . . . . 0.0 108.283 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.65 -7.68 68.27 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.416 ' O ' HG12 ' A' ' 33' ' ' VAL . 15.4 mm-40 -124.03 155.89 37.48 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.466 0.745 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -105.52 176.63 5.1 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.566 1.166 . . . . 0.0 110.459 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.2 p -154.46 68.76 0.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.52 1.138 . . . . 0.0 108.329 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.672 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -74.78 -21.32 16.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.533 1.145 . . . . 0.0 109.338 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.95 -6.31 40.12 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.552 1.158 . . . . 0.0 111.035 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.82 21.46 28.41 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 21' ' ' THR . 2.5 m -131.7 79.4 1.87 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.538 0.787 . . . . 0.0 110.428 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.5 p -45.16 -30.94 1.27 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.54 1.15 . . . . 0.0 108.36 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 59.86 16.01 5.34 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.477 1.111 . . . . 0.0 109.312 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.851 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -111.3 150.3 41.84 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.498 1.124 . . . . 0.0 110.393 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.851 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.09 141.54 26.51 Favored 'Trans proline' 0 C--N 1.359 1.103 0 O-C-N 124.52 1.8 . . . . 0.0 111.009 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.84 50.1 5.08 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.506 1.129 . . . . 0.0 110.95 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.406 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -107.13 175.52 5.47 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -141.33 72.15 1.38 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.457 1.098 . . . . 0.0 110.357 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.7 t -38.81 114.56 0.4 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.521 1.138 . . . . 0.0 108.305 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 15.9 t -120.89 -12.09 8.85 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.552 1.158 . . . . 0.0 110.009 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.672 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.46 137.26 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.52 1.138 . . . . 0.0 108.007 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.97 -19.72 17.25 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.058 -2.476 . . . . 0.0 110.99 -0.022 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -113.84 150.27 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.263 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -77.62 166.59 22.83 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.482 1.113 . . . . 0.0 108.366 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.881 HG22 ' HA ' ' A' ' 11' ' ' PRO . 3.0 p -133.36 174.58 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.51 1.131 . . . . 0.0 110.375 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 . . . . . 0 C--N 1.324 -0.524 0 O-C-N 124.527 1.142 . . . . 0.0 110.36 179.932 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.23 -48.62 0.7 Allowed Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.532 1.145 . . . . 0.0 111.009 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -61.5 111.73 4.83 Favored Pre-proline 0 C--N 1.324 -0.525 0 O-C-N 124.585 0.815 . . . . 0.0 109.311 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.7 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.05 69.39 5.6 Favored 'Trans proline' 0 C--N 1.361 1.186 0 O-C-N 124.43 1.753 . . . . 0.0 110.967 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.57 21.79 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 O-C-N 124.483 1.114 . . . . 0.0 109.299 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.593 ' SG ' HG21 ' A' ' 24' ' ' THR . 5.3 t -60.76 -46.08 91.82 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.535 1.147 . . . . 0.0 108.346 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.21 -5.63 65.67 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.452 1.095 . . . . 0.0 110.944 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -123.35 146.15 48.17 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.49 0.759 . . . . 0.0 110.354 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.782 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.81 175.47 5.95 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.409 1.068 . . . . 0.0 110.41 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.56 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.2 p -153.93 65.9 0.72 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 108.27 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.682 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -71.86 -22.39 21.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 O-C-N 124.388 1.055 . . . . 0.0 109.327 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.08 -7.19 50.53 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.491 1.119 . . . . 0.0 110.994 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.97 21.34 23.51 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 22.9 m -138.39 93.71 2.77 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.447 0.733 . . . . 0.0 110.387 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 7.4 p -47.33 -37.6 11.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.384 1.053 . . . . 0.0 108.283 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.494 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER 82.43 -1.05 1.38 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.56 1.162 . . . . 0.0 109.311 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.652 HG23 ' HB3' ' A' ' 27' ' ' CYS . 14.9 t -127.83 144.53 51.64 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.492 1.12 . . . . 0.0 110.436 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.05 179.42 6.12 Favored 'Trans proline' 0 C--N 1.359 1.116 0 O-C-N 124.505 1.792 . . . . 0.0 110.969 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 40.84 32.15 0.5 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.511 1.132 . . . . 0.0 111.019 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.652 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -115.43 166.47 11.85 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 35' ' ' THR . 17.3 m -136.64 74.43 1.49 Allowed 'General case' 0 C--N 1.324 -0.516 0 O-C-N 124.574 1.171 . . . . 0.0 110.385 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.427 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.8 t -39.93 109.78 0.12 Allowed 'General case' 0 C--N 1.326 -0.444 0 O-C-N 124.463 1.102 . . . . 0.0 108.322 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.1 OUTLIER -118.1 -11.27 10.19 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.495 1.122 . . . . 0.0 109.996 179.979 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.682 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.62 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.546 1.154 . . . . 0.0 108.028 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.782 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -20.09 16.87 Favored 'Cis proline' 0 C--N 1.359 1.114 0 C-N-CA 121.026 -2.489 . . . . 0.0 111.001 0.016 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -114.56 148.76 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.492 1.12 . . . . 0.0 109.411 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 21.1 p -74.77 160.18 31.05 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.7 HG22 ' HA ' ' A' ' 11' ' ' PRO . 23.3 p -127.35 -177.86 4.23 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.52 1.138 . . . . 0.0 110.383 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 . . . . . 0 C--N 1.324 -0.506 0 O-C-N 124.533 1.146 . . . . 0.0 110.322 179.963 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.1 p-10 . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.48 -51.12 0.63 Allowed Glycine 0 CA--C 1.53 0.978 0 O-C-N 124.484 1.115 . . . . 0.0 111.047 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.8 mt -56.22 114.73 8.17 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.46 0.741 . . . . 0.0 109.297 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.415 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -74.97 70.86 5.16 Favored 'Trans proline' 0 C--N 1.361 1.191 0 O-C-N 124.446 1.761 . . . . 0.0 111.002 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.1 m -142.24 22.82 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.494 1.121 . . . . 0.0 109.302 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.482 ' SG ' HG21 ' A' ' 24' ' ' THR . 4.6 t -55.94 -43.96 77.93 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.559 1.162 . . . . 0.0 108.239 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.19 -6.13 61.51 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.505 1.128 . . . . 0.0 110.971 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -125.57 175.15 7.75 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.512 0.772 . . . . 0.0 110.363 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.708 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.4 OUTLIER -122.52 176.08 6.11 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 124.493 1.121 . . . . 0.0 110.432 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.605 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 27.3 p -153.36 66.7 0.77 Allowed 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.454 1.096 . . . . 0.0 108.312 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.668 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -73.8 -22.82 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.49 1.119 . . . . 0.0 109.362 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.06 -10.97 44.22 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.466 1.104 . . . . 0.0 111.021 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 103.65 16.17 20.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 21' ' ' THR . 14.5 t -132.84 100.31 4.87 Favored 'General case' 0 C--N 1.326 -0.443 0 O-C-N 124.529 0.782 . . . . 0.0 110.424 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.8 p -59.02 -39.45 81.95 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.519 1.137 . . . . 0.0 108.301 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 69.3 10.09 7.62 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.529 1.143 . . . . 0.0 109.31 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.856 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.6 OUTLIER -107.87 150.14 39.93 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 124.502 1.126 . . . . 0.0 110.338 -179.936 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.856 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.08 141.75 26.78 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.498 1.788 . . . . 0.0 111.003 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 43.45 49.39 6.96 Favored Glycine 0 CA--C 1.531 1.04 0 O-C-N 124.5 1.125 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.28 178.42 4.55 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 28' ' ' THR . 1.2 m -145.01 72.22 1.32 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.498 1.124 . . . . 0.0 110.471 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.45 ' C ' ' O ' ' A' ' 28' ' ' THR . 37.2 t -38.26 113.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.525 1.141 . . . . 0.0 108.368 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 45.5 t -120.93 -12.64 8.75 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.513 1.133 . . . . 0.0 109.963 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.668 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.37 136.22 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.47 0 O-C-N 124.489 1.118 . . . . 0.0 108.003 -179.946 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.708 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.96 -22.0 14.51 Favored 'Cis proline' 0 C--N 1.361 1.188 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -0.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.9 t -109.32 148.79 12.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.558 1.161 . . . . 0.0 109.297 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.4 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.1 p -81.14 162.65 23.57 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.503 1.127 . . . . 0.0 108.291 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.468 ' O ' ' N ' ' A' ' 28' ' ' THR . 40.8 p -121.2 -171.98 2.31 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.484 1.115 . . . . 0.0 110.403 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 76.0 mtp180 . . . . . 0 C--N 1.325 -0.492 0 O-C-N 124.559 1.162 . . . . 0.0 110.281 -179.994 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 36' ' ' ARG . 20.6 p30 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.49 -57.32 0.66 Allowed Glycine 0 CA--C 1.53 0.988 0 O-C-N 124.49 1.119 . . . . 0.0 110.987 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 mt -52.54 109.41 1.42 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.486 0.756 . . . . 0.0 109.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.741 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.06 69.18 5.66 Favored 'Trans proline' 0 C--N 1.361 1.19 0 O-C-N 124.409 1.742 . . . . 0.0 110.972 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -138.5 19.98 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.297 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.545 ' SG ' HG21 ' A' ' 24' ' ' THR . 3.3 t -52.88 -43.53 66.2 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.527 1.142 . . . . 0.0 108.321 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.65 -3.99 63.48 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.471 1.107 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.43 173.46 9.8 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.49 0.759 . . . . 0.0 110.358 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.72 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.8 OUTLIER -120.73 178.81 4.55 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.509 1.131 . . . . 0.0 110.43 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.612 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 31.7 p -155.54 62.86 0.61 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.524 1.14 . . . . 0.0 108.328 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.654 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -70.34 -21.0 23.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.509 1.131 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.07 -4.15 33.57 Favored Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.535 1.147 . . . . 0.0 110.994 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.57 22.16 29.68 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 22' ' ' CYS . 49.9 m -126.69 80.5 1.94 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.482 0.754 . . . . 0.0 110.473 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 21' ' ' THR . 41.1 t -41.56 -49.16 4.07 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.424 1.077 . . . . 0.0 108.327 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.5 t30 71.27 10.0 6.65 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.471 1.107 . . . . 0.0 109.327 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.841 HG22 ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -113.0 148.54 39.62 Favored Pre-proline 0 C--N 1.324 -0.502 0 O-C-N 124.439 1.087 . . . . 0.0 110.436 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.841 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 142.84 28.41 Favored 'Trans proline' 0 C--N 1.36 1.158 0 O-C-N 124.464 1.771 . . . . 0.0 111.054 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.02 49.06 7.9 Favored Glycine 0 CA--C 1.53 0.996 0 O-C-N 124.473 1.108 . . . . 0.0 110.987 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.469 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -108.92 178.11 4.57 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.649 HG22 ' O ' ' A' ' 28' ' ' THR . 1.2 m -145.77 73.33 1.34 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.518 1.136 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.477 ' C ' ' O ' ' A' ' 28' ' ' THR . 40.0 t -36.68 112.37 0.18 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.47 1.106 . . . . 0.0 108.258 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 16.5 t -119.97 -13.99 8.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.425 1.078 . . . . 0.0 110.001 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.67 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.59 136.72 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.523 0 O-C-N 124.564 1.165 . . . . 0.0 108.013 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.98 -20.99 15.88 Favored 'Cis proline' 0 C--N 1.36 1.172 0 C-N-CA 120.986 -2.506 . . . . 0.0 111.005 -0.042 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 15' ' ' GLU . 1.4 t -112.62 146.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.458 1.099 . . . . 0.0 109.3 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 1.8 p -78.36 161.46 27.17 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 124.544 1.153 . . . . 0.0 108.249 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.741 HG22 ' HA ' ' A' ' 11' ' ' PRO . 22.1 p -126.07 -175.99 3.52 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.526 1.141 . . . . 0.0 110.391 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.404 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.463 1.102 . . . . 0.0 110.299 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 140.7 -49.24 0.79 Allowed Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.545 1.153 . . . . 0.0 110.976 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 mt -54.79 114.15 6.47 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.568 0.805 . . . . 0.0 109.26 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -75.01 71.46 5.01 Favored 'Trans proline' 0 C--N 1.36 1.16 0 O-C-N 124.522 1.801 . . . . 0.0 111.003 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 m -142.39 23.52 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 O-C-N 124.595 1.185 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.443 ' SG ' HG21 ' A' ' 24' ' ' THR . 11.8 t -64.02 -45.68 87.83 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.499 1.125 . . . . 0.0 108.32 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.33 -6.43 71.68 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 124.575 1.172 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.407 ' HG3' HG21 ' A' ' 24' ' ' THR . 3.4 mm-40 -121.76 144.76 48.61 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.416 0.715 . . . . 0.0 110.258 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.808 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -95.82 174.72 6.82 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.487 1.117 . . . . 0.0 110.398 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.506 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.1 p -154.28 66.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.455 1.097 . . . . 0.0 108.342 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.693 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -71.69 -22.54 21.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.585 1.178 . . . . 0.0 109.377 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.38 -7.56 45.69 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.465 1.103 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.8 20.66 23.49 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 111.016 -0.833 . . . . 0.0 111.016 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 98.4 m -136.11 94.11 3.0 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 0.773 . . . . 0.0 110.394 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 4.7 m -46.59 -38.2 9.19 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.583 1.177 . . . . 0.0 108.303 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER 84.33 -0.93 0.97 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.506 1.129 . . . . 0.0 109.213 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.443 HG21 ' SG ' ' A' ' 13' ' ' CYS . 13.7 t -128.03 144.95 53.42 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.457 1.098 . . . . 0.0 110.378 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.92 166.05 30.07 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.418 1.747 . . . . 0.0 111.006 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 50.61 47.48 45.36 Favored Glycine 0 CA--C 1.531 1.064 0 O-C-N 124.483 1.115 . . . . 0.0 111.003 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.448 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -128.14 174.96 8.8 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 -179.995 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.523 HG22 ' O ' ' A' ' 28' ' ' THR . 1.3 m -145.4 82.01 1.64 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.471 1.107 . . . . 0.0 110.409 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.449 ' C ' ' O ' ' A' ' 28' ' ' THR . 34.0 t -38.29 114.43 0.36 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.52 1.138 . . . . 0.0 108.273 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.3 t -119.73 -19.79 7.89 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 109.978 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.22 135.97 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.531 0 O-C-N 124.546 1.154 . . . . 0.0 108.033 -179.922 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.808 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -17.52 19.9 Favored 'Cis proline' 0 C--N 1.36 1.175 0 C-N-CA 121.035 -2.486 . . . . 0.0 110.963 0.052 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -114.05 148.97 16.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.547 1.155 . . . . 0.0 109.287 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.456 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 16.3 p -78.24 163.96 25.32 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.512 1.133 . . . . 0.0 108.233 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 28' ' ' THR . 44.4 p -131.17 -177.62 4.47 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.473 1.108 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 . . . . . 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.297 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.04 -36.07 2.2 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.533 1.146 . . . . 0.0 111.034 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.446 HD23 ' HA ' ' A' ' 10' ' ' LEU . 12.5 mt -74.34 116.88 57.21 Favored Pre-proline 0 C--N 1.324 -0.513 0 O-C-N 124.555 0.797 . . . . 0.0 109.208 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 1.006 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.02 68.37 5.79 Favored 'Trans proline' 0 C--N 1.361 1.217 0 O-C-N 124.506 1.793 . . . . 0.0 111.036 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.89 16.33 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 O-C-N 124.496 1.122 . . . . 0.0 109.269 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.557 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.6 t -64.31 -47.65 78.63 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.434 1.084 . . . . 0.0 108.248 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.22 3.36 75.84 Favored Glycine 0 CA--C 1.529 0.935 0 O-C-N 124.58 1.175 . . . . 0.0 111.041 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.0 mm-40 -121.98 145.92 47.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.438 0.728 . . . . 0.0 110.315 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.96 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -105.75 162.77 13.24 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.509 1.131 . . . . 0.0 110.458 179.957 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' N ' ' A' ' 22' ' ' CYS . 1.2 p -135.42 53.25 1.98 Allowed 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.481 1.113 . . . . 0.0 108.325 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.747 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.2 t -67.05 -20.85 27.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.509 1.13 . . . . 0.0 109.316 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.54 -3.16 59.83 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.464 1.102 . . . . 0.0 110.978 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.48 24.21 19.24 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 21' ' ' THR . 10.1 t -158.58 115.76 2.83 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.556 0.797 . . . . 0.0 110.397 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.497 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 6.4 p -55.51 -36.1 66.33 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.496 1.122 . . . . 0.0 108.278 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.497 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.2 t30 82.53 -0.93 1.35 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 109.337 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.707 HG23 ' HB3' ' A' ' 27' ' ' CYS . 15.2 t -127.32 144.75 51.85 Favored Pre-proline 0 C--N 1.326 -0.446 0 O-C-N 124.461 1.101 . . . . 0.0 110.438 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.04 177.81 8.1 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.454 1.765 . . . . 0.0 110.986 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.83 35.89 0.7 Allowed Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.543 1.152 . . . . 0.0 111.022 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.707 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -119.44 158.19 26.72 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.733 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -125.48 71.02 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.538 1.148 . . . . 0.0 110.384 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.405 ' C ' ' O ' ' A' ' 28' ' ' THR . 12.5 t -41.11 114.29 0.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.547 1.154 . . . . 0.0 108.318 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 85.4 p -125.4 -7.56 6.96 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.517 1.135 . . . . 0.0 109.985 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.747 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 61.87 138.69 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.518 0 O-C-N 124.497 1.123 . . . . 0.0 107.97 179.963 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.96 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -20.67 16.26 Favored 'Cis proline' 0 C--N 1.36 1.165 0 C-N-CA 120.976 -2.51 . . . . 0.0 110.974 -0.007 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.458 HG22 HG23 ' A' ' 16' ' ' THR . 1.6 t -118.46 144.43 26.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.451 1.094 . . . . 0.0 109.313 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.403 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 25.4 p -71.29 164.65 25.3 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.556 1.16 . . . . 0.0 108.244 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 1.006 HG22 ' HA ' ' A' ' 11' ' ' PRO . 15.2 p -131.19 177.01 7.79 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.524 1.14 . . . . 0.0 110.396 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.513 1.133 . . . . 0.0 110.305 179.96 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 36' ' ' ARG . 24.6 t30 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.43 25.85 5.88 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.569 1.168 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.462 ' HB3' HG22 ' A' ' 12' ' ' VAL . 20.9 mt -127.12 121.34 22.72 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.46 0.741 . . . . 0.0 109.284 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.2 Cg_endo -75.0 60.93 5.57 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.537 1.809 . . . . 0.0 111.015 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.462 HG22 ' HB3' ' A' ' 10' ' ' LEU . 27.4 m -143.79 20.77 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.53 1.144 . . . . 0.0 109.288 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.655 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.2 t -51.31 -46.01 62.42 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.467 1.105 . . . . 0.0 108.284 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.92 -3.75 45.26 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.422 1.076 . . . . 0.0 111.037 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -130.8 171.29 13.3 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.543 0.79 . . . . 0.0 110.242 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.714 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -122.06 175.39 6.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.431 1.082 . . . . 0.0 110.425 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.606 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.5 p -153.13 68.91 0.82 Allowed 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.662 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.4 -23.36 16.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.516 1.135 . . . . 0.0 109.287 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.59 -12.63 50.26 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 111.022 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.23 15.13 16.68 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -138.02 113.16 9.25 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.453 0.737 . . . . 0.0 110.397 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.58 ' HB2' HG22 ' A' ' 24' ' ' THR . 2.1 p -59.86 -35.34 74.59 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.516 1.135 . . . . 0.0 108.313 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.459 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.3 t30 79.26 -0.98 2.28 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.495 1.122 . . . . 0.0 109.272 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.655 HG21 ' SG ' ' A' ' 13' ' ' CYS . 9.0 t -124.46 145.48 49.16 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.535 1.147 . . . . 0.0 110.465 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.3 Cg_endo -75.02 176.93 9.27 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.561 1.821 . . . . 0.0 111.007 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.82 43.99 0.89 Allowed Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.441 1.088 . . . . 0.0 110.999 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.635 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.3 OUTLIER -122.77 173.5 7.71 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.654 HG22 ' O ' ' A' ' 28' ' ' THR . 1.2 m -142.59 73.34 1.4 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.54 1.15 . . . . 0.0 110.447 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.5 t -41.4 117.0 0.83 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.512 1.133 . . . . 0.0 108.346 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 31' ' ' TRP . 92.2 p -124.94 -10.79 7.17 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.481 1.113 . . . . 0.0 109.99 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.68 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.16 135.61 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.46 0 O-C-N 124.505 1.128 . . . . 0.0 107.997 -179.983 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 16' ' ' THR . 18.1 Cg_endo -74.99 -23.73 12.26 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.987 -2.505 . . . . 0.0 110.952 -0.04 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.1 t -110.7 147.71 14.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.462 1.101 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 7.3 p -77.39 167.33 21.85 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.523 1.139 . . . . 0.0 108.297 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 28' ' ' THR . 1.4 p -124.96 172.56 9.3 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.549 1.156 . . . . 0.0 110.425 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 8' ' ' ASN . 6.6 ptm180 . . . . . 0 C--N 1.324 -0.518 0 O-C-N 124.513 1.133 . . . . 0.0 110.345 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.456 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -143.55 -89.66 0.11 Allowed Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.512 1.133 . . . . 0.0 111.002 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.48 161.74 28.5 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.517 0.775 . . . . 0.0 109.29 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 70.69 5.27 Favored 'Trans proline' 0 C--N 1.36 1.159 0 O-C-N 124.456 1.766 . . . . 0.0 110.988 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.24 20.92 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.296 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.522 ' SG ' ' CG2' ' A' ' 24' ' ' THR . 8.9 t -51.93 -40.54 60.96 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.446 1.091 . . . . 0.0 108.289 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.61 -4.65 69.45 Favored Glycine 0 CA--C 1.53 0.987 0 O-C-N 124.518 1.136 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.5 OUTLIER -125.27 173.74 8.6 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.502 0.766 . . . . 0.0 110.343 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -121.38 176.13 5.81 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.393 1.058 . . . . 0.0 110.382 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.598 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 10.7 p -155.93 71.57 0.74 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.609 1.193 . . . . 0.0 108.319 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.685 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.37 -24.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.537 1.148 . . . . 0.0 109.334 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -92.31 -11.58 59.57 Favored Glycine 0 CA--C 1.529 0.952 0 O-C-N 124.44 1.087 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.58 19.99 20.97 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 21' ' ' THR . 14.0 t -149.83 104.53 3.32 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.485 0.756 . . . . 0.0 110.385 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 1.9 p -55.65 147.05 19.21 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.547 1.154 . . . . 0.0 108.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -81.22 -0.7 41.76 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.507 1.13 . . . . 0.0 109.292 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.522 ' CG2' ' SG ' ' A' ' 13' ' ' CYS . 15.2 t -126.36 144.02 47.94 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.561 1.163 . . . . 0.0 110.385 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.01 -178.05 3.9 Favored 'Trans proline' 0 C--N 1.361 1.192 0 O-C-N 124.422 1.749 . . . . 0.0 110.984 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 48.27 1.7 Allowed Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.521 1.138 . . . . 0.0 111.037 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -123.75 168.37 12.79 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.707 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -127.27 71.95 1.35 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.496 1.123 . . . . 0.0 110.406 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.436 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.0 t -39.59 118.94 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.495 1.122 . . . . 0.0 108.33 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.3 OUTLIER -121.66 -14.89 8.08 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.505 1.128 . . . . 0.0 110.018 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.32 135.27 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.703 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.08 -21.83 14.82 Favored 'Cis proline' 0 C--N 1.36 1.132 0 C-N-CA 120.961 -2.516 . . . . 0.0 110.971 0.014 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.2 t -106.35 149.44 9.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.485 1.116 . . . . 0.0 109.277 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 8.0 p -84.26 171.04 13.1 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.527 1.142 . . . . 0.0 108.309 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.409 ' OG1' ' HB ' ' A' ' 28' ' ' THR . 22.3 p -133.33 -173.76 3.31 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.53 1.144 . . . . 0.0 110.372 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.456 ' C ' ' N ' ' A' ' 9' ' ' GLY . 2.0 ttp180 . . . . . 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.16 . . . . 0.0 110.292 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.412 ' CA ' ' HB ' ' A' ' 35' ' ' THR . . . 149.36 -52.34 0.53 Allowed Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.479 1.112 . . . . 0.0 110.963 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.33 111.64 2.71 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.533 0.784 . . . . 0.0 109.32 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -74.97 66.5 6.0 Favored 'Trans proline' 0 C--N 1.361 1.189 0 O-C-N 124.401 1.738 . . . . 0.0 110.955 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.81 20.73 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.448 1.092 . . . . 0.0 109.223 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.404 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -65.39 -47.95 74.57 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.471 1.107 . . . . 0.0 108.329 -179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.24 -5.1 78.03 Favored Glycine 0 CA--C 1.531 1.066 0 O-C-N 124.468 1.105 . . . . 0.0 111.013 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.404 ' OE2' ' O ' ' A' ' 13' ' ' CYS . 20.1 mp0 -117.89 141.69 48.15 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.497 0.763 . . . . 0.0 110.271 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.793 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.34 173.36 7.02 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.476 1.11 . . . . 0.0 110.395 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.563 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.0 p -152.28 71.63 0.96 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.594 1.184 . . . . 0.0 108.314 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.691 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.2 -22.84 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.516 1.135 . . . . 0.0 109.26 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.62 -10.35 55.58 Favored Glycine 0 CA--C 1.529 0.924 0 O-C-N 124.476 1.11 . . . . 0.0 110.995 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.13 20.05 21.91 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.7 HG23 ' O ' ' A' ' 21' ' ' THR . 14.6 t -143.82 93.09 2.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.507 0.769 . . . . 0.0 110.428 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.581 ' HB2' HG22 ' A' ' 24' ' ' THR . 9.4 p -45.91 -31.37 2.13 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.336 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 1.5 t-20 79.57 -1.2 2.18 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.402 1.064 . . . . 0.0 109.354 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.581 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.8 t -118.66 147.72 42.73 Favored Pre-proline 0 C--N 1.325 -0.487 0 O-C-N 124.509 1.131 . . . . 0.0 110.475 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.3 Cg_endo -74.94 172.64 15.95 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.459 1.768 . . . . 0.0 110.961 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 45.17 1.36 Allowed Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.532 1.145 . . . . 0.0 110.997 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.78 161.26 20.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.626 HG22 ' O ' ' A' ' 28' ' ' THR . 1.5 m -130.61 70.98 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.412 1.07 . . . . 0.0 110.427 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.467 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -37.51 112.53 0.21 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.56 1.163 . . . . 0.0 108.327 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.0 p -117.16 -15.67 10.46 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.504 1.127 . . . . 0.0 109.999 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.58 136.71 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.793 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.05 -19.01 18.11 Favored 'Cis proline' 0 C--N 1.361 1.193 0 C-N-CA 120.96 -2.517 . . . . 0.0 110.947 0.049 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.7 t -112.17 149.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.405 1.066 . . . . 0.0 109.335 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -67.3 171.68 5.62 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.571 1.17 . . . . 0.0 108.305 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.412 ' HB ' ' CA ' ' A' ' 9' ' ' GLY . 34.2 p -136.55 161.73 35.06 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.5 1.125 . . . . 0.0 110.395 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.464 1.102 . . . . 0.0 110.318 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.453 -0.324 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.61 -44.24 1.24 Allowed Glycine 0 CA--C 1.531 1.043 0 O-C-N 124.499 1.124 . . . . 0.0 110.982 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.438 ' HB3' HG22 ' A' ' 12' ' ' VAL . 0.4 OUTLIER -59.36 114.6 9.71 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.515 0.773 . . . . 0.0 109.308 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.421 ' HD2' HD23 ' A' ' 10' ' ' LEU . 18.2 Cg_endo -75.07 67.44 5.99 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.52 1.8 . . . . 0.0 110.981 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 10' ' ' LEU . 19.2 m -140.0 21.59 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.533 1.146 . . . . 0.0 109.346 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.5 t -57.29 -43.83 83.51 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 124.504 1.128 . . . . 0.0 108.299 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.28 -5.24 71.13 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.525 1.141 . . . . 0.0 110.958 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.445 ' HG3' HG21 ' A' ' 24' ' ' THR . 6.7 mm-40 -124.43 143.36 50.67 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.449 0.735 . . . . 0.0 110.289 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.751 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.27 174.13 7.04 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.396 1.06 . . . . 0.0 110.416 179.983 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.583 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.9 p -152.5 74.8 1.09 Allowed 'General case' 0 C--N 1.326 -0.432 0 O-C-N 124.48 1.113 . . . . 0.0 108.273 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.714 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.0 t -81.81 -20.52 10.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.511 1.132 . . . . 0.0 109.364 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.17 -8.57 44.15 Favored Glycine 0 CA--C 1.53 1.005 0 O-C-N 124.541 1.15 . . . . 0.0 110.994 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.24 21.89 23.78 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 21' ' ' THR . 14.7 t -133.15 94.0 3.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.534 0.785 . . . . 0.0 110.414 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 2.8 t -41.7 -43.75 2.95 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.552 1.157 . . . . 0.0 108.344 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.1 t-20 83.27 -1.8 1.19 Allowed 'General case' 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 109.339 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.445 HG21 ' HG3' ' A' ' 15' ' ' GLU . 14.8 t -136.73 144.64 47.73 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.53 1.144 . . . . 0.0 110.406 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.0 177.6 8.38 Favored 'Trans proline' 0 C--N 1.361 1.209 0 O-C-N 124.527 1.804 . . . . 0.0 111.014 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.86 43.79 5.41 Favored Glycine 0 CA--C 1.529 0.944 0 O-C-N 124.565 1.166 . . . . 0.0 111.006 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -127.85 177.13 7.05 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.997 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.721 HG22 ' O ' ' A' ' 28' ' ' THR . 1.1 m -148.23 72.99 1.23 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.475 1.109 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.1 t -38.86 114.85 0.42 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 108.272 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.9 t -121.74 -11.82 8.55 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.509 1.131 . . . . 0.0 109.966 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.714 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.65 135.94 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.982 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.751 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.06 -22.6 13.77 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.948 -2.522 . . . . 0.0 111.033 -0.003 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.31 148.81 13.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.459 1.1 . . . . 0.0 109.29 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 15.6 p -79.23 163.96 24.55 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.593 1.183 . . . . 0.0 108.311 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 73.3 p -123.99 -176.88 3.6 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.542 1.152 . . . . 0.0 110.5 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.6 ttp85 . . . . . 0 C--N 1.324 -0.526 0 O-C-N 124.475 1.109 . . . . 0.0 110.333 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.25 -39.35 2.09 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.46 1.1 . . . . 0.0 110.942 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.418 ' O ' ' HB ' ' A' ' 35' ' ' THR . 5.9 mt -67.02 123.06 85.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.471 0.747 . . . . 0.0 109.29 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.876 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.01 71.85 4.86 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.509 1.794 . . . . 0.0 111.035 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.1 22.42 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.514 1.134 . . . . 0.0 109.314 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.3 t -57.08 -45.06 83.63 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.464 1.103 . . . . 0.0 108.302 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.31 -5.12 58.81 Favored Glycine 0 CA--C 1.531 1.074 0 O-C-N 124.498 1.124 . . . . 0.0 110.995 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.1 OUTLIER -126.09 175.01 8.05 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.572 0.807 . . . . 0.0 110.284 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.776 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.66 175.75 5.86 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 124.558 1.161 . . . . 0.0 110.419 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 28.3 p -154.59 68.75 0.73 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.674 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.5 t -73.4 -23.29 19.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.548 1.155 . . . . 0.0 109.368 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.06 -8.37 53.9 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.51 1.131 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.92 23.75 26.96 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 m -146.92 97.69 2.93 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.55 0.794 . . . . 0.0 110.399 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.499 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 3.3 m -57.2 140.29 50.09 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.445 1.091 . . . . 0.0 108.312 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -78.75 -0.25 29.55 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.506 1.129 . . . . 0.0 109.253 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 14.1 t -124.62 144.99 47.95 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.455 1.097 . . . . 0.0 110.423 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.99 179.8 5.73 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.508 1.794 . . . . 0.0 110.983 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.07 52.42 2.68 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.458 1.099 . . . . 0.0 110.997 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -124.03 176.41 6.37 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 28' ' ' THR . 3.1 m -137.8 75.92 1.55 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.494 1.122 . . . . 0.0 110.391 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.435 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.9 t -39.05 113.98 0.36 Allowed 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.544 1.153 . . . . 0.0 108.237 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 1.4 p -120.27 -20.02 7.46 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.483 1.114 . . . . 0.0 109.959 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.42 134.26 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.776 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.01 -19.65 17.37 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 121.011 -2.496 . . . . 0.0 110.946 0.069 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.6 t -110.76 149.01 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.492 1.12 . . . . 0.0 109.289 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.499 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 2.7 p -83.44 169.43 15.55 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 124.521 1.138 . . . . 0.0 108.27 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.876 HG22 ' HA ' ' A' ' 11' ' ' PRO . 25.3 p -129.06 -177.99 4.45 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.477 1.111 . . . . 0.0 110.376 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.326 -0.441 0 O-C-N 124.43 1.081 . . . . 0.0 110.257 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.9 p-10 . . . . . 0 N--CA 1.453 -0.299 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.429 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -135.9 -72.47 0.07 OUTLIER Glycine 0 CA--C 1.53 1.018 0 O-C-N 124.488 1.117 . . . . 0.0 110.935 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -137.09 162.97 52.53 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.454 0.738 . . . . 0.0 109.336 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.989 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.0 Cg_endo -75.01 57.04 4.44 Favored 'Trans proline' 0 C--N 1.359 1.122 0 O-C-N 124.472 1.775 . . . . 0.0 110.943 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.78 12.59 4.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 O-C-N 124.451 1.095 . . . . 0.0 109.302 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.461 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.4 t -44.41 -39.35 4.63 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.487 1.117 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.53 -1.66 62.17 Favored Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.444 1.09 . . . . 0.0 110.986 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.774 ' O ' HG12 ' A' ' 33' ' ' VAL . 2.4 tp10 -128.4 173.47 10.17 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.489 0.758 . . . . 0.0 110.331 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -126.04 175.04 8.01 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.488 1.118 . . . . 0.0 110.447 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.587 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 4.6 p -155.18 72.58 0.83 Allowed 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.478 1.111 . . . . 0.0 108.281 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.8 t -78.73 -24.33 13.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 O-C-N 124.544 1.152 . . . . 0.0 109.321 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.69 -9.49 64.36 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.459 1.099 . . . . 0.0 110.951 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.7 24.85 24.59 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 21' ' ' THR . 15.1 t -146.87 103.45 3.63 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.489 0.758 . . . . 0.0 110.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.9 OUTLIER -52.41 130.24 30.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.442 1.089 . . . . 0.0 108.299 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -77.79 -0.84 28.65 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.474 1.109 . . . . 0.0 109.325 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.461 HG21 ' SG ' ' A' ' 13' ' ' CYS . 14.1 t -130.31 143.82 50.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.591 1.182 . . . . 0.0 110.385 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.98 -178.56 4.25 Favored 'Trans proline' 0 C--N 1.36 1.148 0 O-C-N 124.535 1.808 . . . . 0.0 111.018 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.54 39.95 0.62 Allowed Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.486 1.116 . . . . 0.0 111.031 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.1 OUTLIER -116.05 176.45 5.09 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.976 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.533 HG22 ' O ' ' A' ' 28' ' ' THR . 2.9 m -135.9 70.72 1.42 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.401 1.063 . . . . 0.0 110.417 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.435 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 31.9 t -42.59 116.4 0.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.566 1.166 . . . . 0.0 108.25 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 18.0 m -123.12 -11.36 8.04 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.444 1.09 . . . . 0.0 110.017 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.33 135.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.979 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.737 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -23.72 12.26 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 121.064 -2.473 . . . . 0.0 110.984 -0.103 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -110.37 146.47 15.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.53 1.144 . . . . 0.0 109.278 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 10.6 p -77.54 173.68 11.73 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.455 1.097 . . . . 0.0 108.344 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.989 HG22 ' HA ' ' A' ' 11' ' ' PRO . 63.4 p -136.74 -177.3 4.68 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.489 1.118 . . . . 0.0 110.398 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.429 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.528 0 O-C-N 124.578 1.174 . . . . 0.0 110.319 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.418 ' HA ' HG21 ' A' ' 28' ' ' THR . 0.7 OUTLIER . . . . . 0 N--CA 1.454 -0.275 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.14 -63.63 0.32 Allowed Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.549 1.156 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -53.62 110.89 2.29 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.512 0.772 . . . . 0.0 109.316 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 77.7 3.06 Favored 'Trans proline' 0 C--N 1.361 1.201 0 O-C-N 124.436 1.756 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -140.77 24.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.525 1.14 . . . . 0.0 109.297 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 56.2 m -69.7 -45.5 68.12 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.508 1.13 . . . . 0.0 108.282 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.8 -10.39 72.39 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.522 1.139 . . . . 0.0 110.966 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.607 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -112.68 175.46 5.43 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.482 0.754 . . . . 0.0 110.309 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.746 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -125.92 177.26 6.42 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.483 1.114 . . . . 0.0 110.414 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.9 p -154.58 71.86 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 O-C-N 124.456 1.097 . . . . 0.0 108.236 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.663 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -76.95 -23.09 14.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.533 1.145 . . . . 0.0 109.31 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.99 -8.74 56.67 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.548 1.155 . . . . 0.0 111.019 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.74 23.0 26.93 Favored Glycine 0 CA--C 1.531 1.065 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 m -149.18 91.43 1.84 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.56 0.8 . . . . 0.0 110.358 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.4 p -50.02 153.7 1.3 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.541 1.151 . . . . 0.0 108.353 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.18 -0.73 57.68 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.478 1.111 . . . . 0.0 109.355 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 7.8 t -117.64 146.17 38.07 Favored Pre-proline 0 C--N 1.326 -0.435 0 O-C-N 124.481 1.113 . . . . 0.0 110.389 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.2 Cg_endo -74.99 177.95 7.9 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.549 1.815 . . . . 0.0 110.995 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 34.71 51.7 0.79 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.567 1.167 . . . . 0.0 111.047 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -121.92 159.06 27.66 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.736 HG22 ' O ' ' A' ' 28' ' ' THR . 1.0 OUTLIER -120.32 72.83 0.96 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.447 1.092 . . . . 0.0 110.402 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.451 ' C ' ' O ' ' A' ' 28' ' ' THR . 41.8 t -38.55 118.88 0.78 Allowed 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.536 1.147 . . . . 0.0 108.285 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 31' ' ' TRP . 46.3 t -120.63 -16.36 8.28 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.474 1.109 . . . . 0.0 110.002 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 134.99 0.04 OUTLIER Pre-proline 0 C--N 1.326 -0.43 0 O-C-N 124.493 1.12 . . . . 0.0 108.006 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.746 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -21.17 15.64 Favored 'Cis proline' 0 C--N 1.36 1.145 0 C-N-CA 121.027 -2.489 . . . . 0.0 110.98 0.018 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -110.97 148.33 14.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.489 1.118 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.488 ' SG ' ' N ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -67.05 177.98 1.56 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.531 1.144 . . . . 0.0 108.305 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.488 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 8.4 p -146.24 161.53 40.07 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.543 1.152 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 ttp85 . . . . . 0 C--N 1.325 -0.471 0 O-C-N 124.47 1.106 . . . . 0.0 110.346 -180.0 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.05 -55.13 0.36 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.464 1.103 . . . . 0.0 111.046 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.458 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 3.8 mt -62.9 114.97 14.05 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.476 0.751 . . . . 0.0 109.372 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 81.26 2.25 Favored 'Trans proline' 0 C--N 1.36 1.137 0 O-C-N 124.503 1.791 . . . . 0.0 110.937 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m -147.84 23.64 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.531 1.144 . . . . 0.0 109.276 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.412 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -66.51 -53.95 29.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.485 1.115 . . . . 0.0 108.3 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.531 1.041 0 O-C-N 124.458 1.099 . . . . 0.0 111.019 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.604 ' OE2' HG21 ' A' ' 24' ' ' THR . 9.1 mp0 -124.96 141.99 51.77 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.605 0.826 . . . . 0.0 110.245 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.797 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.02 173.67 7.31 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.495 1.122 . . . . 0.0 110.425 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.569 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 20.6 p -151.81 73.46 1.06 Allowed 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.523 1.139 . . . . 0.0 108.243 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -79.62 -24.62 12.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 124.561 1.163 . . . . 0.0 109.348 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.73 -13.29 55.49 Favored Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.515 1.134 . . . . 0.0 111.004 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.1 17.78 19.36 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 m -143.23 94.98 2.69 Favored 'General case' 0 C--N 1.326 -0.438 0 O-C-N 124.478 0.752 . . . . 0.0 110.375 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.52 ' HB2' HG22 ' A' ' 24' ' ' THR . 12.7 p -45.99 -31.09 2.06 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.523 1.139 . . . . 0.0 108.316 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.482 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 21.4 t30 80.72 -1.36 1.86 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.429 1.081 . . . . 0.0 109.285 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.604 HG21 ' OE2' ' A' ' 15' ' ' GLU . 6.0 t -119.72 147.81 44.75 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.47 1.106 . . . . 0.0 110.342 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.445 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.02 173.16 15.0 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.485 1.782 . . . . 0.0 110.994 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.91 44.91 1.52 Allowed Glycine 0 CA--C 1.529 0.963 0 O-C-N 124.487 1.117 . . . . 0.0 110.977 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.488 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.48 160.77 21.14 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.587 HG22 ' O ' ' A' ' 28' ' ' THR . 2.0 m -129.57 70.31 1.42 Allowed 'General case' 0 C--N 1.324 -0.515 0 O-C-N 124.496 1.122 . . . . 0.0 110.388 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.447 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -38.55 113.35 0.29 Allowed 'General case' 0 C--N 1.323 -0.553 0 O-C-N 124.572 1.17 . . . . 0.0 108.23 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -118.93 -14.72 9.4 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.528 1.143 . . . . 0.0 110.056 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.49 136.38 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 107.935 179.92 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.797 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -75.01 -19.86 17.15 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 121.057 -2.476 . . . . 0.0 110.977 0.056 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.89 149.2 14.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.542 1.151 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -68.46 171.27 7.63 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.484 1.115 . . . . 0.0 108.333 179.919 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.402 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 33.6 p -135.21 166.58 22.76 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.137 . . . . 0.0 110.435 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.458 ' CG ' ' HB2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.473 0 O-C-N 124.507 1.129 . . . . 0.0 110.309 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.93 45.16 4.91 Favored Glycine 0 CA--C 1.53 1.007 0 O-C-N 124.47 1.106 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.681 ' C ' HG22 ' A' ' 35' ' ' THR . 20.1 mt -128.58 125.62 23.18 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.543 0.79 . . . . 0.0 109.289 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.428 ' N ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.04 55.47 3.98 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.528 1.804 . . . . 0.0 110.977 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.587 HG22 ' HB3' ' A' ' 10' ' ' LEU . 14.7 m -144.25 17.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.597 1.186 . . . . 0.0 109.256 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' HG21 ' A' ' 24' ' ' THR . 51.1 t -48.94 -26.58 2.57 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.52 1.138 . . . . 0.0 108.304 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.99 -11.54 56.94 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.436 1.085 . . . . 0.0 111.017 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' HG3' HG23 ' A' ' 24' ' ' THR . 4.4 mm-40 -124.58 145.51 49.56 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.502 0.766 . . . . 0.0 110.276 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.747 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -95.84 179.69 5.01 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.551 1.157 . . . . 0.0 110.399 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.604 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 32.0 p -156.69 69.16 0.6 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.506 1.129 . . . . 0.0 108.262 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.658 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.93 -22.0 15.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.598 1.186 . . . . 0.0 109.327 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.85 -8.28 34.69 Favored Glycine 0 CA--C 1.531 1.032 0 O-C-N 124.49 1.119 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.74 19.8 28.36 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' HG22 ' A' ' 21' ' ' THR . 11.0 m -124.53 72.37 1.2 Allowed 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.499 0.764 . . . . 0.0 110.401 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.7 p -41.42 -36.07 0.79 Allowed 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.529 1.143 . . . . 0.0 108.357 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.5 t30 60.91 21.9 12.09 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 124.565 1.165 . . . . 0.0 109.297 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.906 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -116.76 151.0 46.73 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.363 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.906 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.3 Cg_endo -75.0 139.65 24.51 Favored 'Trans proline' 0 C--N 1.36 1.17 0 O-C-N 124.448 1.762 . . . . 0.0 111.002 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.6 50.45 8.33 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.464 1.103 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -109.75 169.6 8.61 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.736 ' O ' HG23 ' A' ' 28' ' ' THR . 13.4 t -139.68 63.62 1.48 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.427 1.079 . . . . 0.0 110.461 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.623 ' C ' ' O ' ' A' ' 28' ' ' THR . 39.2 t -24.05 116.55 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.604 1.19 . . . . 0.0 108.34 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 40.5 t -119.51 -13.8 9.18 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.571 1.169 . . . . 0.0 109.989 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.666 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.54 137.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.478 0 O-C-N 124.58 1.175 . . . . 0.0 107.986 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.747 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.98 -19.27 17.75 Favored 'Cis proline' 0 C--N 1.36 1.183 0 C-N-CA 120.975 -2.51 . . . . 0.0 110.933 0.017 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 16' ' ' THR . 2.8 t -110.7 152.4 12.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.556 1.16 . . . . 0.0 109.21 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.2 158.0 22.5 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.532 1.145 . . . . 0.0 108.275 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.681 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -126.37 152.83 45.76 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.501 1.126 . . . . 0.0 110.401 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 8.9 mtp180 . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.482 1.114 . . . . 0.0 110.339 179.932 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.85 -53.61 0.57 Allowed Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.557 1.161 . . . . 0.0 110.938 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -57.45 109.54 1.83 Allowed Pre-proline 0 C--N 1.325 -0.468 0 O-C-N 124.444 0.732 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.97 69.29 5.57 Favored 'Trans proline' 0 C--N 1.36 1.171 0 O-C-N 124.486 1.782 . . . . 0.0 111.03 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 m -135.32 20.77 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.469 1.106 . . . . 0.0 109.288 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 17.6 m -63.35 -43.39 97.84 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.474 1.109 . . . . 0.0 108.3 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.87 -6.44 82.85 Favored Glycine 0 CA--C 1.529 0.923 0 O-C-N 124.474 1.109 . . . . 0.0 110.993 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -120.3 141.53 49.93 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.456 0.739 . . . . 0.0 110.268 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.777 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -96.28 176.56 6.02 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.454 1.096 . . . . 0.0 110.383 -179.965 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.61 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.4 p -152.2 74.15 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.447 1.092 . . . . 0.0 108.316 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -80.37 -21.91 11.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.443 1.089 . . . . 0.0 109.286 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.67 -10.56 43.39 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.448 1.092 . . . . 0.0 111.035 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.8 18.36 25.42 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.599 0.823 . . . . 0.0 111.047 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.417 ' C ' ' N ' ' A' ' 23' ' ' ASN . 57.2 m -137.31 86.26 2.18 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.526 0.78 . . . . 0.0 110.391 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.777 ' HB2' HG22 ' A' ' 24' ' ' THR . 0.8 OUTLIER -41.79 -31.89 0.35 Allowed 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.462 1.101 . . . . 0.0 108.263 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.462 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 5.8 t-20 79.61 -1.7 2.15 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 109.261 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.777 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.0 t -119.57 147.89 44.66 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.533 1.146 . . . . 0.0 110.414 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 174.05 13.44 Favored 'Trans proline' 0 C--N 1.36 1.146 0 O-C-N 124.421 1.748 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.69 47.19 1.2 Allowed Glycine 0 CA--C 1.53 0.98 0 O-C-N 124.422 1.076 . . . . 0.0 111.049 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.509 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -127.26 148.88 50.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.974 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.84 HG22 ' O ' ' A' ' 35' ' ' THR . 9.5 t -119.74 70.47 0.86 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.499 1.125 . . . . 0.0 110.414 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.491 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.6 t -34.5 117.2 0.35 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.459 1.099 . . . . 0.0 108.305 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 22.5 p -119.6 -12.43 9.29 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.459 1.099 . . . . 0.0 110.034 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.679 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.02 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.462 0 O-C-N 124.511 1.132 . . . . 0.0 107.988 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.777 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.04 -20.89 16.05 Favored 'Cis proline' 0 C--N 1.361 1.223 0 C-N-CA 120.969 -2.513 . . . . 0.0 111.01 0.006 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.401 HG22 HG23 ' A' ' 16' ' ' THR . 0.9 OUTLIER -114.81 148.99 17.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 O-C-N 124.468 1.105 . . . . 0.0 109.289 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.481 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -67.09 177.31 1.8 Allowed 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.579 1.174 . . . . 0.0 108.349 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.84 ' O ' HG22 ' A' ' 28' ' ' THR . 1.0 OUTLIER -147.29 151.71 37.07 Favored 'General case' 0 C--N 1.323 -0.546 0 O-C-N 124.538 1.149 . . . . 0.0 110.443 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.519 1.137 . . . . 0.0 110.246 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.47 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -150.16 -92.65 0.1 OUTLIER Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.54 1.15 . . . . 0.0 110.981 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.413 ' O ' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -109.86 158.39 35.06 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.485 0.756 . . . . 0.0 109.34 179.958 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 74.24 4.07 Favored 'Trans proline' 0 C--N 1.36 1.183 0 O-C-N 124.445 1.76 . . . . 0.0 110.981 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 m -131.46 15.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 O-C-N 124.492 1.12 . . . . 0.0 109.268 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.512 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.7 t -51.04 -42.85 60.75 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.513 1.133 . . . . 0.0 108.342 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.75 62.74 Favored Glycine 0 CA--C 1.529 0.949 0 O-C-N 124.559 1.162 . . . . 0.0 111.033 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.732 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -130.83 173.13 11.26 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.517 0.775 . . . . 0.0 110.315 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.932 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -120.05 173.88 6.82 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.511 1.132 . . . . 0.0 110.402 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.593 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 23.3 p -151.78 67.43 0.88 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.501 1.125 . . . . 0.0 108.276 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.2 t -73.97 -20.88 17.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 O-C-N 124.474 1.109 . . . . 0.0 109.306 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.51 -10.56 28.92 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.513 1.133 . . . . 0.0 111.019 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.3 17.85 20.98 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 m -129.68 87.43 2.54 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.432 0.724 . . . . 0.0 110.418 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 16' ' ' THR . 26.5 p -53.45 -39.28 64.31 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 124.446 1.091 . . . . 0.0 108.343 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 69.64 8.19 6.61 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.524 1.14 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.884 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -104.27 150.46 38.42 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.539 1.149 . . . . 0.0 110.36 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.884 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.99 139.79 24.72 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.563 1.822 . . . . 0.0 110.968 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 47.25 50.42 17.08 Favored Glycine 0 CA--C 1.529 0.939 0 O-C-N 124.462 1.101 . . . . 0.0 110.988 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.75 165.6 13.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.98 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.72 ' O ' HG23 ' A' ' 28' ' ' THR . 2.6 t -137.24 90.82 2.56 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.538 1.149 . . . . 0.0 110.424 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.438 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.6 t -38.49 112.82 0.25 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.427 1.08 . . . . 0.0 108.268 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.7 t -116.45 -21.14 9.37 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.452 1.095 . . . . 0.0 109.982 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.35 136.28 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 108.043 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.813 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -16.42 21.19 Favored 'Cis proline' 0 C--N 1.359 1.12 0 C-N-CA 121.025 -2.49 . . . . 0.0 110.983 0.064 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.932 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -117.05 150.72 18.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.486 1.117 . . . . 0.0 109.284 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 27' ' ' CYS . 1.4 p -82.69 162.51 21.79 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.443 1.089 . . . . 0.0 108.296 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.518 ' OG1' HG22 ' A' ' 28' ' ' THR . 16.8 p -131.97 178.21 6.95 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.527 1.142 . . . . 0.0 110.377 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.47 ' C ' ' N ' ' A' ' 9' ' ' GLY . 4.7 mtp180 . . . . . 0 C--N 1.325 -0.481 0 O-C-N 124.571 1.17 . . . . 0.0 110.341 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HA ' HG21 ' A' ' 28' ' ' THR . 2.3 t-20 . . . . . 0 N--CA 1.453 -0.321 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.481 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -149.14 -60.39 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.536 1.147 . . . . 0.0 110.994 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 27.1 mt -141.84 160.53 55.58 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.529 0.782 . . . . 0.0 109.326 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 70.84 5.18 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.416 1.745 . . . . 0.0 111.023 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 m -127.71 16.61 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.476 1.11 . . . . 0.0 109.313 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -46.1 87.35 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.543 1.152 . . . . 0.0 108.381 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.73 -5.88 76.86 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.769 ' O ' HG12 ' A' ' 33' ' ' VAL . 8.9 tp10 -116.7 165.46 13.25 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.425 0.721 . . . . 0.0 110.327 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -118.52 174.22 6.38 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.521 1.138 . . . . 0.0 110.319 -179.912 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.532 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 8.6 p -153.89 72.33 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.5 1.125 . . . . 0.0 108.312 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -77.83 -25.06 14.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.558 1.162 . . . . 0.0 109.331 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.2 -11.71 64.38 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.525 1.14 . . . . 0.0 110.966 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.81 22.02 19.44 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.1 m -157.85 97.05 1.53 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.52 0.777 . . . . 0.0 110.445 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 24' ' ' THR . 17.4 p -47.84 165.29 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.565 1.165 . . . . 0.0 108.274 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -97.16 -0.77 46.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.437 1.086 . . . . 0.0 109.311 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.438 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.9 t -117.53 147.53 40.96 Favored Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.536 1.147 . . . . 0.0 110.383 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.438 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.97 174.57 12.55 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.538 1.809 . . . . 0.0 110.996 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.41 51.6 1.34 Allowed Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.481 1.113 . . . . 0.0 110.96 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -115.75 162.78 16.79 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 179.943 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.474 HG22 ' O ' ' A' ' 28' ' ' THR . 8.3 m -120.92 68.35 0.87 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.491 1.12 . . . . 0.0 110.364 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 28' ' ' THR . 49.3 t -40.99 115.49 0.6 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.481 1.113 . . . . 0.0 108.313 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.435 ' O ' ' O ' ' A' ' 31' ' ' TRP . 23.1 t -120.32 -14.4 8.76 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.498 1.124 . . . . 0.0 110.057 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.694 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.14 135.74 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.95 -21.16 15.63 Favored 'Cis proline' 0 C--N 1.359 1.112 0 C-N-CA 121.029 -2.488 . . . . 0.0 111.001 -0.01 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.769 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -110.55 149.15 13.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.493 1.12 . . . . 0.0 109.274 -179.964 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -71.24 177.46 3.85 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.52 1.138 . . . . 0.0 108.255 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.458 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 41.6 p -141.05 167.2 22.75 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.472 1.108 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.481 ' C ' ' N ' ' A' ' 9' ' ' GLY . 12.3 ttp85 . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.562 1.164 . . . . 0.0 110.21 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.38 43.49 0.29 Allowed Glycine 0 CA--C 1.529 0.936 0 O-C-N 124.487 1.117 . . . . 0.0 111.06 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.717 ' C ' HG22 ' A' ' 35' ' ' THR . 23.3 mt -141.32 109.72 6.31 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.399 0.705 . . . . 0.0 109.309 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 56.51 4.26 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.458 1.767 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 10' ' ' LEU . 21.9 m -138.38 21.37 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 124.515 1.135 . . . . 0.0 109.307 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -46.09 86.61 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.576 1.172 . . . . 0.0 108.278 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.84 -7.17 62.8 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.105 . . . . 0.0 110.935 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.468 ' HG3' HG23 ' A' ' 24' ' ' THR . 7.4 mm-40 -124.44 147.87 48.01 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.523 0.778 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -101.42 179.38 4.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.462 1.101 . . . . 0.0 110.374 -179.935 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.6 p -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.453 1.096 . . . . 0.0 108.319 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -79.83 -23.46 11.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.519 1.137 . . . . 0.0 109.367 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.96 -11.2 37.88 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.538 1.149 . . . . 0.0 111.002 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.46 18.93 26.84 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -123.17 76.61 1.4 Allowed 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.504 0.767 . . . . 0.0 110.38 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.601 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 41.9 t -39.99 -45.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.556 1.16 . . . . 0.0 108.312 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 68.52 8.96 7.01 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.522 1.139 . . . . 0.0 109.296 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.897 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -107.74 151.22 41.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.493 1.12 . . . . 0.0 110.42 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.897 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.01 140.76 25.8 Favored 'Trans proline' 0 C--N 1.36 1.161 0 O-C-N 124.529 1.805 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.68 50.8 5.8 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 124.527 1.142 . . . . 0.0 111.018 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.446 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -112.18 163.64 14.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.795 ' O ' HG23 ' A' ' 28' ' ' THR . 8.0 t -133.67 69.32 1.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.478 1.111 . . . . 0.0 110.363 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.569 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.6 t -28.56 119.5 0.12 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.478 1.111 . . . . 0.0 108.292 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 31' ' ' TRP . 53.7 p -120.54 -14.57 8.63 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.473 1.108 . . . . 0.0 109.975 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.681 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 136.67 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.755 ' O ' HG22 ' A' ' 16' ' ' THR . 18.5 Cg_endo -74.93 -20.87 15.96 Favored 'Cis proline' 0 C--N 1.361 1.187 0 C-N-CA 121.007 -2.497 . . . . 0.0 111.027 -0.065 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -113.34 148.46 16.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 O-C-N 124.432 1.083 . . . . 0.0 109.282 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.601 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER -65.62 177.92 1.11 Allowed 'General case' 0 C--N 1.326 -0.427 0 O-C-N 124.45 1.094 . . . . 0.0 108.274 -179.962 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.717 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -151.67 158.21 43.13 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.514 1.134 . . . . 0.0 110.36 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 . . . . . 0 C--N 1.326 -0.444 0 O-C-N 124.459 1.1 . . . . 0.0 110.343 -179.944 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.468 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -131.27 -71.78 0.1 Allowed Glycine 0 CA--C 1.53 0.989 0 O-C-N 124.477 1.11 . . . . 0.0 110.978 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.25 159.74 65.0 Favored Pre-proline 0 C--N 1.325 -0.473 0 O-C-N 124.457 0.74 . . . . 0.0 109.341 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.777 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.3 Cg_endo -75.01 67.18 5.98 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.511 1.796 . . . . 0.0 111.033 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.0 m -137.83 26.68 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.549 1.155 . . . . 0.0 109.258 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.45 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.5 OUTLIER -58.72 -36.42 74.27 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.506 1.129 . . . . 0.0 108.29 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.48 -11.24 64.23 Favored Glycine 0 CA--C 1.529 0.913 0 O-C-N 124.532 1.145 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.559 ' OE1' HG23 ' A' ' 24' ' ' THR . 0.6 OUTLIER -116.55 169.54 9.26 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.433 0.725 . . . . 0.0 110.334 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.709 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.61 173.47 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.419 1.074 . . . . 0.0 110.348 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.567 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 7.0 p -150.13 60.53 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.471 1.107 . . . . 0.0 108.228 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.6 t -70.45 -23.7 24.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 O-C-N 124.476 1.11 . . . . 0.0 109.324 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.77 -7.46 55.47 Favored Glycine 0 CA--C 1.531 1.059 0 O-C-N 124.467 1.104 . . . . 0.0 110.984 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.88 19.8 23.29 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 21' ' ' THR . 14.8 t -137.8 94.67 2.93 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.551 0.795 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.9 p -54.87 -32.88 61.28 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.517 1.136 . . . . 0.0 108.251 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 63.41 13.14 6.87 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.472 1.107 . . . . 0.0 109.292 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.918 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -108.49 151.53 41.64 Favored Pre-proline 0 C--N 1.325 -0.486 0 O-C-N 124.466 1.104 . . . . 0.0 110.419 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.918 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.5 Cg_endo -74.9 141.42 26.93 Favored 'Trans proline' 0 C--N 1.359 1.096 0 O-C-N 124.475 1.776 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.42 50.95 4.62 Favored Glycine 0 CA--C 1.53 1.026 0 O-C-N 124.43 1.081 . . . . 0.0 111.026 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.45 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -109.28 163.62 13.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.726 ' O ' HG23 ' A' ' 28' ' ' THR . 13.8 t -129.75 61.24 1.57 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.533 1.145 . . . . 0.0 110.427 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.599 ' C ' ' O ' ' A' ' 28' ' ' THR . 22.6 t -26.09 117.36 0.07 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.546 1.154 . . . . 0.0 108.314 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -120.19 -14.23 8.83 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.428 1.08 . . . . 0.0 109.968 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.53 138.01 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.512 1.133 . . . . 0.0 107.983 179.965 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.709 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.03 -19.71 17.33 Favored 'Cis proline' 0 C--N 1.36 1.15 0 C-N-CA 121.054 -2.478 . . . . 0.0 110.94 0.029 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.8 t -113.67 147.93 16.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.485 1.116 . . . . 0.0 109.307 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -77.22 174.0 11.24 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.459 1.1 . . . . 0.0 108.303 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' HA ' ' A' ' 11' ' ' PRO . 1.1 p -145.01 164.64 30.54 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.539 1.149 . . . . 0.0 110.397 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.468 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.478 0 O-C-N 124.507 1.129 . . . . 0.0 110.306 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.26 -39.84 1.68 Allowed Glycine 0 CA--C 1.529 0.942 0 O-C-N 124.544 1.152 . . . . 0.0 111.021 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -61.95 113.49 8.64 Favored Pre-proline 0 C--N 1.325 -0.457 0 O-C-N 124.437 0.728 . . . . 0.0 109.271 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.881 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.5 Cg_endo -75.08 64.97 6.15 Favored 'Trans proline' 0 C--N 1.36 1.165 0 O-C-N 124.479 1.778 . . . . 0.0 110.983 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -138.85 21.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.435 1.085 . . . . 0.0 109.335 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.428 ' SG ' HG21 ' A' ' 24' ' ' THR . 26.7 t -57.96 -41.96 83.98 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.475 1.109 . . . . 0.0 108.283 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.65 -7.68 68.27 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.416 ' O ' HG12 ' A' ' 33' ' ' VAL . 15.4 mm-40 -124.03 155.89 37.48 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.466 0.745 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -105.52 176.63 5.1 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.566 1.166 . . . . 0.0 110.459 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.2 p -154.46 68.76 0.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.52 1.138 . . . . 0.0 108.329 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.672 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -74.78 -21.32 16.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.533 1.145 . . . . 0.0 109.338 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.95 -6.31 40.12 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.552 1.158 . . . . 0.0 111.035 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.82 21.46 28.41 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 21' ' ' THR . 2.5 m -131.7 79.4 1.87 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.538 0.787 . . . . 0.0 110.428 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.5 p -45.16 -30.94 1.27 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.54 1.15 . . . . 0.0 108.36 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 59.86 16.01 5.34 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.477 1.111 . . . . 0.0 109.312 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.851 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -111.3 150.3 41.84 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.498 1.124 . . . . 0.0 110.393 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.851 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.09 141.54 26.51 Favored 'Trans proline' 0 C--N 1.359 1.103 0 O-C-N 124.52 1.8 . . . . 0.0 111.009 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.84 50.1 5.08 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.506 1.129 . . . . 0.0 110.95 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.406 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -107.13 175.52 5.47 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.724 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -141.33 72.15 1.38 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.457 1.098 . . . . 0.0 110.357 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.7 t -38.81 114.56 0.4 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.521 1.138 . . . . 0.0 108.305 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 15.9 t -120.89 -12.09 8.85 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.552 1.158 . . . . 0.0 110.009 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.672 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.46 137.26 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.52 1.138 . . . . 0.0 108.007 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.97 -19.72 17.25 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.058 -2.476 . . . . 0.0 110.99 -0.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -113.84 150.27 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.263 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -77.62 166.59 22.83 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.482 1.113 . . . . 0.0 108.366 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.881 HG22 ' HA ' ' A' ' 11' ' ' PRO . 3.0 p -133.36 174.58 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.51 1.131 . . . . 0.0 110.375 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 . . . . . 0 C--N 1.324 -0.524 0 O-C-N 124.527 1.142 . . . . 0.0 110.36 179.932 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.23 -48.62 0.7 Allowed Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.532 1.145 . . . . 0.0 111.009 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -61.5 111.73 4.83 Favored Pre-proline 0 C--N 1.324 -0.525 0 O-C-N 124.585 0.815 . . . . 0.0 109.311 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.7 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.05 69.39 5.6 Favored 'Trans proline' 0 C--N 1.361 1.186 0 O-C-N 124.43 1.753 . . . . 0.0 110.967 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.57 21.79 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 O-C-N 124.483 1.114 . . . . 0.0 109.299 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.593 ' SG ' HG21 ' A' ' 24' ' ' THR . 5.3 t -60.76 -46.08 91.82 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.535 1.147 . . . . 0.0 108.346 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.21 -5.63 65.67 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.452 1.095 . . . . 0.0 110.944 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -123.35 146.15 48.17 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.49 0.759 . . . . 0.0 110.354 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.782 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.81 175.47 5.95 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.409 1.068 . . . . 0.0 110.41 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.56 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.2 p -153.93 65.9 0.72 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 108.27 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.682 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -71.86 -22.39 21.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 O-C-N 124.388 1.055 . . . . 0.0 109.327 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.08 -7.19 50.53 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.491 1.119 . . . . 0.0 110.994 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.97 21.34 23.51 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 22.9 m -138.39 93.71 2.77 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.447 0.733 . . . . 0.0 110.387 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 7.4 p -47.33 -37.6 11.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.384 1.053 . . . . 0.0 108.283 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.494 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER 82.43 -1.05 1.38 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.56 1.162 . . . . 0.0 109.311 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.652 HG23 ' HB3' ' A' ' 27' ' ' CYS . 14.9 t -127.83 144.53 51.64 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.492 1.12 . . . . 0.0 110.436 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.05 179.42 6.12 Favored 'Trans proline' 0 C--N 1.359 1.116 0 O-C-N 124.505 1.792 . . . . 0.0 110.969 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 40.84 32.15 0.5 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.511 1.132 . . . . 0.0 111.019 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.652 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -115.43 166.47 11.85 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 35' ' ' THR . 17.3 m -136.64 74.43 1.49 Allowed 'General case' 0 C--N 1.324 -0.516 0 O-C-N 124.574 1.171 . . . . 0.0 110.385 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.427 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.8 t -39.93 109.78 0.12 Allowed 'General case' 0 C--N 1.326 -0.444 0 O-C-N 124.463 1.102 . . . . 0.0 108.322 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.1 OUTLIER -118.1 -11.27 10.19 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.495 1.122 . . . . 0.0 109.996 179.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.682 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.62 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.546 1.154 . . . . 0.0 108.028 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.782 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -20.09 16.87 Favored 'Cis proline' 0 C--N 1.359 1.114 0 C-N-CA 121.026 -2.489 . . . . 0.0 111.001 0.016 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -114.56 148.76 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.492 1.12 . . . . 0.0 109.411 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 21.1 p -74.77 160.18 31.05 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.7 HG22 ' HA ' ' A' ' 11' ' ' PRO . 23.3 p -127.35 -177.86 4.23 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.52 1.138 . . . . 0.0 110.383 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 . . . . . 0 C--N 1.324 -0.506 0 O-C-N 124.533 1.146 . . . . 0.0 110.322 179.963 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.1 p-10 . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.48 -51.12 0.63 Allowed Glycine 0 CA--C 1.53 0.978 0 O-C-N 124.484 1.115 . . . . 0.0 111.047 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.8 mt -56.22 114.73 8.17 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.46 0.741 . . . . 0.0 109.297 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.415 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -74.97 70.86 5.16 Favored 'Trans proline' 0 C--N 1.361 1.191 0 O-C-N 124.446 1.761 . . . . 0.0 111.002 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.1 m -142.24 22.82 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.494 1.121 . . . . 0.0 109.302 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.482 ' SG ' HG21 ' A' ' 24' ' ' THR . 4.6 t -55.94 -43.96 77.93 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.559 1.162 . . . . 0.0 108.239 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.19 -6.13 61.51 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.505 1.128 . . . . 0.0 110.971 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -125.57 175.15 7.75 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.512 0.772 . . . . 0.0 110.363 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.708 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.4 OUTLIER -122.52 176.08 6.11 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 124.493 1.121 . . . . 0.0 110.432 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.605 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 27.3 p -153.36 66.7 0.77 Allowed 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.454 1.096 . . . . 0.0 108.312 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.668 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -73.8 -22.82 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.49 1.119 . . . . 0.0 109.362 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.06 -10.97 44.22 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.466 1.104 . . . . 0.0 111.021 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 103.65 16.17 20.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 21' ' ' THR . 14.5 t -132.84 100.31 4.87 Favored 'General case' 0 C--N 1.326 -0.443 0 O-C-N 124.529 0.782 . . . . 0.0 110.424 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.8 p -59.02 -39.45 81.95 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.519 1.137 . . . . 0.0 108.301 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 69.3 10.09 7.62 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.529 1.143 . . . . 0.0 109.31 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.856 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.6 OUTLIER -107.87 150.14 39.93 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 124.502 1.126 . . . . 0.0 110.338 -179.936 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.856 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.08 141.75 26.78 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.498 1.788 . . . . 0.0 111.003 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 43.45 49.39 6.96 Favored Glycine 0 CA--C 1.531 1.04 0 O-C-N 124.5 1.125 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.28 178.42 4.55 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.667 ' O ' HG22 ' A' ' 28' ' ' THR . 1.2 m -145.01 72.22 1.32 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.498 1.124 . . . . 0.0 110.471 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.45 ' C ' ' O ' ' A' ' 28' ' ' THR . 37.2 t -38.26 113.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.525 1.141 . . . . 0.0 108.368 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 45.5 t -120.93 -12.64 8.75 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.513 1.133 . . . . 0.0 109.963 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.668 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.37 136.22 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.47 0 O-C-N 124.489 1.118 . . . . 0.0 108.003 -179.946 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.708 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.96 -22.0 14.51 Favored 'Cis proline' 0 C--N 1.361 1.188 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -0.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.9 t -109.32 148.79 12.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.558 1.161 . . . . 0.0 109.297 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.4 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.1 p -81.14 162.65 23.57 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.503 1.127 . . . . 0.0 108.291 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.468 ' O ' ' N ' ' A' ' 28' ' ' THR . 40.8 p -121.2 -171.98 2.31 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.484 1.115 . . . . 0.0 110.403 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 76.0 mtp180 . . . . . 0 C--N 1.325 -0.492 0 O-C-N 124.559 1.162 . . . . 0.0 110.281 -179.994 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 36' ' ' ARG . 20.6 p30 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.49 -57.32 0.66 Allowed Glycine 0 CA--C 1.53 0.988 0 O-C-N 124.49 1.119 . . . . 0.0 110.987 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 mt -52.54 109.41 1.42 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.486 0.756 . . . . 0.0 109.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.741 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.06 69.18 5.66 Favored 'Trans proline' 0 C--N 1.361 1.19 0 O-C-N 124.409 1.742 . . . . 0.0 110.972 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -138.5 19.98 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.297 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.545 ' SG ' HG21 ' A' ' 24' ' ' THR . 3.3 t -52.88 -43.53 66.2 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.527 1.142 . . . . 0.0 108.321 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.65 -3.99 63.48 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.471 1.107 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.43 173.46 9.8 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.49 0.759 . . . . 0.0 110.358 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.72 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.8 OUTLIER -120.73 178.81 4.55 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.509 1.131 . . . . 0.0 110.43 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.612 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 31.7 p -155.54 62.86 0.61 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.524 1.14 . . . . 0.0 108.328 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.654 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -70.34 -21.0 23.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.509 1.131 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.07 -4.15 33.57 Favored Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.535 1.147 . . . . 0.0 110.994 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.57 22.16 29.68 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 22' ' ' CYS . 49.9 m -126.69 80.5 1.94 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.482 0.754 . . . . 0.0 110.473 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 21' ' ' THR . 41.1 t -41.56 -49.16 4.07 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.424 1.077 . . . . 0.0 108.327 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.5 t30 71.27 10.0 6.65 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.471 1.107 . . . . 0.0 109.327 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.841 HG22 ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -113.0 148.54 39.62 Favored Pre-proline 0 C--N 1.324 -0.502 0 O-C-N 124.439 1.087 . . . . 0.0 110.436 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.841 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 142.84 28.41 Favored 'Trans proline' 0 C--N 1.36 1.158 0 O-C-N 124.464 1.771 . . . . 0.0 111.054 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.02 49.06 7.9 Favored Glycine 0 CA--C 1.53 0.996 0 O-C-N 124.473 1.108 . . . . 0.0 110.987 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.469 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -108.92 178.11 4.57 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.649 ' O ' HG22 ' A' ' 28' ' ' THR . 1.2 m -145.77 73.33 1.34 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.518 1.136 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.477 ' C ' ' O ' ' A' ' 28' ' ' THR . 40.0 t -36.68 112.37 0.18 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.47 1.106 . . . . 0.0 108.258 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 16.5 t -119.97 -13.99 8.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.425 1.078 . . . . 0.0 110.001 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.67 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.59 136.72 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.523 0 O-C-N 124.564 1.165 . . . . 0.0 108.013 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.98 -20.99 15.88 Favored 'Cis proline' 0 C--N 1.36 1.172 0 C-N-CA 120.986 -2.506 . . . . 0.0 111.005 -0.042 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 15' ' ' GLU . 1.4 t -112.62 146.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.458 1.099 . . . . 0.0 109.3 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 1.8 p -78.36 161.46 27.17 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 124.544 1.153 . . . . 0.0 108.249 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.741 HG22 ' HA ' ' A' ' 11' ' ' PRO . 22.1 p -126.07 -175.99 3.52 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.526 1.141 . . . . 0.0 110.391 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.404 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.463 1.102 . . . . 0.0 110.299 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 140.7 -49.24 0.79 Allowed Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.545 1.153 . . . . 0.0 110.976 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 mt -54.79 114.15 6.47 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.568 0.805 . . . . 0.0 109.26 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -75.01 71.46 5.01 Favored 'Trans proline' 0 C--N 1.36 1.16 0 O-C-N 124.522 1.801 . . . . 0.0 111.003 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 m -142.39 23.52 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 O-C-N 124.595 1.185 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.443 ' SG ' HG21 ' A' ' 24' ' ' THR . 11.8 t -64.02 -45.68 87.83 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.499 1.125 . . . . 0.0 108.32 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.33 -6.43 71.68 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 124.575 1.172 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.407 ' HG3' HG21 ' A' ' 24' ' ' THR . 3.4 mm-40 -121.76 144.76 48.61 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.416 0.715 . . . . 0.0 110.258 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.808 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -95.82 174.72 6.82 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.487 1.117 . . . . 0.0 110.398 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.506 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.1 p -154.28 66.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.455 1.097 . . . . 0.0 108.342 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.693 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -71.69 -22.54 21.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.585 1.178 . . . . 0.0 109.377 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.38 -7.56 45.69 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.465 1.103 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.8 20.66 23.49 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 111.016 -0.833 . . . . 0.0 111.016 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 98.4 m -136.11 94.11 3.0 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 0.773 . . . . 0.0 110.394 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 4.7 m -46.59 -38.2 9.19 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.583 1.177 . . . . 0.0 108.303 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.0 t-20 84.33 -0.93 0.97 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.506 1.129 . . . . 0.0 109.213 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.443 HG21 ' SG ' ' A' ' 13' ' ' CYS . 13.7 t -128.03 144.95 53.42 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.457 1.098 . . . . 0.0 110.378 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.92 166.05 30.07 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.418 1.747 . . . . 0.0 111.006 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 50.61 47.48 45.36 Favored Glycine 0 CA--C 1.531 1.064 0 O-C-N 124.483 1.115 . . . . 0.0 111.003 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.448 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -128.14 174.96 8.8 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 -179.995 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.523 ' O ' HG22 ' A' ' 28' ' ' THR . 1.3 m -145.4 82.01 1.64 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.471 1.107 . . . . 0.0 110.409 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.449 ' C ' ' O ' ' A' ' 28' ' ' THR . 34.0 t -38.29 114.43 0.36 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.52 1.138 . . . . 0.0 108.273 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.3 t -119.73 -19.79 7.89 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 109.978 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.22 135.97 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.531 0 O-C-N 124.546 1.154 . . . . 0.0 108.033 -179.922 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.808 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -17.52 19.9 Favored 'Cis proline' 0 C--N 1.36 1.175 0 C-N-CA 121.035 -2.486 . . . . 0.0 110.963 0.052 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -114.05 148.97 16.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.547 1.155 . . . . 0.0 109.287 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.456 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 16.3 p -78.24 163.96 25.32 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.512 1.133 . . . . 0.0 108.233 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 28' ' ' THR . 44.4 p -131.17 -177.62 4.47 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.473 1.108 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 . . . . . 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.297 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.04 -36.07 2.2 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.533 1.146 . . . . 0.0 111.034 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.446 HD23 ' HA ' ' A' ' 10' ' ' LEU . 12.5 mt -74.34 116.88 57.21 Favored Pre-proline 0 C--N 1.324 -0.513 0 O-C-N 124.555 0.797 . . . . 0.0 109.208 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 1.006 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.02 68.37 5.79 Favored 'Trans proline' 0 C--N 1.361 1.217 0 O-C-N 124.506 1.793 . . . . 0.0 111.036 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.89 16.33 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 O-C-N 124.496 1.122 . . . . 0.0 109.269 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.557 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.6 t -64.31 -47.65 78.63 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.434 1.084 . . . . 0.0 108.248 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.22 3.36 75.84 Favored Glycine 0 CA--C 1.529 0.935 0 O-C-N 124.58 1.175 . . . . 0.0 111.041 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.0 mm-40 -121.98 145.92 47.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.438 0.728 . . . . 0.0 110.315 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.96 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -105.75 162.77 13.24 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.509 1.131 . . . . 0.0 110.458 179.957 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' N ' ' A' ' 22' ' ' CYS . 1.2 p -135.42 53.25 1.98 Allowed 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.481 1.113 . . . . 0.0 108.325 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.747 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.2 t -67.05 -20.85 27.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.509 1.13 . . . . 0.0 109.316 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.54 -3.16 59.83 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.464 1.102 . . . . 0.0 110.978 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.48 24.21 19.24 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 21' ' ' THR . 10.1 t -158.58 115.76 2.83 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.556 0.797 . . . . 0.0 110.397 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.497 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 6.4 p -55.51 -36.1 66.33 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.496 1.122 . . . . 0.0 108.278 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.497 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.2 t30 82.53 -0.93 1.35 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 109.337 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.707 HG23 ' HB3' ' A' ' 27' ' ' CYS . 15.2 t -127.32 144.75 51.85 Favored Pre-proline 0 C--N 1.326 -0.446 0 O-C-N 124.461 1.101 . . . . 0.0 110.438 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.04 177.81 8.1 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.454 1.765 . . . . 0.0 110.986 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.83 35.89 0.7 Allowed Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.543 1.152 . . . . 0.0 111.022 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.707 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -119.44 158.19 26.72 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.733 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -125.48 71.02 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.538 1.148 . . . . 0.0 110.384 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.405 ' C ' ' O ' ' A' ' 28' ' ' THR . 12.5 t -41.11 114.29 0.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.547 1.154 . . . . 0.0 108.318 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 85.4 p -125.4 -7.56 6.96 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.517 1.135 . . . . 0.0 109.985 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.747 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 61.87 138.69 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.518 0 O-C-N 124.497 1.123 . . . . 0.0 107.97 179.963 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.96 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -20.67 16.26 Favored 'Cis proline' 0 C--N 1.36 1.165 0 C-N-CA 120.976 -2.51 . . . . 0.0 110.974 -0.007 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.458 HG22 HG23 ' A' ' 16' ' ' THR . 1.6 t -118.46 144.43 26.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.451 1.094 . . . . 0.0 109.313 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.403 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 25.4 p -71.29 164.65 25.3 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.556 1.16 . . . . 0.0 108.244 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 1.006 HG22 ' HA ' ' A' ' 11' ' ' PRO . 15.2 p -131.19 177.01 7.79 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.524 1.14 . . . . 0.0 110.396 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.513 1.133 . . . . 0.0 110.305 179.96 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 36' ' ' ARG . 24.6 t30 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.43 25.85 5.88 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.569 1.168 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.462 ' HB3' HG22 ' A' ' 12' ' ' VAL . 20.9 mt -127.12 121.34 22.72 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.46 0.741 . . . . 0.0 109.284 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.2 Cg_endo -75.0 60.93 5.57 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.537 1.809 . . . . 0.0 111.015 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.462 HG22 ' HB3' ' A' ' 10' ' ' LEU . 27.4 m -143.79 20.77 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.53 1.144 . . . . 0.0 109.288 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.655 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.2 t -51.31 -46.01 62.42 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.467 1.105 . . . . 0.0 108.284 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.92 -3.75 45.26 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.422 1.076 . . . . 0.0 111.037 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -130.8 171.29 13.3 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.543 0.79 . . . . 0.0 110.242 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.714 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -122.06 175.39 6.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.431 1.082 . . . . 0.0 110.425 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.606 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.5 p -153.13 68.91 0.82 Allowed 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.662 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.4 -23.36 16.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.516 1.135 . . . . 0.0 109.287 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.59 -12.63 50.26 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 111.022 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.23 15.13 16.68 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -138.02 113.16 9.25 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.453 0.737 . . . . 0.0 110.397 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.58 ' HB2' HG22 ' A' ' 24' ' ' THR . 2.1 p -59.86 -35.34 74.59 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.516 1.135 . . . . 0.0 108.313 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.459 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.3 t30 79.26 -0.98 2.28 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.495 1.122 . . . . 0.0 109.272 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.655 HG21 ' SG ' ' A' ' 13' ' ' CYS . 9.0 t -124.46 145.48 49.16 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.535 1.147 . . . . 0.0 110.465 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.3 Cg_endo -75.02 176.93 9.27 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.561 1.821 . . . . 0.0 111.007 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.82 43.99 0.89 Allowed Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.441 1.088 . . . . 0.0 110.999 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.635 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.3 OUTLIER -122.77 173.5 7.71 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.654 ' O ' HG22 ' A' ' 28' ' ' THR . 1.2 m -142.59 73.34 1.4 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.54 1.15 . . . . 0.0 110.447 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.5 t -41.4 117.0 0.83 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.512 1.133 . . . . 0.0 108.346 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 31' ' ' TRP . 92.2 p -124.94 -10.79 7.17 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.481 1.113 . . . . 0.0 109.99 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.68 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.16 135.61 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.46 0 O-C-N 124.505 1.128 . . . . 0.0 107.997 -179.983 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 16' ' ' THR . 18.1 Cg_endo -74.99 -23.73 12.26 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.987 -2.505 . . . . 0.0 110.952 -0.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.1 t -110.7 147.71 14.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.462 1.101 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 7.3 p -77.39 167.33 21.85 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.523 1.139 . . . . 0.0 108.297 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 28' ' ' THR . 1.4 p -124.96 172.56 9.3 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.549 1.156 . . . . 0.0 110.425 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 8' ' ' ASN . 6.6 ptm180 . . . . . 0 C--N 1.324 -0.518 0 O-C-N 124.513 1.133 . . . . 0.0 110.345 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.456 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -143.55 -89.66 0.11 Allowed Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.512 1.133 . . . . 0.0 111.002 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.48 161.74 28.5 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.517 0.775 . . . . 0.0 109.29 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 70.69 5.27 Favored 'Trans proline' 0 C--N 1.36 1.159 0 O-C-N 124.456 1.766 . . . . 0.0 110.988 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.24 20.92 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.296 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.522 ' SG ' ' CG2' ' A' ' 24' ' ' THR . 8.9 t -51.93 -40.54 60.96 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.446 1.091 . . . . 0.0 108.289 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.61 -4.65 69.45 Favored Glycine 0 CA--C 1.53 0.987 0 O-C-N 124.518 1.136 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.5 OUTLIER -125.27 173.74 8.6 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.502 0.766 . . . . 0.0 110.343 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -121.38 176.13 5.81 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.393 1.058 . . . . 0.0 110.382 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.598 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 10.7 p -155.93 71.57 0.74 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.609 1.193 . . . . 0.0 108.319 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.685 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.37 -24.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.537 1.148 . . . . 0.0 109.334 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -92.31 -11.58 59.57 Favored Glycine 0 CA--C 1.529 0.952 0 O-C-N 124.44 1.087 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.58 19.99 20.97 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 21' ' ' THR . 14.0 t -149.83 104.53 3.32 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.485 0.756 . . . . 0.0 110.385 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 1.9 p -55.65 147.05 19.21 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.547 1.154 . . . . 0.0 108.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -81.22 -0.7 41.76 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.507 1.13 . . . . 0.0 109.292 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.522 ' CG2' ' SG ' ' A' ' 13' ' ' CYS . 15.2 t -126.36 144.02 47.94 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.561 1.163 . . . . 0.0 110.385 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.01 -178.05 3.9 Favored 'Trans proline' 0 C--N 1.361 1.192 0 O-C-N 124.422 1.749 . . . . 0.0 110.984 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 48.27 1.7 Allowed Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.521 1.138 . . . . 0.0 111.037 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -123.75 168.37 12.79 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.707 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -127.27 71.95 1.35 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.496 1.123 . . . . 0.0 110.406 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.436 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.0 t -39.59 118.94 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.495 1.122 . . . . 0.0 108.33 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.3 OUTLIER -121.66 -14.89 8.08 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.505 1.128 . . . . 0.0 110.018 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.32 135.27 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.703 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.08 -21.83 14.82 Favored 'Cis proline' 0 C--N 1.36 1.132 0 C-N-CA 120.961 -2.516 . . . . 0.0 110.971 0.014 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.2 t -106.35 149.44 9.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.485 1.116 . . . . 0.0 109.277 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 8.0 p -84.26 171.04 13.1 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.527 1.142 . . . . 0.0 108.309 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.409 ' OG1' ' HB ' ' A' ' 28' ' ' THR . 22.3 p -133.33 -173.76 3.31 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.53 1.144 . . . . 0.0 110.372 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.456 ' C ' ' N ' ' A' ' 9' ' ' GLY . 2.0 ttp180 . . . . . 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.16 . . . . 0.0 110.292 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.412 ' CA ' ' HB ' ' A' ' 35' ' ' THR . . . 149.36 -52.34 0.53 Allowed Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.479 1.112 . . . . 0.0 110.963 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.33 111.64 2.71 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.533 0.784 . . . . 0.0 109.32 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -74.97 66.5 6.0 Favored 'Trans proline' 0 C--N 1.361 1.189 0 O-C-N 124.401 1.738 . . . . 0.0 110.955 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.81 20.73 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.448 1.092 . . . . 0.0 109.223 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.404 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -65.39 -47.95 74.57 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.471 1.107 . . . . 0.0 108.329 -179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.24 -5.1 78.03 Favored Glycine 0 CA--C 1.531 1.066 0 O-C-N 124.468 1.105 . . . . 0.0 111.013 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.404 ' OE2' ' O ' ' A' ' 13' ' ' CYS . 20.1 mp0 -117.89 141.69 48.15 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.497 0.763 . . . . 0.0 110.271 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.793 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.34 173.36 7.02 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.476 1.11 . . . . 0.0 110.395 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.563 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.0 p -152.28 71.63 0.96 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.594 1.184 . . . . 0.0 108.314 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.691 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.2 -22.84 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.516 1.135 . . . . 0.0 109.26 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.62 -10.35 55.58 Favored Glycine 0 CA--C 1.529 0.924 0 O-C-N 124.476 1.11 . . . . 0.0 110.995 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.13 20.05 21.91 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.7 HG23 ' O ' ' A' ' 21' ' ' THR . 14.6 t -143.82 93.09 2.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.507 0.769 . . . . 0.0 110.428 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.581 ' HB2' HG22 ' A' ' 24' ' ' THR . 9.4 p -45.91 -31.37 2.13 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.336 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 1.5 t-20 79.57 -1.2 2.18 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.402 1.064 . . . . 0.0 109.354 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.581 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.8 t -118.66 147.72 42.73 Favored Pre-proline 0 C--N 1.325 -0.487 0 O-C-N 124.509 1.131 . . . . 0.0 110.475 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.3 Cg_endo -74.94 172.64 15.95 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.459 1.768 . . . . 0.0 110.961 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 45.17 1.36 Allowed Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.532 1.145 . . . . 0.0 110.997 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.78 161.26 20.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.626 ' O ' HG22 ' A' ' 28' ' ' THR . 1.5 m -130.61 70.98 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.412 1.07 . . . . 0.0 110.427 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.467 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -37.51 112.53 0.21 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.56 1.163 . . . . 0.0 108.327 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.0 p -117.16 -15.67 10.46 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.504 1.127 . . . . 0.0 109.999 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.58 136.71 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.793 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.05 -19.01 18.11 Favored 'Cis proline' 0 C--N 1.361 1.193 0 C-N-CA 120.96 -2.517 . . . . 0.0 110.947 0.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.7 t -112.17 149.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.405 1.066 . . . . 0.0 109.335 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -67.3 171.68 5.62 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.571 1.17 . . . . 0.0 108.305 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.412 ' HB ' ' CA ' ' A' ' 9' ' ' GLY . 34.2 p -136.55 161.73 35.06 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.5 1.125 . . . . 0.0 110.395 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.464 1.102 . . . . 0.0 110.318 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.453 -0.324 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.61 -44.24 1.24 Allowed Glycine 0 CA--C 1.531 1.043 0 O-C-N 124.499 1.124 . . . . 0.0 110.982 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.438 ' HB3' HG22 ' A' ' 12' ' ' VAL . 0.4 OUTLIER -59.36 114.6 9.71 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.515 0.773 . . . . 0.0 109.308 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.421 ' HD2' HD23 ' A' ' 10' ' ' LEU . 18.2 Cg_endo -75.07 67.44 5.99 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.52 1.8 . . . . 0.0 110.981 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 10' ' ' LEU . 19.2 m -140.0 21.59 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.533 1.146 . . . . 0.0 109.346 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.5 t -57.29 -43.83 83.51 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 124.504 1.128 . . . . 0.0 108.299 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.28 -5.24 71.13 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.525 1.141 . . . . 0.0 110.958 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.445 ' HG3' HG21 ' A' ' 24' ' ' THR . 6.7 mm-40 -124.43 143.36 50.67 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.449 0.735 . . . . 0.0 110.289 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.751 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.27 174.13 7.04 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.396 1.06 . . . . 0.0 110.416 179.983 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.583 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.9 p -152.5 74.8 1.09 Allowed 'General case' 0 C--N 1.326 -0.432 0 O-C-N 124.48 1.113 . . . . 0.0 108.273 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.714 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.0 t -81.81 -20.52 10.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.511 1.132 . . . . 0.0 109.364 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.17 -8.57 44.15 Favored Glycine 0 CA--C 1.53 1.005 0 O-C-N 124.541 1.15 . . . . 0.0 110.994 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.24 21.89 23.78 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 21' ' ' THR . 14.7 t -133.15 94.0 3.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.534 0.785 . . . . 0.0 110.414 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 2.8 t -41.7 -43.75 2.95 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.552 1.157 . . . . 0.0 108.344 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.1 t-20 83.27 -1.8 1.19 Allowed 'General case' 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 109.339 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.445 HG21 ' HG3' ' A' ' 15' ' ' GLU . 14.8 t -136.73 144.64 47.73 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.53 1.144 . . . . 0.0 110.406 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.0 177.6 8.38 Favored 'Trans proline' 0 C--N 1.361 1.209 0 O-C-N 124.527 1.804 . . . . 0.0 111.014 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.86 43.79 5.41 Favored Glycine 0 CA--C 1.529 0.944 0 O-C-N 124.565 1.166 . . . . 0.0 111.006 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -127.85 177.13 7.05 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.997 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.721 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -148.23 72.99 1.23 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.475 1.109 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.1 t -38.86 114.85 0.42 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 108.272 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.9 t -121.74 -11.82 8.55 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.509 1.131 . . . . 0.0 109.966 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.714 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.65 135.94 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.982 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.751 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.06 -22.6 13.77 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.948 -2.522 . . . . 0.0 111.033 -0.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.31 148.81 13.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.459 1.1 . . . . 0.0 109.29 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 15.6 p -79.23 163.96 24.55 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.593 1.183 . . . . 0.0 108.311 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 73.3 p -123.99 -176.88 3.6 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.542 1.152 . . . . 0.0 110.5 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.6 ttp85 . . . . . 0 C--N 1.324 -0.526 0 O-C-N 124.475 1.109 . . . . 0.0 110.333 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.25 -39.35 2.09 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.46 1.1 . . . . 0.0 110.942 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.418 ' O ' ' HB ' ' A' ' 35' ' ' THR . 5.9 mt -67.02 123.06 85.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.471 0.747 . . . . 0.0 109.29 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.876 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.01 71.85 4.86 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.509 1.794 . . . . 0.0 111.035 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.1 22.42 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.514 1.134 . . . . 0.0 109.314 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.3 t -57.08 -45.06 83.63 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.464 1.103 . . . . 0.0 108.302 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.31 -5.12 58.81 Favored Glycine 0 CA--C 1.531 1.074 0 O-C-N 124.498 1.124 . . . . 0.0 110.995 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.1 OUTLIER -126.09 175.01 8.05 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.572 0.807 . . . . 0.0 110.284 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.776 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.66 175.75 5.86 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 124.558 1.161 . . . . 0.0 110.419 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 28.3 p -154.59 68.75 0.73 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.674 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.5 t -73.4 -23.29 19.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.548 1.155 . . . . 0.0 109.368 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.06 -8.37 53.9 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.51 1.131 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.92 23.75 26.96 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 m -146.92 97.69 2.93 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.55 0.794 . . . . 0.0 110.399 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.499 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 3.3 m -57.2 140.29 50.09 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.445 1.091 . . . . 0.0 108.312 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -78.75 -0.25 29.55 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.506 1.129 . . . . 0.0 109.253 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 14.1 t -124.62 144.99 47.95 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.455 1.097 . . . . 0.0 110.423 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.99 179.8 5.73 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.508 1.794 . . . . 0.0 110.983 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.07 52.42 2.68 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.458 1.099 . . . . 0.0 110.997 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -124.03 176.41 6.37 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.454 ' O ' HG22 ' A' ' 28' ' ' THR . 3.1 m -137.8 75.92 1.55 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.494 1.122 . . . . 0.0 110.391 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.435 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.9 t -39.05 113.98 0.36 Allowed 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.544 1.153 . . . . 0.0 108.237 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 1.4 p -120.27 -20.02 7.46 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.483 1.114 . . . . 0.0 109.959 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.42 134.26 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.776 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.01 -19.65 17.37 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 121.011 -2.496 . . . . 0.0 110.946 0.069 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.6 t -110.76 149.01 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.492 1.12 . . . . 0.0 109.289 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.499 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 2.7 p -83.44 169.43 15.55 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 124.521 1.138 . . . . 0.0 108.27 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.876 HG22 ' HA ' ' A' ' 11' ' ' PRO . 25.3 p -129.06 -177.99 4.45 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.477 1.111 . . . . 0.0 110.376 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.326 -0.441 0 O-C-N 124.43 1.081 . . . . 0.0 110.257 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.9 p-10 . . . . . 0 N--CA 1.453 -0.299 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.429 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -135.9 -72.47 0.07 OUTLIER Glycine 0 CA--C 1.53 1.018 0 O-C-N 124.488 1.117 . . . . 0.0 110.935 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -137.09 162.97 52.53 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.454 0.738 . . . . 0.0 109.336 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.989 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.0 Cg_endo -75.01 57.04 4.44 Favored 'Trans proline' 0 C--N 1.359 1.122 0 O-C-N 124.472 1.775 . . . . 0.0 110.943 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.78 12.59 4.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 O-C-N 124.451 1.095 . . . . 0.0 109.302 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.461 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.4 t -44.41 -39.35 4.63 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.487 1.117 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.53 -1.66 62.17 Favored Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.444 1.09 . . . . 0.0 110.986 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.774 ' O ' HG12 ' A' ' 33' ' ' VAL . 2.4 tp10 -128.4 173.47 10.17 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.489 0.758 . . . . 0.0 110.331 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -126.04 175.04 8.01 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.488 1.118 . . . . 0.0 110.447 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.587 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 4.6 p -155.18 72.58 0.83 Allowed 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.478 1.111 . . . . 0.0 108.281 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.8 t -78.73 -24.33 13.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 O-C-N 124.544 1.152 . . . . 0.0 109.321 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.69 -9.49 64.36 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.459 1.099 . . . . 0.0 110.951 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.7 24.85 24.59 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 21' ' ' THR . 15.1 t -146.87 103.45 3.63 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.489 0.758 . . . . 0.0 110.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.9 OUTLIER -52.41 130.24 30.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.442 1.089 . . . . 0.0 108.299 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -77.79 -0.84 28.65 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.474 1.109 . . . . 0.0 109.325 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.461 HG21 ' SG ' ' A' ' 13' ' ' CYS . 14.1 t -130.31 143.82 50.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.591 1.182 . . . . 0.0 110.385 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.98 -178.56 4.25 Favored 'Trans proline' 0 C--N 1.36 1.148 0 O-C-N 124.535 1.808 . . . . 0.0 111.018 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.54 39.95 0.62 Allowed Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.486 1.116 . . . . 0.0 111.031 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.1 OUTLIER -116.05 176.45 5.09 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.976 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.533 ' O ' HG22 ' A' ' 28' ' ' THR . 2.9 m -135.9 70.72 1.42 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.401 1.063 . . . . 0.0 110.417 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.435 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 31.9 t -42.59 116.4 0.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.566 1.166 . . . . 0.0 108.25 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 18.0 m -123.12 -11.36 8.04 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.444 1.09 . . . . 0.0 110.017 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.33 135.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.979 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.737 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -23.72 12.26 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 121.064 -2.473 . . . . 0.0 110.984 -0.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -110.37 146.47 15.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.53 1.144 . . . . 0.0 109.278 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 10.6 p -77.54 173.68 11.73 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.455 1.097 . . . . 0.0 108.344 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.989 HG22 ' HA ' ' A' ' 11' ' ' PRO . 63.4 p -136.74 -177.3 4.68 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.489 1.118 . . . . 0.0 110.398 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.429 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.528 0 O-C-N 124.578 1.174 . . . . 0.0 110.319 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' A' ' 36' ' ' ARG . 20.1 p30 . . . . . 0 N--CA 1.454 -0.275 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.14 -63.63 0.32 Allowed Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.549 1.156 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -53.62 110.89 2.29 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.512 0.772 . . . . 0.0 109.316 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 77.7 3.06 Favored 'Trans proline' 0 C--N 1.361 1.201 0 O-C-N 124.436 1.756 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -140.77 24.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.525 1.14 . . . . 0.0 109.297 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 56.2 m -69.7 -45.5 68.12 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.508 1.13 . . . . 0.0 108.282 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.8 -10.39 72.39 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.522 1.139 . . . . 0.0 110.966 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.607 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -112.68 175.46 5.43 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.482 0.754 . . . . 0.0 110.309 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.746 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -125.92 177.26 6.42 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.483 1.114 . . . . 0.0 110.414 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.9 p -154.58 71.86 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 O-C-N 124.456 1.097 . . . . 0.0 108.236 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.663 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -76.95 -23.09 14.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.533 1.145 . . . . 0.0 109.31 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.99 -8.74 56.67 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.548 1.155 . . . . 0.0 111.019 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.74 23.0 26.93 Favored Glycine 0 CA--C 1.531 1.065 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 m -149.18 91.43 1.84 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.56 0.8 . . . . 0.0 110.358 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.4 p -50.02 153.7 1.3 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.541 1.151 . . . . 0.0 108.353 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.18 -0.73 57.68 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.478 1.111 . . . . 0.0 109.355 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 7.8 t -117.64 146.17 38.07 Favored Pre-proline 0 C--N 1.326 -0.435 0 O-C-N 124.481 1.113 . . . . 0.0 110.389 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.2 Cg_endo -74.99 177.95 7.9 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.549 1.815 . . . . 0.0 110.995 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 34.71 51.7 0.79 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.567 1.167 . . . . 0.0 111.047 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -121.92 159.06 27.66 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.736 ' O ' HG22 ' A' ' 28' ' ' THR . 1.0 OUTLIER -120.32 72.83 0.96 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.447 1.092 . . . . 0.0 110.402 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.451 ' C ' ' O ' ' A' ' 28' ' ' THR . 41.8 t -38.55 118.88 0.78 Allowed 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.536 1.147 . . . . 0.0 108.285 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 31' ' ' TRP . 46.3 t -120.63 -16.36 8.28 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.474 1.109 . . . . 0.0 110.002 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 134.99 0.04 OUTLIER Pre-proline 0 C--N 1.326 -0.43 0 O-C-N 124.493 1.12 . . . . 0.0 108.006 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.746 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -21.17 15.64 Favored 'Cis proline' 0 C--N 1.36 1.145 0 C-N-CA 121.027 -2.489 . . . . 0.0 110.98 0.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -110.97 148.33 14.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.489 1.118 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.488 ' SG ' ' N ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -67.05 177.98 1.56 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.531 1.144 . . . . 0.0 108.305 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.488 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 8.4 p -146.24 161.53 40.07 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.543 1.152 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.442 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 2.8 ttp85 . . . . . 0 C--N 1.325 -0.471 0 O-C-N 124.47 1.106 . . . . 0.0 110.346 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.05 -55.13 0.36 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.464 1.103 . . . . 0.0 111.046 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.458 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 3.8 mt -62.9 114.97 14.05 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.476 0.751 . . . . 0.0 109.372 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 81.26 2.25 Favored 'Trans proline' 0 C--N 1.36 1.137 0 O-C-N 124.503 1.791 . . . . 0.0 110.937 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m -147.84 23.64 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.531 1.144 . . . . 0.0 109.276 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.412 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -66.51 -53.95 29.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.485 1.115 . . . . 0.0 108.3 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.531 1.041 0 O-C-N 124.458 1.099 . . . . 0.0 111.019 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.604 ' OE2' HG21 ' A' ' 24' ' ' THR . 9.1 mp0 -124.96 141.99 51.77 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.605 0.826 . . . . 0.0 110.245 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.797 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.02 173.67 7.31 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.495 1.122 . . . . 0.0 110.425 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.569 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 20.6 p -151.81 73.46 1.06 Allowed 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.523 1.139 . . . . 0.0 108.243 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -79.62 -24.62 12.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 124.561 1.163 . . . . 0.0 109.348 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.73 -13.29 55.49 Favored Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.515 1.134 . . . . 0.0 111.004 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.1 17.78 19.36 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 m -143.23 94.98 2.69 Favored 'General case' 0 C--N 1.326 -0.438 0 O-C-N 124.478 0.752 . . . . 0.0 110.375 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.52 ' HB2' HG22 ' A' ' 24' ' ' THR . 12.7 p -45.99 -31.09 2.06 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.523 1.139 . . . . 0.0 108.316 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.482 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 21.4 t30 80.72 -1.36 1.86 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.429 1.081 . . . . 0.0 109.285 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.604 HG21 ' OE2' ' A' ' 15' ' ' GLU . 6.0 t -119.72 147.81 44.75 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.47 1.106 . . . . 0.0 110.342 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.445 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.02 173.16 15.0 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.485 1.782 . . . . 0.0 110.994 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.91 44.91 1.52 Allowed Glycine 0 CA--C 1.529 0.963 0 O-C-N 124.487 1.117 . . . . 0.0 110.977 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.488 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.48 160.77 21.14 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.587 ' O ' HG22 ' A' ' 28' ' ' THR . 2.0 m -129.57 70.31 1.42 Allowed 'General case' 0 C--N 1.324 -0.515 0 O-C-N 124.496 1.122 . . . . 0.0 110.388 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.447 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -38.55 113.35 0.29 Allowed 'General case' 0 C--N 1.323 -0.553 0 O-C-N 124.572 1.17 . . . . 0.0 108.23 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -118.93 -14.72 9.4 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.528 1.143 . . . . 0.0 110.056 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.49 136.38 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 107.935 179.92 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.797 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -75.01 -19.86 17.15 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 121.057 -2.476 . . . . 0.0 110.977 0.056 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.89 149.2 14.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.542 1.151 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -68.46 171.27 7.63 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.484 1.115 . . . . 0.0 108.333 179.919 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.402 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 33.6 p -135.21 166.58 22.76 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.137 . . . . 0.0 110.435 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.458 ' CG ' ' HB2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.473 0 O-C-N 124.507 1.129 . . . . 0.0 110.309 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.93 45.16 4.91 Favored Glycine 0 CA--C 1.53 1.007 0 O-C-N 124.47 1.106 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.681 ' C ' HG22 ' A' ' 35' ' ' THR . 20.1 mt -128.58 125.62 23.18 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.543 0.79 . . . . 0.0 109.289 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.428 ' N ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.04 55.47 3.98 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.528 1.804 . . . . 0.0 110.977 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.587 HG22 ' HB3' ' A' ' 10' ' ' LEU . 14.7 m -144.25 17.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.597 1.186 . . . . 0.0 109.256 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' HG21 ' A' ' 24' ' ' THR . 51.1 t -48.94 -26.58 2.57 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.52 1.138 . . . . 0.0 108.304 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.99 -11.54 56.94 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.436 1.085 . . . . 0.0 111.017 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.521 ' HG3' HG23 ' A' ' 24' ' ' THR . 4.4 mm-40 -124.58 145.51 49.56 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.502 0.766 . . . . 0.0 110.276 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.747 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -95.84 179.69 5.01 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.551 1.157 . . . . 0.0 110.399 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.604 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 32.0 p -156.69 69.16 0.6 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.506 1.129 . . . . 0.0 108.262 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.658 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.93 -22.0 15.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.598 1.186 . . . . 0.0 109.327 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.85 -8.28 34.69 Favored Glycine 0 CA--C 1.531 1.032 0 O-C-N 124.49 1.119 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.74 19.8 28.36 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' HG22 ' A' ' 21' ' ' THR . 11.0 m -124.53 72.37 1.2 Allowed 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.499 0.764 . . . . 0.0 110.401 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.7 p -41.42 -36.07 0.79 Allowed 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.529 1.143 . . . . 0.0 108.357 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.5 t30 60.91 21.9 12.09 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 124.565 1.165 . . . . 0.0 109.297 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.906 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -116.76 151.0 46.73 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.363 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.906 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.3 Cg_endo -75.0 139.65 24.51 Favored 'Trans proline' 0 C--N 1.36 1.17 0 O-C-N 124.448 1.762 . . . . 0.0 111.002 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.6 50.45 8.33 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.464 1.103 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -109.75 169.6 8.61 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.736 HG23 ' O ' ' A' ' 28' ' ' THR . 13.4 t -139.68 63.62 1.48 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.427 1.079 . . . . 0.0 110.461 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.623 ' C ' ' O ' ' A' ' 28' ' ' THR . 39.2 t -24.05 116.55 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.604 1.19 . . . . 0.0 108.34 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 40.5 t -119.51 -13.8 9.18 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.571 1.169 . . . . 0.0 109.989 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.666 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.54 137.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.478 0 O-C-N 124.58 1.175 . . . . 0.0 107.986 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.747 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.98 -19.27 17.75 Favored 'Cis proline' 0 C--N 1.36 1.183 0 C-N-CA 120.975 -2.51 . . . . 0.0 110.933 0.017 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 16' ' ' THR . 2.8 t -110.7 152.4 12.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.556 1.16 . . . . 0.0 109.21 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.2 158.0 22.5 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.532 1.145 . . . . 0.0 108.275 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.681 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -126.37 152.83 45.76 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.501 1.126 . . . . 0.0 110.401 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 8.9 mtp180 . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.482 1.114 . . . . 0.0 110.339 179.932 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.85 -53.61 0.57 Allowed Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.557 1.161 . . . . 0.0 110.938 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -57.45 109.54 1.83 Allowed Pre-proline 0 C--N 1.325 -0.468 0 O-C-N 124.444 0.732 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.97 69.29 5.57 Favored 'Trans proline' 0 C--N 1.36 1.171 0 O-C-N 124.486 1.782 . . . . 0.0 111.03 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 m -135.32 20.77 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.469 1.106 . . . . 0.0 109.288 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 17.6 m -63.35 -43.39 97.84 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.474 1.109 . . . . 0.0 108.3 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.87 -6.44 82.85 Favored Glycine 0 CA--C 1.529 0.923 0 O-C-N 124.474 1.109 . . . . 0.0 110.993 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -120.3 141.53 49.93 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.456 0.739 . . . . 0.0 110.268 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.777 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -96.28 176.56 6.02 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.454 1.096 . . . . 0.0 110.383 -179.965 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.61 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.4 p -152.2 74.15 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.447 1.092 . . . . 0.0 108.316 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -80.37 -21.91 11.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.443 1.089 . . . . 0.0 109.286 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.67 -10.56 43.39 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.448 1.092 . . . . 0.0 111.035 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.8 18.36 25.42 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.599 0.823 . . . . 0.0 111.047 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.417 ' C ' ' N ' ' A' ' 23' ' ' ASN . 57.2 m -137.31 86.26 2.18 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.526 0.78 . . . . 0.0 110.391 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.777 ' HB2' HG22 ' A' ' 24' ' ' THR . 0.8 OUTLIER -41.79 -31.89 0.35 Allowed 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.462 1.101 . . . . 0.0 108.263 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.462 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 5.8 t-20 79.61 -1.7 2.15 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 109.261 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.777 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.0 t -119.57 147.89 44.66 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.533 1.146 . . . . 0.0 110.414 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 174.05 13.44 Favored 'Trans proline' 0 C--N 1.36 1.146 0 O-C-N 124.421 1.748 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.69 47.19 1.2 Allowed Glycine 0 CA--C 1.53 0.98 0 O-C-N 124.422 1.076 . . . . 0.0 111.049 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.509 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -127.26 148.88 50.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.974 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.84 HG22 ' O ' ' A' ' 35' ' ' THR . 9.5 t -119.74 70.47 0.86 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.499 1.125 . . . . 0.0 110.414 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.491 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.6 t -34.5 117.2 0.35 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.459 1.099 . . . . 0.0 108.305 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 22.5 p -119.6 -12.43 9.29 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.459 1.099 . . . . 0.0 110.034 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.679 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.02 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.462 0 O-C-N 124.511 1.132 . . . . 0.0 107.988 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.777 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.04 -20.89 16.05 Favored 'Cis proline' 0 C--N 1.361 1.223 0 C-N-CA 120.969 -2.513 . . . . 0.0 111.01 0.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.401 HG22 HG23 ' A' ' 16' ' ' THR . 0.9 OUTLIER -114.81 148.99 17.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 O-C-N 124.468 1.105 . . . . 0.0 109.289 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.481 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -67.09 177.31 1.8 Allowed 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.579 1.174 . . . . 0.0 108.349 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.84 ' O ' HG22 ' A' ' 28' ' ' THR . 1.0 OUTLIER -147.29 151.71 37.07 Favored 'General case' 0 C--N 1.323 -0.546 0 O-C-N 124.538 1.149 . . . . 0.0 110.443 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.519 1.137 . . . . 0.0 110.246 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.47 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -150.16 -92.65 0.1 OUTLIER Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.54 1.15 . . . . 0.0 110.981 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.413 ' O ' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -109.86 158.39 35.06 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.485 0.756 . . . . 0.0 109.34 179.958 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 74.24 4.07 Favored 'Trans proline' 0 C--N 1.36 1.183 0 O-C-N 124.445 1.76 . . . . 0.0 110.981 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 m -131.46 15.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 O-C-N 124.492 1.12 . . . . 0.0 109.268 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.512 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.7 t -51.04 -42.85 60.75 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.513 1.133 . . . . 0.0 108.342 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.75 62.74 Favored Glycine 0 CA--C 1.529 0.949 0 O-C-N 124.559 1.162 . . . . 0.0 111.033 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.732 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -130.83 173.13 11.26 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.517 0.775 . . . . 0.0 110.315 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.932 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -120.05 173.88 6.82 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.511 1.132 . . . . 0.0 110.402 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.593 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 23.3 p -151.78 67.43 0.88 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.501 1.125 . . . . 0.0 108.276 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.2 t -73.97 -20.88 17.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 O-C-N 124.474 1.109 . . . . 0.0 109.306 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.51 -10.56 28.92 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.513 1.133 . . . . 0.0 111.019 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.3 17.85 20.98 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 m -129.68 87.43 2.54 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.432 0.724 . . . . 0.0 110.418 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 16' ' ' THR . 26.5 p -53.45 -39.28 64.31 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 124.446 1.091 . . . . 0.0 108.343 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 69.64 8.19 6.61 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.524 1.14 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.884 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -104.27 150.46 38.42 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.539 1.149 . . . . 0.0 110.36 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.884 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.99 139.79 24.72 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.563 1.822 . . . . 0.0 110.968 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 47.25 50.42 17.08 Favored Glycine 0 CA--C 1.529 0.939 0 O-C-N 124.462 1.101 . . . . 0.0 110.988 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.75 165.6 13.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.98 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.72 HG23 ' O ' ' A' ' 28' ' ' THR . 2.6 t -137.24 90.82 2.56 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.538 1.149 . . . . 0.0 110.424 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.438 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.6 t -38.49 112.82 0.25 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.427 1.08 . . . . 0.0 108.268 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.7 t -116.45 -21.14 9.37 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.452 1.095 . . . . 0.0 109.982 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.35 136.28 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 108.043 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.813 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -16.42 21.19 Favored 'Cis proline' 0 C--N 1.359 1.12 0 C-N-CA 121.025 -2.49 . . . . 0.0 110.983 0.064 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.932 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -117.05 150.72 18.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.486 1.117 . . . . 0.0 109.284 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 27' ' ' CYS . 1.4 p -82.69 162.51 21.79 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.443 1.089 . . . . 0.0 108.296 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.518 ' OG1' HG22 ' A' ' 28' ' ' THR . 16.8 p -131.97 178.21 6.95 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.527 1.142 . . . . 0.0 110.377 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.47 ' C ' ' N ' ' A' ' 9' ' ' GLY . 4.7 mtp180 . . . . . 0 C--N 1.325 -0.481 0 O-C-N 124.571 1.17 . . . . 0.0 110.341 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HA ' HG21 ' A' ' 28' ' ' THR . 2.3 t-20 . . . . . 0 N--CA 1.453 -0.321 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.481 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -149.14 -60.39 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.536 1.147 . . . . 0.0 110.994 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 27.1 mt -141.84 160.53 55.58 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.529 0.782 . . . . 0.0 109.326 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 70.84 5.18 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.416 1.745 . . . . 0.0 111.023 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 m -127.71 16.61 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.476 1.11 . . . . 0.0 109.313 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -46.1 87.35 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.543 1.152 . . . . 0.0 108.381 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.73 -5.88 76.86 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.769 ' O ' HG12 ' A' ' 33' ' ' VAL . 8.9 tp10 -116.7 165.46 13.25 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.425 0.721 . . . . 0.0 110.327 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -118.52 174.22 6.38 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.521 1.138 . . . . 0.0 110.319 -179.912 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.532 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 8.6 p -153.89 72.33 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.5 1.125 . . . . 0.0 108.312 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -77.83 -25.06 14.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.558 1.162 . . . . 0.0 109.331 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.2 -11.71 64.38 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.525 1.14 . . . . 0.0 110.966 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.81 22.02 19.44 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.1 m -157.85 97.05 1.53 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.52 0.777 . . . . 0.0 110.445 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 24' ' ' THR . 17.4 p -47.84 165.29 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.565 1.165 . . . . 0.0 108.274 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -97.16 -0.77 46.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.437 1.086 . . . . 0.0 109.311 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.438 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.9 t -117.53 147.53 40.96 Favored Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.536 1.147 . . . . 0.0 110.383 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.438 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.97 174.57 12.55 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.538 1.809 . . . . 0.0 110.996 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.41 51.6 1.34 Allowed Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.481 1.113 . . . . 0.0 110.96 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -115.75 162.78 16.79 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 179.943 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.474 ' O ' HG22 ' A' ' 28' ' ' THR . 8.3 m -120.92 68.35 0.87 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.491 1.12 . . . . 0.0 110.364 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 28' ' ' THR . 49.3 t -40.99 115.49 0.6 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.481 1.113 . . . . 0.0 108.313 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.435 ' O ' ' O ' ' A' ' 31' ' ' TRP . 23.1 t -120.32 -14.4 8.76 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.498 1.124 . . . . 0.0 110.057 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.694 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.14 135.74 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.95 -21.16 15.63 Favored 'Cis proline' 0 C--N 1.359 1.112 0 C-N-CA 121.029 -2.488 . . . . 0.0 111.001 -0.01 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.769 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -110.55 149.15 13.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.493 1.12 . . . . 0.0 109.274 -179.964 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -71.24 177.46 3.85 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.52 1.138 . . . . 0.0 108.255 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.458 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 41.6 p -141.05 167.2 22.75 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.472 1.108 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.481 ' C ' ' N ' ' A' ' 9' ' ' GLY . 12.3 ttp85 . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.562 1.164 . . . . 0.0 110.21 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.38 43.49 0.29 Allowed Glycine 0 CA--C 1.529 0.936 0 O-C-N 124.487 1.117 . . . . 0.0 111.06 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.717 ' C ' HG22 ' A' ' 35' ' ' THR . 23.3 mt -141.32 109.72 6.31 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.399 0.705 . . . . 0.0 109.309 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 56.51 4.26 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.458 1.767 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 10' ' ' LEU . 21.9 m -138.38 21.37 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 124.515 1.135 . . . . 0.0 109.307 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -46.09 86.61 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.576 1.172 . . . . 0.0 108.278 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.84 -7.17 62.8 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.105 . . . . 0.0 110.935 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.468 ' HG3' HG23 ' A' ' 24' ' ' THR . 7.4 mm-40 -124.44 147.87 48.01 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.523 0.778 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -101.42 179.38 4.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.462 1.101 . . . . 0.0 110.374 -179.935 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.6 p -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.453 1.096 . . . . 0.0 108.319 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -79.83 -23.46 11.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.519 1.137 . . . . 0.0 109.367 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.96 -11.2 37.88 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.538 1.149 . . . . 0.0 111.002 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.46 18.93 26.84 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -123.17 76.61 1.4 Allowed 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.504 0.767 . . . . 0.0 110.38 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.601 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 41.9 t -39.99 -45.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.556 1.16 . . . . 0.0 108.312 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 68.52 8.96 7.01 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.522 1.139 . . . . 0.0 109.296 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.897 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -107.74 151.22 41.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.493 1.12 . . . . 0.0 110.42 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.897 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.01 140.76 25.8 Favored 'Trans proline' 0 C--N 1.36 1.161 0 O-C-N 124.529 1.805 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.68 50.8 5.8 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 124.527 1.142 . . . . 0.0 111.018 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.446 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -112.18 163.64 14.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.795 HG23 ' O ' ' A' ' 28' ' ' THR . 8.0 t -133.67 69.32 1.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.478 1.111 . . . . 0.0 110.363 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.569 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.6 t -28.56 119.5 0.12 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.478 1.111 . . . . 0.0 108.292 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 31' ' ' TRP . 53.7 p -120.54 -14.57 8.63 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.473 1.108 . . . . 0.0 109.975 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.681 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 136.67 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.755 ' O ' HG22 ' A' ' 16' ' ' THR . 18.5 Cg_endo -74.93 -20.87 15.96 Favored 'Cis proline' 0 C--N 1.361 1.187 0 C-N-CA 121.007 -2.497 . . . . 0.0 111.027 -0.065 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -113.34 148.46 16.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 O-C-N 124.432 1.083 . . . . 0.0 109.282 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.601 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER -65.62 177.92 1.11 Allowed 'General case' 0 C--N 1.326 -0.427 0 O-C-N 124.45 1.094 . . . . 0.0 108.274 -179.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.717 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -151.67 158.21 43.13 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.514 1.134 . . . . 0.0 110.36 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 . . . . . 0 C--N 1.326 -0.444 0 O-C-N 124.459 1.1 . . . . 0.0 110.343 -179.944 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.468 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -131.27 -71.78 0.1 Allowed Glycine 0 CA--C 1.53 0.989 0 O-C-N 124.477 1.11 . . . . 0.0 110.978 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.25 159.74 65.0 Favored Pre-proline 0 C--N 1.325 -0.473 0 O-C-N 124.457 0.74 . . . . 0.0 109.341 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.777 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.3 Cg_endo -75.01 67.18 5.98 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.511 1.796 . . . . 0.0 111.033 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.0 m -137.83 26.68 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.549 1.155 . . . . 0.0 109.258 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.45 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.5 OUTLIER -58.72 -36.42 74.27 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.506 1.129 . . . . 0.0 108.29 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.48 -11.24 64.23 Favored Glycine 0 CA--C 1.529 0.913 0 O-C-N 124.532 1.145 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.559 ' OE1' HG23 ' A' ' 24' ' ' THR . 0.6 OUTLIER -116.55 169.54 9.26 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.433 0.725 . . . . 0.0 110.334 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.709 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.61 173.47 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.419 1.074 . . . . 0.0 110.348 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.567 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 7.0 p -150.13 60.53 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.471 1.107 . . . . 0.0 108.228 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.6 t -70.45 -23.7 24.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 O-C-N 124.476 1.11 . . . . 0.0 109.324 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.77 -7.46 55.47 Favored Glycine 0 CA--C 1.531 1.059 0 O-C-N 124.467 1.104 . . . . 0.0 110.984 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.88 19.8 23.29 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 21' ' ' THR . 14.8 t -137.8 94.67 2.93 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.551 0.795 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.9 p -54.87 -32.88 61.28 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.517 1.136 . . . . 0.0 108.251 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 63.41 13.14 6.87 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.472 1.107 . . . . 0.0 109.292 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.918 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -108.49 151.53 41.64 Favored Pre-proline 0 C--N 1.325 -0.486 0 O-C-N 124.466 1.104 . . . . 0.0 110.419 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.918 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.5 Cg_endo -74.9 141.42 26.93 Favored 'Trans proline' 0 C--N 1.359 1.096 0 O-C-N 124.475 1.776 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.42 50.95 4.62 Favored Glycine 0 CA--C 1.53 1.026 0 O-C-N 124.43 1.081 . . . . 0.0 111.026 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.45 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -109.28 163.62 13.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.726 HG23 ' O ' ' A' ' 28' ' ' THR . 13.8 t -129.75 61.24 1.57 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.533 1.145 . . . . 0.0 110.427 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.599 ' C ' ' O ' ' A' ' 28' ' ' THR . 22.6 t -26.09 117.36 0.07 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.546 1.154 . . . . 0.0 108.314 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -120.19 -14.23 8.83 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.428 1.08 . . . . 0.0 109.968 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.53 138.01 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.512 1.133 . . . . 0.0 107.983 179.965 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.709 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.03 -19.71 17.33 Favored 'Cis proline' 0 C--N 1.36 1.15 0 C-N-CA 121.054 -2.478 . . . . 0.0 110.94 0.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.8 t -113.67 147.93 16.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.485 1.116 . . . . 0.0 109.307 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -77.22 174.0 11.24 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.459 1.1 . . . . 0.0 108.303 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' HA ' ' A' ' 11' ' ' PRO . 1.1 p -145.01 164.64 30.54 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.539 1.149 . . . . 0.0 110.397 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.468 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.478 0 O-C-N 124.507 1.129 . . . . 0.0 110.306 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.26 -39.84 1.68 Allowed Glycine 0 CA--C 1.529 0.942 0 O-C-N 124.544 1.152 . . . . 0.0 111.021 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -61.95 113.49 8.64 Favored Pre-proline 0 C--N 1.325 -0.457 0 O-C-N 124.437 0.728 . . . . 0.0 109.271 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.881 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.5 Cg_endo -75.08 64.97 6.15 Favored 'Trans proline' 0 C--N 1.36 1.165 0 O-C-N 124.479 1.778 . . . . 0.0 110.983 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -138.85 21.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.435 1.085 . . . . 0.0 109.335 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.428 ' SG ' HG21 ' A' ' 24' ' ' THR . 26.7 t -57.96 -41.96 83.98 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.475 1.109 . . . . 0.0 108.283 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.65 -7.68 68.27 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.416 ' O ' HG12 ' A' ' 33' ' ' VAL . 15.4 mm-40 -124.03 155.89 37.48 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.466 0.745 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -105.52 176.63 5.1 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.566 1.166 . . . . 0.0 110.459 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.2 p -154.46 68.76 0.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.52 1.138 . . . . 0.0 108.329 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.672 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -74.78 -21.32 16.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.533 1.145 . . . . 0.0 109.338 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.95 -6.31 40.12 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.552 1.158 . . . . 0.0 111.035 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.82 21.46 28.41 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 21' ' ' THR . 2.5 m -131.7 79.4 1.87 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.538 0.787 . . . . 0.0 110.428 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.5 p -45.16 -30.94 1.27 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.54 1.15 . . . . 0.0 108.36 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 59.86 16.01 5.34 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.477 1.111 . . . . 0.0 109.312 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.851 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -111.3 150.3 41.84 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.498 1.124 . . . . 0.0 110.393 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.851 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.09 141.54 26.51 Favored 'Trans proline' 0 C--N 1.359 1.103 0 O-C-N 124.52 1.8 . . . . 0.0 111.009 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.84 50.1 5.08 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.506 1.129 . . . . 0.0 110.95 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.406 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -107.13 175.52 5.47 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.724 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -141.33 72.15 1.38 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.457 1.098 . . . . 0.0 110.357 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.7 t -38.81 114.56 0.4 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.521 1.138 . . . . 0.0 108.305 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 15.9 t -120.89 -12.09 8.85 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.552 1.158 . . . . 0.0 110.009 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.672 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.46 137.26 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.52 1.138 . . . . 0.0 108.007 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.97 -19.72 17.25 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.058 -2.476 . . . . 0.0 110.99 -0.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -113.84 150.27 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.263 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -77.62 166.59 22.83 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.482 1.113 . . . . 0.0 108.366 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.881 HG22 ' HA ' ' A' ' 11' ' ' PRO . 3.0 p -133.36 174.58 10.24 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.51 1.131 . . . . 0.0 110.375 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 . . . . . 0 C--N 1.324 -0.524 0 O-C-N 124.527 1.142 . . . . 0.0 110.36 179.932 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.23 -48.62 0.7 Allowed Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.532 1.145 . . . . 0.0 111.009 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -61.5 111.73 4.83 Favored Pre-proline 0 C--N 1.324 -0.525 0 O-C-N 124.585 0.815 . . . . 0.0 109.311 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.7 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.05 69.39 5.6 Favored 'Trans proline' 0 C--N 1.361 1.186 0 O-C-N 124.43 1.753 . . . . 0.0 110.967 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.57 21.79 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 O-C-N 124.483 1.114 . . . . 0.0 109.299 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.593 ' SG ' HG21 ' A' ' 24' ' ' THR . 5.3 t -60.76 -46.08 91.82 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.535 1.147 . . . . 0.0 108.346 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.21 -5.63 65.67 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.452 1.095 . . . . 0.0 110.944 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -123.35 146.15 48.17 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.49 0.759 . . . . 0.0 110.354 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.782 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.81 175.47 5.95 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.409 1.068 . . . . 0.0 110.41 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.56 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.2 p -153.93 65.9 0.72 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 108.27 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.682 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -71.86 -22.39 21.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 O-C-N 124.388 1.055 . . . . 0.0 109.327 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.08 -7.19 50.53 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.491 1.119 . . . . 0.0 110.994 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.97 21.34 23.51 Favored Glycine 0 CA--C 1.529 0.959 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 22.9 m -138.39 93.71 2.77 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.447 0.733 . . . . 0.0 110.387 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 7.4 p -47.33 -37.6 11.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.384 1.053 . . . . 0.0 108.283 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.494 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 0.3 OUTLIER 82.43 -1.05 1.38 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.56 1.162 . . . . 0.0 109.311 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.652 HG23 ' HB3' ' A' ' 27' ' ' CYS . 14.9 t -127.83 144.53 51.64 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.492 1.12 . . . . 0.0 110.436 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.05 179.42 6.12 Favored 'Trans proline' 0 C--N 1.359 1.116 0 O-C-N 124.505 1.792 . . . . 0.0 110.969 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 40.84 32.15 0.5 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.511 1.132 . . . . 0.0 111.019 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.652 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -115.43 166.47 11.85 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 35' ' ' THR . 17.3 m -136.64 74.43 1.49 Allowed 'General case' 0 C--N 1.324 -0.516 0 O-C-N 124.574 1.171 . . . . 0.0 110.385 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.427 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.8 t -39.93 109.78 0.12 Allowed 'General case' 0 C--N 1.326 -0.444 0 O-C-N 124.463 1.102 . . . . 0.0 108.322 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.1 OUTLIER -118.1 -11.27 10.19 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.495 1.122 . . . . 0.0 109.996 179.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.682 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.62 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.546 1.154 . . . . 0.0 108.028 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.782 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -20.09 16.87 Favored 'Cis proline' 0 C--N 1.359 1.114 0 C-N-CA 121.026 -2.489 . . . . 0.0 111.001 0.016 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 16' ' ' THR . 2.1 t -114.56 148.76 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.492 1.12 . . . . 0.0 109.411 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 21.1 p -74.77 160.18 31.05 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.7 HG22 ' HA ' ' A' ' 11' ' ' PRO . 23.3 p -127.35 -177.86 4.23 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.52 1.138 . . . . 0.0 110.383 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 . . . . . 0 C--N 1.324 -0.506 0 O-C-N 124.533 1.146 . . . . 0.0 110.322 179.963 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.1 p-10 . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.48 -51.12 0.63 Allowed Glycine 0 CA--C 1.53 0.978 0 O-C-N 124.484 1.115 . . . . 0.0 111.047 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.8 mt -56.22 114.73 8.17 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.46 0.741 . . . . 0.0 109.297 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.415 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -74.97 70.86 5.16 Favored 'Trans proline' 0 C--N 1.361 1.191 0 O-C-N 124.446 1.761 . . . . 0.0 111.002 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.1 m -142.24 22.82 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.494 1.121 . . . . 0.0 109.302 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.482 ' SG ' HG21 ' A' ' 24' ' ' THR . 4.6 t -55.94 -43.96 77.93 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.559 1.162 . . . . 0.0 108.239 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.19 -6.13 61.51 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.505 1.128 . . . . 0.0 110.971 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.6 OUTLIER -125.57 175.15 7.75 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.512 0.772 . . . . 0.0 110.363 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.708 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.4 OUTLIER -122.52 176.08 6.11 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 124.493 1.121 . . . . 0.0 110.432 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.605 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 27.3 p -153.36 66.7 0.77 Allowed 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.454 1.096 . . . . 0.0 108.312 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.668 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -73.8 -22.82 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.49 1.119 . . . . 0.0 109.362 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.06 -10.97 44.22 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.466 1.104 . . . . 0.0 111.021 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 103.65 16.17 20.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.622 HG23 ' O ' ' A' ' 21' ' ' THR . 14.5 t -132.84 100.31 4.87 Favored 'General case' 0 C--N 1.326 -0.443 0 O-C-N 124.529 0.782 . . . . 0.0 110.424 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.8 p -59.02 -39.45 81.95 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.519 1.137 . . . . 0.0 108.301 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 69.3 10.09 7.62 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.529 1.143 . . . . 0.0 109.31 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.856 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.6 OUTLIER -107.87 150.14 39.93 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 124.502 1.126 . . . . 0.0 110.338 -179.936 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.856 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.08 141.75 26.78 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.498 1.788 . . . . 0.0 111.003 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 43.45 49.39 6.96 Favored Glycine 0 CA--C 1.531 1.04 0 O-C-N 124.5 1.125 . . . . 0.0 110.967 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.28 178.42 4.55 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.667 ' O ' HG22 ' A' ' 28' ' ' THR . 1.2 m -145.01 72.22 1.32 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.498 1.124 . . . . 0.0 110.471 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.45 ' C ' ' O ' ' A' ' 28' ' ' THR . 37.2 t -38.26 113.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.525 1.141 . . . . 0.0 108.368 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 45.5 t -120.93 -12.64 8.75 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.513 1.133 . . . . 0.0 109.963 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.668 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.37 136.22 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.47 0 O-C-N 124.489 1.118 . . . . 0.0 108.003 -179.946 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.708 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.96 -22.0 14.51 Favored 'Cis proline' 0 C--N 1.361 1.188 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -0.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.9 t -109.32 148.79 12.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.558 1.161 . . . . 0.0 109.297 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.4 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.1 p -81.14 162.65 23.57 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.503 1.127 . . . . 0.0 108.291 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.468 ' O ' ' N ' ' A' ' 28' ' ' THR . 40.8 p -121.2 -171.98 2.31 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.484 1.115 . . . . 0.0 110.403 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 76.0 mtp180 . . . . . 0 C--N 1.325 -0.492 0 O-C-N 124.559 1.162 . . . . 0.0 110.281 -179.994 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 36' ' ' ARG . 20.6 p30 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.49 -57.32 0.66 Allowed Glycine 0 CA--C 1.53 0.988 0 O-C-N 124.49 1.119 . . . . 0.0 110.987 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 mt -52.54 109.41 1.42 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.486 0.756 . . . . 0.0 109.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.741 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.06 69.18 5.66 Favored 'Trans proline' 0 C--N 1.361 1.19 0 O-C-N 124.409 1.742 . . . . 0.0 110.972 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -138.5 19.98 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 O-C-N 124.546 1.154 . . . . 0.0 109.297 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.545 ' SG ' HG21 ' A' ' 24' ' ' THR . 3.3 t -52.88 -43.53 66.2 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.527 1.142 . . . . 0.0 108.321 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.65 -3.99 63.48 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.471 1.107 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.43 173.46 9.8 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.49 0.759 . . . . 0.0 110.358 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.72 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.8 OUTLIER -120.73 178.81 4.55 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.509 1.131 . . . . 0.0 110.43 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.612 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 31.7 p -155.54 62.86 0.61 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.524 1.14 . . . . 0.0 108.328 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.654 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.3 t -70.34 -21.0 23.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.509 1.131 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.07 -4.15 33.57 Favored Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.535 1.147 . . . . 0.0 110.994 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.57 22.16 29.68 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 22' ' ' CYS . 49.9 m -126.69 80.5 1.94 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.482 0.754 . . . . 0.0 110.473 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 21' ' ' THR . 41.1 t -41.56 -49.16 4.07 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.424 1.077 . . . . 0.0 108.327 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.5 t30 71.27 10.0 6.65 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.471 1.107 . . . . 0.0 109.327 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.841 HG22 ' HD2' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -113.0 148.54 39.62 Favored Pre-proline 0 C--N 1.324 -0.502 0 O-C-N 124.439 1.087 . . . . 0.0 110.436 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.841 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 142.84 28.41 Favored 'Trans proline' 0 C--N 1.36 1.158 0 O-C-N 124.464 1.771 . . . . 0.0 111.054 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.02 49.06 7.9 Favored Glycine 0 CA--C 1.53 0.996 0 O-C-N 124.473 1.108 . . . . 0.0 110.987 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.469 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -108.92 178.11 4.57 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.649 ' O ' HG22 ' A' ' 28' ' ' THR . 1.2 m -145.77 73.33 1.34 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.518 1.136 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.477 ' C ' ' O ' ' A' ' 28' ' ' THR . 40.0 t -36.68 112.37 0.18 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.47 1.106 . . . . 0.0 108.258 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 16.5 t -119.97 -13.99 8.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.425 1.078 . . . . 0.0 110.001 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.67 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.59 136.72 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.523 0 O-C-N 124.564 1.165 . . . . 0.0 108.013 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -74.98 -20.99 15.88 Favored 'Cis proline' 0 C--N 1.36 1.172 0 C-N-CA 120.986 -2.506 . . . . 0.0 111.005 -0.042 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 15' ' ' GLU . 1.4 t -112.62 146.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.458 1.099 . . . . 0.0 109.3 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 1.8 p -78.36 161.46 27.17 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 124.544 1.153 . . . . 0.0 108.249 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.741 HG22 ' HA ' ' A' ' 11' ' ' PRO . 22.1 p -126.07 -175.99 3.52 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.526 1.141 . . . . 0.0 110.391 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.404 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.463 1.102 . . . . 0.0 110.299 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 140.7 -49.24 0.79 Allowed Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.545 1.153 . . . . 0.0 110.976 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 mt -54.79 114.15 6.47 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.568 0.805 . . . . 0.0 109.26 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -75.01 71.46 5.01 Favored 'Trans proline' 0 C--N 1.36 1.16 0 O-C-N 124.522 1.801 . . . . 0.0 111.003 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.5 m -142.39 23.52 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 O-C-N 124.595 1.185 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.443 ' SG ' HG21 ' A' ' 24' ' ' THR . 11.8 t -64.02 -45.68 87.83 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.499 1.125 . . . . 0.0 108.32 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.33 -6.43 71.68 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 124.575 1.172 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.407 ' HG3' HG21 ' A' ' 24' ' ' THR . 3.4 mm-40 -121.76 144.76 48.61 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.416 0.715 . . . . 0.0 110.258 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.808 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -95.82 174.72 6.82 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 124.487 1.117 . . . . 0.0 110.398 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.506 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 29.1 p -154.28 66.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.455 1.097 . . . . 0.0 108.342 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.693 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -71.69 -22.54 21.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.585 1.178 . . . . 0.0 109.377 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.38 -7.56 45.69 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.465 1.103 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.8 20.66 23.49 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 111.016 -0.833 . . . . 0.0 111.016 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 98.4 m -136.11 94.11 3.0 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 0.773 . . . . 0.0 110.394 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.523 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 4.7 m -46.59 -38.2 9.19 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.583 1.177 . . . . 0.0 108.303 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.523 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.0 t-20 84.33 -0.93 0.97 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.506 1.129 . . . . 0.0 109.213 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.443 HG21 ' SG ' ' A' ' 13' ' ' CYS . 13.7 t -128.03 144.95 53.42 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.457 1.098 . . . . 0.0 110.378 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.92 166.05 30.07 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.418 1.747 . . . . 0.0 111.006 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 50.61 47.48 45.36 Favored Glycine 0 CA--C 1.531 1.064 0 O-C-N 124.483 1.115 . . . . 0.0 111.003 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.448 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -128.14 174.96 8.8 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 -179.995 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.523 ' O ' HG22 ' A' ' 28' ' ' THR . 1.3 m -145.4 82.01 1.64 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.471 1.107 . . . . 0.0 110.409 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.449 ' C ' ' O ' ' A' ' 28' ' ' THR . 34.0 t -38.29 114.43 0.36 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.52 1.138 . . . . 0.0 108.273 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.3 t -119.73 -19.79 7.89 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 109.978 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.22 135.97 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.531 0 O-C-N 124.546 1.154 . . . . 0.0 108.033 -179.922 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.808 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -17.52 19.9 Favored 'Cis proline' 0 C--N 1.36 1.175 0 C-N-CA 121.035 -2.486 . . . . 0.0 110.963 0.052 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -114.05 148.97 16.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.547 1.155 . . . . 0.0 109.287 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.456 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 16.3 p -78.24 163.96 25.32 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.512 1.133 . . . . 0.0 108.233 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 28' ' ' THR . 44.4 p -131.17 -177.62 4.47 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.473 1.108 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.5 ptm180 . . . . . 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.297 179.989 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 133.04 -36.07 2.2 Favored Glycine 0 CA--C 1.53 1.003 0 O-C-N 124.533 1.146 . . . . 0.0 111.034 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.446 HD23 ' HA ' ' A' ' 10' ' ' LEU . 12.5 mt -74.34 116.88 57.21 Favored Pre-proline 0 C--N 1.324 -0.513 0 O-C-N 124.555 0.797 . . . . 0.0 109.208 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 1.006 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.02 68.37 5.79 Favored 'Trans proline' 0 C--N 1.361 1.217 0 O-C-N 124.506 1.793 . . . . 0.0 111.036 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -131.89 16.33 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 O-C-N 124.496 1.122 . . . . 0.0 109.269 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.557 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.6 t -64.31 -47.65 78.63 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.434 1.084 . . . . 0.0 108.248 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.22 3.36 75.84 Favored Glycine 0 CA--C 1.529 0.935 0 O-C-N 124.58 1.175 . . . . 0.0 111.041 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.0 mm-40 -121.98 145.92 47.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.438 0.728 . . . . 0.0 110.315 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.96 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -105.75 162.77 13.24 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.509 1.131 . . . . 0.0 110.458 179.957 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' N ' ' A' ' 22' ' ' CYS . 1.2 p -135.42 53.25 1.98 Allowed 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.481 1.113 . . . . 0.0 108.325 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.747 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.2 t -67.05 -20.85 27.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.509 1.13 . . . . 0.0 109.316 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.54 -3.16 59.83 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.464 1.102 . . . . 0.0 110.978 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.48 24.21 19.24 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 21' ' ' THR . 10.1 t -158.58 115.76 2.83 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.556 0.797 . . . . 0.0 110.397 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.497 ' O ' ' CB ' ' A' ' 23' ' ' ASN . 6.4 p -55.51 -36.1 66.33 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.496 1.122 . . . . 0.0 108.278 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.497 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.2 t30 82.53 -0.93 1.35 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.517 1.136 . . . . 0.0 109.337 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.707 HG23 ' HB3' ' A' ' 27' ' ' CYS . 15.2 t -127.32 144.75 51.85 Favored Pre-proline 0 C--N 1.326 -0.446 0 O-C-N 124.461 1.101 . . . . 0.0 110.438 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.04 177.81 8.1 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.454 1.765 . . . . 0.0 110.986 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.83 35.89 0.7 Allowed Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.543 1.152 . . . . 0.0 111.022 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.707 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.5 OUTLIER -119.44 158.19 26.72 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.733 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -125.48 71.02 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.538 1.148 . . . . 0.0 110.384 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.405 ' C ' ' O ' ' A' ' 28' ' ' THR . 12.5 t -41.11 114.29 0.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.547 1.154 . . . . 0.0 108.318 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 85.4 p -125.4 -7.56 6.96 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.517 1.135 . . . . 0.0 109.985 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.747 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 61.87 138.69 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.518 0 O-C-N 124.497 1.123 . . . . 0.0 107.97 179.963 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.96 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.0 -20.67 16.26 Favored 'Cis proline' 0 C--N 1.36 1.165 0 C-N-CA 120.976 -2.51 . . . . 0.0 110.974 -0.007 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.458 HG22 HG23 ' A' ' 16' ' ' THR . 1.6 t -118.46 144.43 26.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.451 1.094 . . . . 0.0 109.313 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.403 ' CB ' ' HA ' ' A' ' 29' ' ' CYS . 25.4 p -71.29 164.65 25.3 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.556 1.16 . . . . 0.0 108.244 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 1.006 HG22 ' HA ' ' A' ' 11' ' ' PRO . 15.2 p -131.19 177.01 7.79 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.524 1.14 . . . . 0.0 110.396 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.513 1.133 . . . . 0.0 110.305 179.96 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 36' ' ' ARG . 24.6 t30 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.43 25.85 5.88 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.569 1.168 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.462 ' HB3' HG22 ' A' ' 12' ' ' VAL . 20.9 mt -127.12 121.34 22.72 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.46 0.741 . . . . 0.0 109.284 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.2 Cg_endo -75.0 60.93 5.57 Favored 'Trans proline' 0 C--N 1.36 1.164 0 O-C-N 124.537 1.809 . . . . 0.0 111.015 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.462 HG22 ' HB3' ' A' ' 10' ' ' LEU . 27.4 m -143.79 20.77 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.53 1.144 . . . . 0.0 109.288 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.655 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.2 t -51.31 -46.01 62.42 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.467 1.105 . . . . 0.0 108.284 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.92 -3.75 45.26 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.422 1.076 . . . . 0.0 111.037 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.483 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -130.8 171.29 13.3 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.543 0.79 . . . . 0.0 110.242 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.714 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -122.06 175.39 6.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.431 1.082 . . . . 0.0 110.425 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.606 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.5 p -153.13 68.91 0.82 Allowed 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.662 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.4 -23.36 16.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.516 1.135 . . . . 0.0 109.287 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.59 -12.63 50.26 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 111.022 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.23 15.13 16.68 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -138.02 113.16 9.25 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.453 0.737 . . . . 0.0 110.397 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.58 ' HB2' HG22 ' A' ' 24' ' ' THR . 2.1 p -59.86 -35.34 74.59 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.516 1.135 . . . . 0.0 108.313 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.459 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 2.3 t30 79.26 -0.98 2.28 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.495 1.122 . . . . 0.0 109.272 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.655 HG21 ' SG ' ' A' ' 13' ' ' CYS . 9.0 t -124.46 145.48 49.16 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.535 1.147 . . . . 0.0 110.465 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.3 Cg_endo -75.02 176.93 9.27 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.561 1.821 . . . . 0.0 111.007 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.82 43.99 0.89 Allowed Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.441 1.088 . . . . 0.0 110.999 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.635 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.3 OUTLIER -122.77 173.5 7.71 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.654 ' O ' HG22 ' A' ' 28' ' ' THR . 1.2 m -142.59 73.34 1.4 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.54 1.15 . . . . 0.0 110.447 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.5 t -41.4 117.0 0.83 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.512 1.133 . . . . 0.0 108.346 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 31' ' ' TRP . 92.2 p -124.94 -10.79 7.17 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.481 1.113 . . . . 0.0 109.99 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.68 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.16 135.61 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.46 0 O-C-N 124.505 1.128 . . . . 0.0 107.997 -179.983 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 16' ' ' THR . 18.1 Cg_endo -74.99 -23.73 12.26 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.987 -2.505 . . . . 0.0 110.952 -0.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.1 t -110.7 147.71 14.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 O-C-N 124.462 1.101 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 7.3 p -77.39 167.33 21.85 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.523 1.139 . . . . 0.0 108.297 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 28' ' ' THR . 1.4 p -124.96 172.56 9.3 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.549 1.156 . . . . 0.0 110.425 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 8' ' ' ASN . 6.6 ptm180 . . . . . 0 C--N 1.324 -0.518 0 O-C-N 124.513 1.133 . . . . 0.0 110.345 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.456 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -143.55 -89.66 0.11 Allowed Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.512 1.133 . . . . 0.0 111.002 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.48 161.74 28.5 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.517 0.775 . . . . 0.0 109.29 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -75.06 70.69 5.27 Favored 'Trans proline' 0 C--N 1.36 1.159 0 O-C-N 124.456 1.766 . . . . 0.0 110.988 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.24 20.92 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.296 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.522 ' SG ' ' CG2' ' A' ' 24' ' ' THR . 8.9 t -51.93 -40.54 60.96 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.446 1.091 . . . . 0.0 108.289 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.61 -4.65 69.45 Favored Glycine 0 CA--C 1.53 0.987 0 O-C-N 124.518 1.136 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.5 OUTLIER -125.27 173.74 8.6 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.502 0.766 . . . . 0.0 110.343 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -121.38 176.13 5.81 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.393 1.058 . . . . 0.0 110.382 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.598 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 10.7 p -155.93 71.57 0.74 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.609 1.193 . . . . 0.0 108.319 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.685 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.37 -24.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.537 1.148 . . . . 0.0 109.334 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -92.31 -11.58 59.57 Favored Glycine 0 CA--C 1.529 0.952 0 O-C-N 124.44 1.087 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.58 19.99 20.97 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 21' ' ' THR . 14.0 t -149.83 104.53 3.32 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.485 0.756 . . . . 0.0 110.385 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 1.9 p -55.65 147.05 19.21 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.547 1.154 . . . . 0.0 108.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -81.22 -0.7 41.76 Favored 'General case' 0 C--N 1.326 -0.44 0 O-C-N 124.507 1.13 . . . . 0.0 109.292 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.522 ' CG2' ' SG ' ' A' ' 13' ' ' CYS . 15.2 t -126.36 144.02 47.94 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.561 1.163 . . . . 0.0 110.385 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.01 -178.05 3.9 Favored 'Trans proline' 0 C--N 1.361 1.192 0 O-C-N 124.422 1.749 . . . . 0.0 110.984 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 48.27 1.7 Allowed Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.521 1.138 . . . . 0.0 111.037 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -123.75 168.37 12.79 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.707 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -127.27 71.95 1.35 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.496 1.123 . . . . 0.0 110.406 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.436 ' C ' ' O ' ' A' ' 28' ' ' THR . 38.0 t -39.59 118.94 0.9 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.495 1.122 . . . . 0.0 108.33 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 0.3 OUTLIER -121.66 -14.89 8.08 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.505 1.128 . . . . 0.0 110.018 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.693 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.32 135.27 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.703 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.08 -21.83 14.82 Favored 'Cis proline' 0 C--N 1.36 1.132 0 C-N-CA 120.961 -2.516 . . . . 0.0 110.971 0.014 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 2.2 t -106.35 149.44 9.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.485 1.116 . . . . 0.0 109.277 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 8.0 p -84.26 171.04 13.1 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.527 1.142 . . . . 0.0 108.309 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.409 ' OG1' ' HB ' ' A' ' 28' ' ' THR . 22.3 p -133.33 -173.76 3.31 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.53 1.144 . . . . 0.0 110.372 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.456 ' C ' ' N ' ' A' ' 9' ' ' GLY . 2.0 ttp180 . . . . . 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.16 . . . . 0.0 110.292 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.412 ' CA ' ' HB ' ' A' ' 35' ' ' THR . . . 149.36 -52.34 0.53 Allowed Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.479 1.112 . . . . 0.0 110.963 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.33 111.64 2.71 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.533 0.784 . . . . 0.0 109.32 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -74.97 66.5 6.0 Favored 'Trans proline' 0 C--N 1.361 1.189 0 O-C-N 124.401 1.738 . . . . 0.0 110.955 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.81 20.73 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.448 1.092 . . . . 0.0 109.223 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.404 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -65.39 -47.95 74.57 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.471 1.107 . . . . 0.0 108.329 -179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.24 -5.1 78.03 Favored Glycine 0 CA--C 1.531 1.066 0 O-C-N 124.468 1.105 . . . . 0.0 111.013 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.404 ' OE2' ' O ' ' A' ' 13' ' ' CYS . 20.1 mp0 -117.89 141.69 48.15 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.497 0.763 . . . . 0.0 110.271 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.793 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -98.34 173.36 7.02 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.476 1.11 . . . . 0.0 110.395 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.563 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.0 p -152.28 71.63 0.96 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.594 1.184 . . . . 0.0 108.314 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.691 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -78.2 -22.84 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.516 1.135 . . . . 0.0 109.26 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.62 -10.35 55.58 Favored Glycine 0 CA--C 1.529 0.924 0 O-C-N 124.476 1.11 . . . . 0.0 110.995 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.13 20.05 21.91 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.7 HG23 ' O ' ' A' ' 21' ' ' THR . 14.6 t -143.82 93.09 2.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.507 0.769 . . . . 0.0 110.428 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.581 ' HB2' HG22 ' A' ' 24' ' ' THR . 9.4 p -45.91 -31.37 2.13 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.336 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 1.5 t-20 79.57 -1.2 2.18 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.402 1.064 . . . . 0.0 109.354 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.581 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.8 t -118.66 147.72 42.73 Favored Pre-proline 0 C--N 1.325 -0.487 0 O-C-N 124.509 1.131 . . . . 0.0 110.475 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.3 Cg_endo -74.94 172.64 15.95 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.459 1.768 . . . . 0.0 110.961 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.53 45.17 1.36 Allowed Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.532 1.145 . . . . 0.0 110.997 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.78 161.26 20.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.626 ' O ' HG22 ' A' ' 28' ' ' THR . 1.5 m -130.61 70.98 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.412 1.07 . . . . 0.0 110.427 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.467 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -37.51 112.53 0.21 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.56 1.163 . . . . 0.0 108.327 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 12.0 p -117.16 -15.67 10.46 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.504 1.127 . . . . 0.0 109.999 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.58 136.71 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.793 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.05 -19.01 18.11 Favored 'Cis proline' 0 C--N 1.361 1.193 0 C-N-CA 120.96 -2.517 . . . . 0.0 110.947 0.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.7 t -112.17 149.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.405 1.066 . . . . 0.0 109.335 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -67.3 171.68 5.62 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.571 1.17 . . . . 0.0 108.305 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.412 ' HB ' ' CA ' ' A' ' 9' ' ' GLY . 34.2 p -136.55 161.73 35.06 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.5 1.125 . . . . 0.0 110.395 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.464 1.102 . . . . 0.0 110.318 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 N--CA 1.453 -0.324 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.61 -44.24 1.24 Allowed Glycine 0 CA--C 1.531 1.043 0 O-C-N 124.499 1.124 . . . . 0.0 110.982 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.438 ' HB3' HG22 ' A' ' 12' ' ' VAL . 0.4 OUTLIER -59.36 114.6 9.71 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.515 0.773 . . . . 0.0 109.308 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.421 ' HD2' HD23 ' A' ' 10' ' ' LEU . 18.2 Cg_endo -75.07 67.44 5.99 Favored 'Trans proline' 0 C--N 1.36 1.177 0 O-C-N 124.52 1.8 . . . . 0.0 110.981 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.438 HG22 ' HB3' ' A' ' 10' ' ' LEU . 19.2 m -140.0 21.59 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.533 1.146 . . . . 0.0 109.346 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 2.5 t -57.29 -43.83 83.51 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 124.504 1.128 . . . . 0.0 108.299 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.28 -5.24 71.13 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 124.525 1.141 . . . . 0.0 110.958 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.445 ' HG3' HG21 ' A' ' 24' ' ' THR . 6.7 mm-40 -124.43 143.36 50.67 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.449 0.735 . . . . 0.0 110.289 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.751 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.27 174.13 7.04 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.396 1.06 . . . . 0.0 110.416 179.983 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.583 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 19.9 p -152.5 74.8 1.09 Allowed 'General case' 0 C--N 1.326 -0.432 0 O-C-N 124.48 1.113 . . . . 0.0 108.273 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.714 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.0 t -81.81 -20.52 10.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.511 1.132 . . . . 0.0 109.364 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.17 -8.57 44.15 Favored Glycine 0 CA--C 1.53 1.005 0 O-C-N 124.541 1.15 . . . . 0.0 110.994 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.24 21.89 23.78 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.684 HG23 ' O ' ' A' ' 21' ' ' THR . 14.7 t -133.15 94.0 3.27 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.534 0.785 . . . . 0.0 110.414 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 2.8 t -41.7 -43.75 2.95 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.552 1.157 . . . . 0.0 108.344 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 6.1 t-20 83.27 -1.8 1.19 Allowed 'General case' 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 109.339 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.445 HG21 ' HG3' ' A' ' 15' ' ' GLU . 14.8 t -136.73 144.64 47.73 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.53 1.144 . . . . 0.0 110.406 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.0 177.6 8.38 Favored 'Trans proline' 0 C--N 1.361 1.209 0 O-C-N 124.527 1.804 . . . . 0.0 111.014 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.86 43.79 5.41 Favored Glycine 0 CA--C 1.529 0.944 0 O-C-N 124.565 1.166 . . . . 0.0 111.006 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.483 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.0 OUTLIER -127.85 177.13 7.05 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.997 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.721 ' O ' HG22 ' A' ' 28' ' ' THR . 1.1 m -148.23 72.99 1.23 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.475 1.109 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.1 t -38.86 114.85 0.42 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 108.272 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.426 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.9 t -121.74 -11.82 8.55 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.509 1.131 . . . . 0.0 109.966 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.714 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.65 135.94 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.982 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.751 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -75.06 -22.6 13.77 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 120.948 -2.522 . . . . 0.0 111.033 -0.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.8 t -110.31 148.81 13.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.459 1.1 . . . . 0.0 109.29 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 1.245 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 15.6 p -79.23 163.96 24.55 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.593 1.183 . . . . 0.0 108.311 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 28' ' ' THR . 73.3 p -123.99 -176.88 3.6 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.542 1.152 . . . . 0.0 110.5 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 9.6 ttp85 . . . . . 0 C--N 1.324 -0.526 0 O-C-N 124.475 1.109 . . . . 0.0 110.333 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.25 -39.35 2.09 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.46 1.1 . . . . 0.0 110.942 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.418 ' O ' ' HB ' ' A' ' 35' ' ' THR . 5.9 mt -67.02 123.06 85.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.471 0.747 . . . . 0.0 109.29 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.876 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.4 Cg_endo -75.01 71.85 4.86 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.509 1.794 . . . . 0.0 111.035 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.1 22.42 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.514 1.134 . . . . 0.0 109.314 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.3 t -57.08 -45.06 83.63 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.464 1.103 . . . . 0.0 108.302 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.31 -5.12 58.81 Favored Glycine 0 CA--C 1.531 1.074 0 O-C-N 124.498 1.124 . . . . 0.0 110.995 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.1 OUTLIER -126.09 175.01 8.05 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.572 0.807 . . . . 0.0 110.284 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.776 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -120.66 175.75 5.86 Favored 'General case' 0 C--N 1.324 -0.53 0 O-C-N 124.558 1.161 . . . . 0.0 110.419 179.988 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 28.3 p -154.59 68.75 0.73 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.551 1.157 . . . . 0.0 108.278 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.674 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.5 t -73.4 -23.29 19.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.548 1.155 . . . . 0.0 109.368 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.06 -8.37 53.9 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.51 1.131 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.92 23.75 26.96 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 m -146.92 97.69 2.93 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.55 0.794 . . . . 0.0 110.399 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.499 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 3.3 m -57.2 140.29 50.09 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 124.445 1.091 . . . . 0.0 108.312 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -78.75 -0.25 29.55 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.506 1.129 . . . . 0.0 109.253 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 14.1 t -124.62 144.99 47.95 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.455 1.097 . . . . 0.0 110.423 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.99 179.8 5.73 Favored 'Trans proline' 0 C--N 1.36 1.169 0 O-C-N 124.508 1.794 . . . . 0.0 110.983 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 39.07 52.42 2.68 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.458 1.099 . . . . 0.0 110.997 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.412 ' SG ' ' N ' ' A' ' 28' ' ' THR . 0.1 OUTLIER -124.03 176.41 6.37 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.454 ' O ' HG22 ' A' ' 28' ' ' THR . 3.1 m -137.8 75.92 1.55 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.494 1.122 . . . . 0.0 110.391 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.435 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.9 t -39.05 113.98 0.36 Allowed 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.544 1.153 . . . . 0.0 108.237 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.425 ' O ' ' O ' ' A' ' 31' ' ' TRP . 1.4 p -120.27 -20.02 7.46 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.483 1.114 . . . . 0.0 109.959 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.42 134.26 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.01 -1.108 . . . . 0.0 108.01 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.776 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.01 -19.65 17.37 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 121.011 -2.496 . . . . 0.0 110.946 0.069 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.489 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.6 t -110.76 149.01 13.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.492 1.12 . . . . 0.0 109.289 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.499 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 2.7 p -83.44 169.43 15.55 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 124.521 1.138 . . . . 0.0 108.27 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.876 HG22 ' HA ' ' A' ' 11' ' ' PRO . 25.3 p -129.06 -177.99 4.45 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 124.477 1.111 . . . . 0.0 110.376 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.326 -0.441 0 O-C-N 124.43 1.081 . . . . 0.0 110.257 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.9 p-10 . . . . . 0 N--CA 1.453 -0.299 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.429 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -135.9 -72.47 0.07 OUTLIER Glycine 0 CA--C 1.53 1.018 0 O-C-N 124.488 1.117 . . . . 0.0 110.935 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.5 mt -137.09 162.97 52.53 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.454 0.738 . . . . 0.0 109.336 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.989 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.0 Cg_endo -75.01 57.04 4.44 Favored 'Trans proline' 0 C--N 1.359 1.122 0 O-C-N 124.472 1.775 . . . . 0.0 110.943 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.78 12.59 4.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 O-C-N 124.451 1.095 . . . . 0.0 109.302 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.461 ' SG ' HG21 ' A' ' 24' ' ' THR . 1.4 t -44.41 -39.35 4.63 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.487 1.117 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.53 -1.66 62.17 Favored Glycine 0 CA--C 1.53 1.001 0 O-C-N 124.444 1.09 . . . . 0.0 110.986 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.774 ' O ' HG12 ' A' ' 33' ' ' VAL . 2.4 tp10 -128.4 173.47 10.17 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.489 0.758 . . . . 0.0 110.331 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.807 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -126.04 175.04 8.01 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.488 1.118 . . . . 0.0 110.447 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.587 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 4.6 p -155.18 72.58 0.83 Allowed 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.478 1.111 . . . . 0.0 108.281 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.8 t -78.73 -24.33 13.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 O-C-N 124.544 1.152 . . . . 0.0 109.321 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.69 -9.49 64.36 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.459 1.099 . . . . 0.0 110.951 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.7 24.85 24.59 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.599 HG23 ' O ' ' A' ' 21' ' ' THR . 15.1 t -146.87 103.45 3.63 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.489 0.758 . . . . 0.0 110.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.9 OUTLIER -52.41 130.24 30.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.442 1.089 . . . . 0.0 108.299 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -77.79 -0.84 28.65 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.474 1.109 . . . . 0.0 109.325 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.461 HG21 ' SG ' ' A' ' 13' ' ' CYS . 14.1 t -130.31 143.82 50.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.591 1.182 . . . . 0.0 110.385 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 18.4 Cg_endo -74.98 -178.56 4.25 Favored 'Trans proline' 0 C--N 1.36 1.148 0 O-C-N 124.535 1.808 . . . . 0.0 111.018 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.54 39.95 0.62 Allowed Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.486 1.116 . . . . 0.0 111.031 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.1 OUTLIER -116.05 176.45 5.09 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.976 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.533 ' O ' HG22 ' A' ' 28' ' ' THR . 2.9 m -135.9 70.72 1.42 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.401 1.063 . . . . 0.0 110.417 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.435 ' HA ' ' CB ' ' A' ' 34' ' ' CYS . 31.9 t -42.59 116.4 0.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 O-C-N 124.566 1.166 . . . . 0.0 108.25 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 31' ' ' TRP . 18.0 m -123.12 -11.36 8.04 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.444 1.09 . . . . 0.0 110.017 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.33 135.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.979 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.737 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -23.72 12.26 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 121.064 -2.473 . . . . 0.0 110.984 -0.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.807 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -110.37 146.47 15.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 O-C-N 124.53 1.144 . . . . 0.0 109.278 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.931 ' SG ' ' SG ' ' A' ' 22' ' ' CYS . 10.6 p -77.54 173.68 11.73 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.455 1.097 . . . . 0.0 108.344 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.989 HG22 ' HA ' ' A' ' 11' ' ' PRO . 63.4 p -136.74 -177.3 4.68 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.489 1.118 . . . . 0.0 110.398 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.429 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.528 0 O-C-N 124.578 1.174 . . . . 0.0 110.319 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' A' ' 36' ' ' ARG . 20.1 p30 . . . . . 0 N--CA 1.454 -0.275 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.14 -63.63 0.32 Allowed Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.549 1.156 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -53.62 110.89 2.29 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.512 0.772 . . . . 0.0 109.316 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 77.7 3.06 Favored 'Trans proline' 0 C--N 1.361 1.201 0 O-C-N 124.436 1.756 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -140.77 24.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.525 1.14 . . . . 0.0 109.297 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 56.2 m -69.7 -45.5 68.12 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.508 1.13 . . . . 0.0 108.282 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.8 -10.39 72.39 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.522 1.139 . . . . 0.0 110.966 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.607 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -112.68 175.46 5.43 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.482 0.754 . . . . 0.0 110.309 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.746 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -125.92 177.26 6.42 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.483 1.114 . . . . 0.0 110.414 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.9 p -154.58 71.86 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 O-C-N 124.456 1.097 . . . . 0.0 108.236 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.663 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.4 t -76.95 -23.09 14.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.533 1.145 . . . . 0.0 109.31 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -96.99 -8.74 56.67 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.548 1.155 . . . . 0.0 111.019 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.74 23.0 26.93 Favored Glycine 0 CA--C 1.531 1.065 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 m -149.18 91.43 1.84 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.56 0.8 . . . . 0.0 110.358 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.4 p -50.02 153.7 1.3 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.541 1.151 . . . . 0.0 108.353 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.18 -0.73 57.68 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.478 1.111 . . . . 0.0 109.355 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 7.8 t -117.64 146.17 38.07 Favored Pre-proline 0 C--N 1.326 -0.435 0 O-C-N 124.481 1.113 . . . . 0.0 110.389 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 26' ' ' GLY . 18.2 Cg_endo -74.99 177.95 7.9 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.549 1.815 . . . . 0.0 110.995 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 34.71 51.7 0.79 Allowed Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.567 1.167 . . . . 0.0 111.047 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -121.92 159.06 27.66 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.736 ' O ' HG22 ' A' ' 28' ' ' THR . 1.0 OUTLIER -120.32 72.83 0.96 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.447 1.092 . . . . 0.0 110.402 -179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.451 ' C ' ' O ' ' A' ' 28' ' ' THR . 41.8 t -38.55 118.88 0.78 Allowed 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.536 1.147 . . . . 0.0 108.285 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 31' ' ' TRP . 46.3 t -120.63 -16.36 8.28 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.474 1.109 . . . . 0.0 110.002 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.691 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 134.99 0.04 OUTLIER Pre-proline 0 C--N 1.326 -0.43 0 O-C-N 124.493 1.12 . . . . 0.0 108.006 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.746 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.96 -21.17 15.64 Favored 'Cis proline' 0 C--N 1.36 1.145 0 C-N-CA 121.027 -2.489 . . . . 0.0 110.98 0.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -110.97 148.33 14.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.489 1.118 . . . . 0.0 109.277 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.488 ' SG ' ' N ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -67.05 177.98 1.56 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.531 1.144 . . . . 0.0 108.305 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.488 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 8.4 p -146.24 161.53 40.07 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.543 1.152 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.442 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 2.8 ttp85 . . . . . 0 C--N 1.325 -0.471 0 O-C-N 124.47 1.106 . . . . 0.0 110.346 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.05 -55.13 0.36 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.464 1.103 . . . . 0.0 111.046 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.458 ' HB2' ' CG ' ' A' ' 36' ' ' ARG . 3.8 mt -62.9 114.97 14.05 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.476 0.751 . . . . 0.0 109.372 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -75.01 81.26 2.25 Favored 'Trans proline' 0 C--N 1.36 1.137 0 O-C-N 124.503 1.791 . . . . 0.0 110.937 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m -147.84 23.64 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.531 1.144 . . . . 0.0 109.276 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.412 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -66.51 -53.95 29.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.485 1.115 . . . . 0.0 108.3 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.531 1.041 0 O-C-N 124.458 1.099 . . . . 0.0 111.019 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.604 ' OE2' HG21 ' A' ' 24' ' ' THR . 9.1 mp0 -124.96 141.99 51.77 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.605 0.826 . . . . 0.0 110.245 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.797 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -96.02 173.67 7.31 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.495 1.122 . . . . 0.0 110.425 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.569 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 20.6 p -151.81 73.46 1.06 Allowed 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.523 1.139 . . . . 0.0 108.243 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.688 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -79.62 -24.62 12.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 O-C-N 124.561 1.163 . . . . 0.0 109.348 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.73 -13.29 55.49 Favored Glycine 0 CA--C 1.531 1.078 0 O-C-N 124.515 1.134 . . . . 0.0 111.004 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.1 17.78 19.36 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 m -143.23 94.98 2.69 Favored 'General case' 0 C--N 1.326 -0.438 0 O-C-N 124.478 0.752 . . . . 0.0 110.375 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.52 ' HB2' HG22 ' A' ' 24' ' ' THR . 12.7 p -45.99 -31.09 2.06 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.523 1.139 . . . . 0.0 108.316 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.482 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 21.4 t30 80.72 -1.36 1.86 Allowed 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.429 1.081 . . . . 0.0 109.285 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.604 HG21 ' OE2' ' A' ' 15' ' ' GLU . 6.0 t -119.72 147.81 44.75 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.47 1.106 . . . . 0.0 110.342 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.445 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -75.02 173.16 15.0 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.485 1.782 . . . . 0.0 110.994 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 37.91 44.91 1.52 Allowed Glycine 0 CA--C 1.529 0.963 0 O-C-N 124.487 1.117 . . . . 0.0 110.977 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.488 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -118.48 160.77 21.14 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.587 ' O ' HG22 ' A' ' 28' ' ' THR . 2.0 m -129.57 70.31 1.42 Allowed 'General case' 0 C--N 1.324 -0.515 0 O-C-N 124.496 1.122 . . . . 0.0 110.388 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.447 ' C ' ' O ' ' A' ' 28' ' ' THR . 52.9 t -38.55 113.35 0.29 Allowed 'General case' 0 C--N 1.323 -0.553 0 O-C-N 124.572 1.17 . . . . 0.0 108.23 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -118.93 -14.72 9.4 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.528 1.143 . . . . 0.0 110.056 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.49 136.38 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 107.935 179.92 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.797 ' O ' HG22 ' A' ' 16' ' ' THR . 18.4 Cg_endo -75.01 -19.86 17.15 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 121.057 -2.476 . . . . 0.0 110.977 0.056 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 t -111.89 149.2 14.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 O-C-N 124.542 1.151 . . . . 0.0 109.295 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.0 OUTLIER -68.46 171.27 7.63 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.484 1.115 . . . . 0.0 108.333 179.919 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.402 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 33.6 p -135.21 166.58 22.76 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.137 . . . . 0.0 110.435 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.458 ' CG ' ' HB2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.473 0 O-C-N 124.507 1.129 . . . . 0.0 110.309 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.93 45.16 4.91 Favored Glycine 0 CA--C 1.53 1.007 0 O-C-N 124.47 1.106 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.681 ' C ' HG22 ' A' ' 35' ' ' THR . 20.1 mt -128.58 125.62 23.18 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.543 0.79 . . . . 0.0 109.289 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.428 ' N ' HG22 ' A' ' 35' ' ' THR . 18.1 Cg_endo -75.04 55.47 3.98 Favored 'Trans proline' 0 C--N 1.36 1.149 0 O-C-N 124.528 1.804 . . . . 0.0 110.977 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.587 HG22 ' HB3' ' A' ' 10' ' ' LEU . 14.7 m -144.25 17.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.597 1.186 . . . . 0.0 109.256 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' HG21 ' A' ' 24' ' ' THR . 51.1 t -48.94 -26.58 2.57 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.52 1.138 . . . . 0.0 108.304 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.99 -11.54 56.94 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.436 1.085 . . . . 0.0 111.017 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' HG3' HG23 ' A' ' 24' ' ' THR . 4.4 mm-40 -124.58 145.51 49.56 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.502 0.766 . . . . 0.0 110.276 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.747 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -95.84 179.69 5.01 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.551 1.157 . . . . 0.0 110.399 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.604 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 32.0 p -156.69 69.16 0.6 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.506 1.129 . . . . 0.0 108.262 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.658 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -75.93 -22.0 15.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.598 1.186 . . . . 0.0 109.327 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.85 -8.28 34.69 Favored Glycine 0 CA--C 1.531 1.032 0 O-C-N 124.49 1.119 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 95.74 19.8 28.36 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' HG22 ' A' ' 21' ' ' THR . 11.0 m -124.53 72.37 1.2 Allowed 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.499 0.764 . . . . 0.0 110.401 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 26.7 p -41.42 -36.07 0.79 Allowed 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.529 1.143 . . . . 0.0 108.357 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.5 t30 60.91 21.9 12.09 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 124.565 1.165 . . . . 0.0 109.297 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.906 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -116.76 151.0 46.73 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.363 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.906 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.3 Cg_endo -75.0 139.65 24.51 Favored 'Trans proline' 0 C--N 1.36 1.17 0 O-C-N 124.448 1.762 . . . . 0.0 111.002 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 44.6 50.45 8.33 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.464 1.103 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -109.75 169.6 8.61 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.736 HG23 ' O ' ' A' ' 28' ' ' THR . 13.4 t -139.68 63.62 1.48 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.427 1.079 . . . . 0.0 110.461 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.623 ' C ' ' O ' ' A' ' 28' ' ' THR . 39.2 t -24.05 116.55 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.604 1.19 . . . . 0.0 108.34 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 40.5 t -119.51 -13.8 9.18 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.571 1.169 . . . . 0.0 109.989 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.666 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.54 137.45 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.478 0 O-C-N 124.58 1.175 . . . . 0.0 107.986 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.747 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.98 -19.27 17.75 Favored 'Cis proline' 0 C--N 1.36 1.183 0 C-N-CA 120.975 -2.51 . . . . 0.0 110.933 0.017 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 16' ' ' THR . 2.8 t -110.7 152.4 12.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 O-C-N 124.556 1.16 . . . . 0.0 109.21 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.2 158.0 22.5 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.532 1.145 . . . . 0.0 108.275 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.681 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -126.37 152.83 45.76 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.501 1.126 . . . . 0.0 110.401 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 8.9 mtp180 . . . . . 0 C--N 1.325 -0.487 0 O-C-N 124.482 1.114 . . . . 0.0 110.339 179.932 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 144.85 -53.61 0.57 Allowed Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.557 1.161 . . . . 0.0 110.938 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 mt -57.45 109.54 1.83 Allowed Pre-proline 0 C--N 1.325 -0.468 0 O-C-N 124.444 0.732 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.97 69.29 5.57 Favored 'Trans proline' 0 C--N 1.36 1.171 0 O-C-N 124.486 1.782 . . . . 0.0 111.03 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 m -135.32 20.77 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.469 1.106 . . . . 0.0 109.288 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 17.6 m -63.35 -43.39 97.84 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.474 1.109 . . . . 0.0 108.3 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.87 -6.44 82.85 Favored Glycine 0 CA--C 1.529 0.923 0 O-C-N 124.474 1.109 . . . . 0.0 110.993 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -120.3 141.53 49.93 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 124.456 0.739 . . . . 0.0 110.268 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.777 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -96.28 176.56 6.02 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.454 1.096 . . . . 0.0 110.383 -179.965 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.61 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 25.4 p -152.2 74.15 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.447 1.092 . . . . 0.0 108.316 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.2 t -80.37 -21.91 11.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.443 1.089 . . . . 0.0 109.286 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.67 -10.56 43.39 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.448 1.092 . . . . 0.0 111.035 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.8 18.36 25.42 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.599 0.823 . . . . 0.0 111.047 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.417 ' C ' ' N ' ' A' ' 23' ' ' ASN . 57.2 m -137.31 86.26 2.18 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.526 0.78 . . . . 0.0 110.391 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.777 ' HB2' HG22 ' A' ' 24' ' ' THR . 0.8 OUTLIER -41.79 -31.89 0.35 Allowed 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.462 1.101 . . . . 0.0 108.263 -179.936 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.462 ' CB ' ' O ' ' A' ' 22' ' ' CYS . 5.8 t-20 79.61 -1.7 2.15 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 109.261 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.777 HG22 ' HB2' ' A' ' 22' ' ' CYS . 5.0 t -119.57 147.89 44.66 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.533 1.146 . . . . 0.0 110.414 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.98 174.05 13.44 Favored 'Trans proline' 0 C--N 1.36 1.146 0 O-C-N 124.421 1.748 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.69 47.19 1.2 Allowed Glycine 0 CA--C 1.53 0.98 0 O-C-N 124.422 1.076 . . . . 0.0 111.049 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.509 ' HB3' HG23 ' A' ' 24' ' ' THR . 0.0 OUTLIER -127.26 148.88 50.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.974 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.84 HG22 ' O ' ' A' ' 35' ' ' THR . 9.5 t -119.74 70.47 0.86 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.499 1.125 . . . . 0.0 110.414 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.491 ' C ' ' O ' ' A' ' 28' ' ' THR . 30.6 t -34.5 117.2 0.35 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.459 1.099 . . . . 0.0 108.305 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' O ' ' A' ' 31' ' ' TRP . 22.5 p -119.6 -12.43 9.29 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.459 1.099 . . . . 0.0 110.034 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.679 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.73 137.02 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.462 0 O-C-N 124.511 1.132 . . . . 0.0 107.988 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.777 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.04 -20.89 16.05 Favored 'Cis proline' 0 C--N 1.361 1.223 0 C-N-CA 120.969 -2.513 . . . . 0.0 111.01 0.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.401 HG22 HG23 ' A' ' 16' ' ' THR . 0.9 OUTLIER -114.81 148.99 17.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 O-C-N 124.468 1.105 . . . . 0.0 109.289 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.481 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -67.09 177.31 1.8 Allowed 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.579 1.174 . . . . 0.0 108.349 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.84 ' O ' HG22 ' A' ' 28' ' ' THR . 1.0 OUTLIER -147.29 151.71 37.07 Favored 'General case' 0 C--N 1.323 -0.546 0 O-C-N 124.538 1.149 . . . . 0.0 110.443 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.519 1.137 . . . . 0.0 110.246 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.47 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -150.16 -92.65 0.1 OUTLIER Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.54 1.15 . . . . 0.0 110.981 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.413 ' O ' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -109.86 158.39 35.06 Favored Pre-proline 0 C--N 1.324 -0.503 0 O-C-N 124.485 0.756 . . . . 0.0 109.34 179.958 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -75.0 74.24 4.07 Favored 'Trans proline' 0 C--N 1.36 1.183 0 O-C-N 124.445 1.76 . . . . 0.0 110.981 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 m -131.46 15.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 O-C-N 124.492 1.12 . . . . 0.0 109.268 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.512 ' SG ' HG21 ' A' ' 24' ' ' THR . 9.7 t -51.04 -42.85 60.75 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.513 1.133 . . . . 0.0 108.342 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.75 62.74 Favored Glycine 0 CA--C 1.529 0.949 0 O-C-N 124.559 1.162 . . . . 0.0 111.033 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.732 ' O ' HG12 ' A' ' 33' ' ' VAL . 1.1 tp10 -130.83 173.13 11.26 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.517 0.775 . . . . 0.0 110.315 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.932 HG23 HG13 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -120.05 173.88 6.82 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.511 1.132 . . . . 0.0 110.402 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.593 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 23.3 p -151.78 67.43 0.88 Allowed 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.501 1.125 . . . . 0.0 108.276 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 4.2 t -73.97 -20.88 17.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 O-C-N 124.474 1.109 . . . . 0.0 109.306 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.51 -10.56 28.92 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.513 1.133 . . . . 0.0 111.019 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.3 17.85 20.98 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.4 m -129.68 87.43 2.54 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.432 0.724 . . . . 0.0 110.418 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 16' ' ' THR . 26.5 p -53.45 -39.28 64.31 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 124.446 1.091 . . . . 0.0 108.343 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 69.64 8.19 6.61 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.524 1.14 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.884 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -104.27 150.46 38.42 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.539 1.149 . . . . 0.0 110.36 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.884 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.99 139.79 24.72 Favored 'Trans proline' 0 C--N 1.359 1.127 0 O-C-N 124.563 1.822 . . . . 0.0 110.968 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 47.25 50.42 17.08 Favored Glycine 0 CA--C 1.529 0.939 0 O-C-N 124.462 1.101 . . . . 0.0 110.988 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.75 165.6 13.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.98 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.72 HG23 ' O ' ' A' ' 28' ' ' THR . 2.6 t -137.24 90.82 2.56 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.538 1.149 . . . . 0.0 110.424 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.438 ' C ' ' O ' ' A' ' 28' ' ' THR . 48.6 t -38.49 112.82 0.25 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.427 1.08 . . . . 0.0 108.268 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.43 ' O ' ' O ' ' A' ' 31' ' ' TRP . 14.7 t -116.45 -21.14 9.37 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.452 1.095 . . . . 0.0 109.982 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.697 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.35 136.28 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.548 1.155 . . . . 0.0 108.043 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.813 ' O ' HG22 ' A' ' 16' ' ' THR . 18.3 Cg_endo -74.99 -16.42 21.19 Favored 'Cis proline' 0 C--N 1.359 1.12 0 C-N-CA 121.025 -2.49 . . . . 0.0 110.983 0.064 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.932 HG13 HG23 ' A' ' 16' ' ' THR . 0.1 OUTLIER -117.05 150.72 18.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.486 1.117 . . . . 0.0 109.284 -179.964 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.52 ' SG ' ' SG ' ' A' ' 27' ' ' CYS . 1.4 p -82.69 162.51 21.79 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.443 1.089 . . . . 0.0 108.296 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.518 ' OG1' HG22 ' A' ' 28' ' ' THR . 16.8 p -131.97 178.21 6.95 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.527 1.142 . . . . 0.0 110.377 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.47 ' C ' ' N ' ' A' ' 9' ' ' GLY . 4.7 mtp180 . . . . . 0 C--N 1.325 -0.481 0 O-C-N 124.571 1.17 . . . . 0.0 110.341 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HA ' HG21 ' A' ' 28' ' ' THR . 2.3 t-20 . . . . . 0 N--CA 1.453 -0.321 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.481 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -149.14 -60.39 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 O-C-N 124.536 1.147 . . . . 0.0 110.994 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 27.1 mt -141.84 160.53 55.58 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.529 0.782 . . . . 0.0 109.326 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -74.98 70.84 5.18 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.416 1.745 . . . . 0.0 111.023 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 m -127.71 16.61 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.476 1.11 . . . . 0.0 109.313 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -46.1 87.35 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.543 1.152 . . . . 0.0 108.381 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.73 -5.88 76.86 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.504 1.127 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.769 ' O ' HG12 ' A' ' 33' ' ' VAL . 8.9 tp10 -116.7 165.46 13.25 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.425 0.721 . . . . 0.0 110.327 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.773 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -118.52 174.22 6.38 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 124.521 1.138 . . . . 0.0 110.319 -179.912 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.532 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 8.6 p -153.89 72.33 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.5 1.125 . . . . 0.0 108.312 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.694 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 3.0 t -77.83 -25.06 14.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 O-C-N 124.558 1.162 . . . . 0.0 109.331 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.2 -11.71 64.38 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.525 1.14 . . . . 0.0 110.966 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.81 22.02 19.44 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.1 m -157.85 97.05 1.53 Allowed 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.52 0.777 . . . . 0.0 110.445 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 24' ' ' THR . 17.4 p -47.84 165.29 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.565 1.165 . . . . 0.0 108.274 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -97.16 -0.77 46.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.437 1.086 . . . . 0.0 109.311 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.438 ' OG1' ' HD2' ' A' ' 25' ' ' PRO . 6.9 t -117.53 147.53 40.96 Favored Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.536 1.147 . . . . 0.0 110.383 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.438 ' HD2' ' OG1' ' A' ' 24' ' ' THR . 18.2 Cg_endo -74.97 174.57 12.55 Favored 'Trans proline' 0 C--N 1.359 1.123 0 O-C-N 124.538 1.809 . . . . 0.0 110.996 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 25' ' ' PRO . . . 36.41 51.6 1.34 Allowed Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.481 1.113 . . . . 0.0 110.96 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.1 OUTLIER -115.75 162.78 16.79 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 179.943 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.474 ' O ' HG22 ' A' ' 28' ' ' THR . 8.3 m -120.92 68.35 0.87 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.491 1.12 . . . . 0.0 110.364 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.409 ' C ' ' O ' ' A' ' 28' ' ' THR . 49.3 t -40.99 115.49 0.6 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.481 1.113 . . . . 0.0 108.313 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.435 ' O ' ' O ' ' A' ' 31' ' ' TRP . 23.1 t -120.32 -14.4 8.76 Favored 'General case' 0 C--N 1.324 -0.513 0 O-C-N 124.498 1.124 . . . . 0.0 110.057 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.694 ' CZ2' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER 62.14 135.74 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.773 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -74.95 -21.16 15.63 Favored 'Cis proline' 0 C--N 1.359 1.112 0 C-N-CA 121.029 -2.488 . . . . 0.0 111.001 -0.01 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.769 HG12 ' O ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -110.55 149.15 13.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.493 1.12 . . . . 0.0 109.274 -179.964 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.1 OUTLIER -71.24 177.46 3.85 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.52 1.138 . . . . 0.0 108.255 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.458 ' N ' ' SG ' ' A' ' 34' ' ' CYS . 41.6 p -141.05 167.2 22.75 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.472 1.108 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.481 ' C ' ' N ' ' A' ' 9' ' ' GLY . 12.3 ttp85 . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.562 1.164 . . . . 0.0 110.21 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.38 43.49 0.29 Allowed Glycine 0 CA--C 1.529 0.936 0 O-C-N 124.487 1.117 . . . . 0.0 111.06 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.717 ' C ' HG22 ' A' ' 35' ' ' THR . 23.3 mt -141.32 109.72 6.31 Favored Pre-proline 0 C--N 1.326 -0.445 0 O-C-N 124.399 0.705 . . . . 0.0 109.309 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -74.97 56.51 4.26 Favored 'Trans proline' 0 C--N 1.36 1.18 0 O-C-N 124.458 1.767 . . . . 0.0 111.061 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 10' ' ' LEU . 21.9 m -138.38 21.37 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 124.515 1.135 . . . . 0.0 109.307 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -46.09 86.61 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.576 1.172 . . . . 0.0 108.278 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.84 -7.17 62.8 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.105 . . . . 0.0 110.935 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.468 ' HG3' HG23 ' A' ' 24' ' ' THR . 7.4 mm-40 -124.44 147.87 48.01 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.523 0.778 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -101.42 179.38 4.37 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.462 1.101 . . . . 0.0 110.374 -179.935 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.614 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 26.6 p -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.453 1.096 . . . . 0.0 108.319 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.679 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.9 t -79.83 -23.46 11.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.519 1.137 . . . . 0.0 109.367 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.96 -11.2 37.88 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.538 1.149 . . . . 0.0 111.002 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.46 18.93 26.84 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 21' ' ' THR . 5.4 t -123.17 76.61 1.4 Allowed 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.504 0.767 . . . . 0.0 110.38 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.601 ' SG ' ' CB ' ' A' ' 34' ' ' CYS . 41.9 t -39.99 -45.13 1.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.556 1.16 . . . . 0.0 108.312 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 68.52 8.96 7.01 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.522 1.139 . . . . 0.0 109.296 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.897 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -107.74 151.22 41.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 O-C-N 124.493 1.12 . . . . 0.0 110.42 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.897 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.1 Cg_endo -75.01 140.76 25.8 Favored 'Trans proline' 0 C--N 1.36 1.161 0 O-C-N 124.529 1.805 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 42.68 50.8 5.8 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 124.527 1.142 . . . . 0.0 111.018 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.446 ' HB2' ' SG ' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -112.18 163.64 14.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.795 HG23 ' O ' ' A' ' 28' ' ' THR . 8.0 t -133.67 69.32 1.47 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.478 1.111 . . . . 0.0 110.363 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.569 ' C ' ' O ' ' A' ' 28' ' ' THR . 36.6 t -28.56 119.5 0.12 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.478 1.111 . . . . 0.0 108.292 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 31' ' ' TRP . 53.7 p -120.54 -14.57 8.63 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.473 1.108 . . . . 0.0 109.975 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.681 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.43 136.67 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.755 ' O ' HG22 ' A' ' 16' ' ' THR . 18.5 Cg_endo -74.93 -20.87 15.96 Favored 'Cis proline' 0 C--N 1.361 1.187 0 C-N-CA 121.007 -2.497 . . . . 0.0 111.027 -0.065 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.7 t -113.34 148.46 16.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 O-C-N 124.432 1.083 . . . . 0.0 109.282 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.601 ' CB ' ' SG ' ' A' ' 22' ' ' CYS . 0.1 OUTLIER -65.62 177.92 1.11 Allowed 'General case' 0 C--N 1.326 -0.427 0 O-C-N 124.45 1.094 . . . . 0.0 108.274 -179.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.717 HG22 ' C ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -151.67 158.21 43.13 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.514 1.134 . . . . 0.0 110.36 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 . . . . . 0 C--N 1.326 -0.444 0 O-C-N 124.459 1.1 . . . . 0.0 110.343 -179.944 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.468 ' N ' ' C ' ' A' ' 36' ' ' ARG . . . -131.27 -71.78 0.1 Allowed Glycine 0 CA--C 1.53 0.989 0 O-C-N 124.477 1.11 . . . . 0.0 110.978 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.25 159.74 65.0 Favored Pre-proline 0 C--N 1.325 -0.473 0 O-C-N 124.457 0.74 . . . . 0.0 109.341 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.777 ' HA ' HG22 ' A' ' 35' ' ' THR . 18.3 Cg_endo -75.01 67.18 5.98 Favored 'Trans proline' 0 C--N 1.36 1.136 0 O-C-N 124.511 1.796 . . . . 0.0 111.033 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.0 m -137.83 26.68 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 O-C-N 124.549 1.155 . . . . 0.0 109.258 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.45 ' SG ' ' HB2' ' A' ' 27' ' ' CYS . 0.5 OUTLIER -58.72 -36.42 74.27 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.506 1.129 . . . . 0.0 108.29 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.48 -11.24 64.23 Favored Glycine 0 CA--C 1.529 0.913 0 O-C-N 124.532 1.145 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.559 ' OE1' HG23 ' A' ' 24' ' ' THR . 0.6 OUTLIER -116.55 169.54 9.26 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.433 0.725 . . . . 0.0 110.334 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.709 HG22 ' O ' ' A' ' 32' ' ' PRO . 0.2 OUTLIER -126.61 173.47 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.419 1.074 . . . . 0.0 110.348 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.567 ' O ' ' CD1' ' A' ' 31' ' ' TRP . 7.0 p -150.13 60.53 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.471 1.107 . . . . 0.0 108.228 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' CZ2' ' A' ' 31' ' ' TRP . 2.6 t -70.45 -23.7 24.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 O-C-N 124.476 1.11 . . . . 0.0 109.324 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.77 -7.46 55.47 Favored Glycine 0 CA--C 1.531 1.059 0 O-C-N 124.467 1.104 . . . . 0.0 110.984 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.88 19.8 23.29 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 21' ' ' THR . 14.8 t -137.8 94.67 2.93 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.551 0.795 . . . . 0.0 110.433 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' THR . 25.9 p -54.87 -32.88 61.28 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.517 1.136 . . . . 0.0 108.251 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 63.41 13.14 6.87 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.472 1.107 . . . . 0.0 109.292 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.918 HG22 ' HD2' ' A' ' 25' ' ' PRO . 0.2 OUTLIER -108.49 151.53 41.64 Favored Pre-proline 0 C--N 1.325 -0.486 0 O-C-N 124.466 1.104 . . . . 0.0 110.419 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.918 ' HD2' HG22 ' A' ' 24' ' ' THR . 18.5 Cg_endo -74.9 141.42 26.93 Favored 'Trans proline' 0 C--N 1.359 1.096 0 O-C-N 124.475 1.776 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 41.42 50.95 4.62 Favored Glycine 0 CA--C 1.53 1.026 0 O-C-N 124.43 1.081 . . . . 0.0 111.026 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.45 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -109.28 163.62 13.21 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.726 HG23 ' O ' ' A' ' 28' ' ' THR . 13.8 t -129.75 61.24 1.57 Allowed 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.533 1.145 . . . . 0.0 110.427 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.599 ' C ' ' O ' ' A' ' 28' ' ' THR . 22.6 t -26.09 117.36 0.07 Allowed 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.546 1.154 . . . . 0.0 108.314 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 31' ' ' TRP . 8.5 t -120.19 -14.23 8.83 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.428 1.08 . . . . 0.0 109.968 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CE3' ' HA ' ' A' ' 32' ' ' PRO . 0.0 OUTLIER 62.53 138.01 0.04 OUTLIER Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.512 1.133 . . . . 0.0 107.983 179.965 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.709 ' O ' HG22 ' A' ' 16' ' ' THR . 18.2 Cg_endo -75.03 -19.71 17.33 Favored 'Cis proline' 0 C--N 1.36 1.15 0 C-N-CA 121.054 -2.478 . . . . 0.0 110.94 0.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 1.8 t -113.67 147.93 16.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 O-C-N 124.485 1.116 . . . . 0.0 109.307 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -77.22 174.0 11.24 Favored 'General case' 0 C--N 1.325 -0.5 0 O-C-N 124.459 1.1 . . . . 0.0 108.303 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' HA ' ' A' ' 11' ' ' PRO . 1.1 p -145.01 164.64 30.54 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.539 1.149 . . . . 0.0 110.397 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.468 ' C ' ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.478 0 O-C-N 124.507 1.129 . . . . 0.0 110.306 179.963 . . . . . . . . 2 2 . 1 stop_ save_